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CHAPTER 1
General introduction
8As the world population is increasingly living longer, research is mapping the risk 
factors for age-related diseases to define prevention strategies or therapies that will 
support healthy aging. In this quest, vitamin D has been identified as one of the factors 
receiving growing attention in clinical research. Vitamin D deficiency is prevalent in 
the older population and is suggested to have health implications beyond bone health. 
Deficiency has been linked to a broad range of diseases, and is especially relevant 
for the elderly given the potential effect on muscle function and fall risk. As such, the 
Institute of Medicine (IOM) and the Dutch Health Council re-evaluated the public 
health recommendations for vitamin D intake and supplementation. However, in their 
most recent guidelines, both institutes could base their advice only on the established 
benefits for bone health, as the evidence for other health outcomes was considered 
inconclusive [1, 2]. Further research on the optimal vitamin D treatment for other health 
benefits is needed to guide evidence-based policy making. To contribute to this field of 
research, this thesis aimed to gain insight into the prevalence and main determinants 
of a low vitamin D status, to investigate strategies to prevent or reverse vitamin D 
deficiency, and to study the effect of vitamin D supplementation on muscle strength 
and physical performance in Dutch older adults.
 
Vitamin D
Vitamin D was discovered in the beginning of the 20th century. However, it was 
already in the 1600s that, without being aware of the causal factor, rickets was reported 
as the poor mineralization, softening and bending of bones [3]. During the 1900s, the 
time of the Industrial Revolution, rickets became an epidemic among children living in 
industrialized cities in the US and Europe [4]. In that time, researchers experimented 
with cod-liver oil or ultraviolet radiation using quartz mercury-vapor lamps and noted that 
an unknown factor in both the diet and UV-light could cure the disease [5-8]. It was by 
the work of these scientists that, in 1922, Professor McCollum could ascribe the effect 
in cod-liver oil to the substance, he called ‘vitamin D’[9]. However, it was not until 1980, 
that the cutaneous synthesis of vitamin D was fully unraveled by the identification of 
pre-vitamin D3 in the skin and, shortly after, vitamin D was re-classified as a prohormone 
[10, 11]. Today, vitamin D is still considered essential for human health, and though 
the occurrence of rickets is rare, population based studies show that severe vitamin D 
deficiency is also a condition of modern times [12]. 
 
Vitamin D sources
Vitamin D belongs to a family of fat-soluble molecules that are all based on the 
same secosteroid structure. Vitamin D3 (cholecalciferol) is mainly obtained through 
cutaneous synthesis after exposure to sunlight [13]. Exposure to UV-B radiation with 
wavelengths between 280-320 nm can activate vitamin D synthesis in the skin [14]. This 
is comparable to the sun intensity that occurs from March-October in the Netherlands 
[15]. Furthermore, vitamin D3 or vitamin D2 (ergocalciferol) is in limited amounts available 
in foods. Vitamin D3 is present in animal based food sources, like fatty fish, egg yolks, 
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9meat and dairy [16], whereas vitamin D2 is the plant based source of vitamin D, and is 
mainly found in mushrooms [17]. On top of that, many countries fortify specific food 
products with vitamin D, of which milk, fruit juices, cereals and margarines are the most 
commonly fortified products. In the Netherlands, the Dutch Commodity Act allows 
fortification of margarines with extra vitamin D [18], and since 2007, fortification of other 
food products is allowed up to 4.5 µg per 100 kcal of product [19]. Lastly, supplements 
can be an important source contributing to the total vitamin D intake.
 
Metabolism of vitamin D
After exposure to UV-B radiation, the synthesis of vitamin D3 is performed by 
converting 7-dehydrocholesterol into pre-vitamin D3 by the enzyme 7-dehydrocholesterol 
reductase (DHCR7) (Figure 1.1). Pre-vitamin D3 then isomerizes to form vitamin D3. 
Ingeniously, the body has a feedback mechanism that degrades pre-vitamin D3 into 
inactive photoproducts, like lumisterol and tachysterol, to prevent vitamin D intoxication 
in case of long-term sunlight exposure [20]. Both vitamin D3 obtained after exposure 
to UV-B radiation, and vitamin D3 or vitamin D2 obtained from foods or supplements 
bind to vitamin D binding protein (DBP, also named group-specific component i.e. GC-
globulin) for transport in the bloodstream [21]. To become biologically active, vitamin D 
must undergo two hydroxylation steps. First, vitamin D is hydroxylated in the liver to form 
25-hydroxyvitamin D (25(OH)D), which is performed by several 25-hydroxylase enzymes 
that belong to the cytochrome P450 family, of which CYP2R1 is considered the key 
activator for 25-hydroxylation [22]. The 25(OH)D metabolite is the major circulating form 
of vitamin D and is, given its relatively long half-life of ~2 weeks, currently considered the 
best clinical marker to define vitamin D status. Next, 25(OH)D undergoes hydroxylation 
by the enzyme 1α-hydroxylase (CYP27B1). The activity of 1α-hydroxylase occurs mainly 
in the kidneys, as well as extra-renal tissues, to form the metabolite 1,25-dihydroxyvitamin 
D (1,25(OH)2D) [23]. This metabolite is kept under strict homeostatic control by 
parathyroid hormone (PTH), serum calcium and phosphate, fibroblast growth factor 23 
(FGF23), and activation of the 24-hydroxylase by CYP24A1. Serum 1,25(OH)2D has a 
half-life of 4-7 hours and its serum concentration is 500-1000 times lower than that of 
25(OH)D [24]. The 1,25(OH)2D metabolite acts on the vitamin D receptor (VDR) in many 
cell types throughout the body to modulate its biological responses, of which its main 
function is to regulate calcium homeostasis. Finally, both 25(OH)D and 1,25(OH)2D can 
be metabolized by 24-hydroxylase to form 24,25-dihydroxyvitamin D (24,25(OH)2D) or 
1,24,25-trihydroxyvitamin D (1,24,25(OH)3D), which ensures catabolism of metabolites 
into inactive substrates [25, 26]. 
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Figure 1.1 Schematic overview of vitamin D pathway.
 
 
Vitamin D supplementation regimens
When supplementing with vitamin D, several treatment regimens are available. The 
most common supplementation strategies include cholecalciferol, ergocalciferol, 
calcifediol or calcitriol. Furthermore, numerous vitamin D analogues have been 
synthesized, which represent effective pharmacological compounds, each having their 
distinct indications for choice of treatment. 
 
Cholecalciferol or Ergocalciferol
Supplementation with vitamin D2 or D3 is most commonly used to increase 25(OH)D 
levels in case of insufficient dietary vitamin D intake and cutaneous synthesis of vitamin 
D. Several studies suggest that vitamin D3 is more potent compared to vitamin D2 in 
raising serum 25(OH)D concentrations [27]. This might be explained by the lower affinity 
of vitamin D2 to bind to DBP, due to which it is cleared faster from the bloodstream [28]. 
Neither toxicity nor hypercalcemia are reported for intakes <250 µg/day, however, the 
upper limit is set at 100 µg/day due to limited data on adverse effects over the long-term [2]. 
 
Introduction
CHAPTER 1
Cholecalciferol
Diet/ supplementsUV-B
DHCR7
GC/ DBP
Vitamin D binding protein
25-hydroxylase CYP2R1
CYP27B1
PTH, FGF23
Ca, Pi
CYP24A1
CYP24A1
24-hydroxylase
24-hydroxylase
1-α-hydroxylase
DHC-7 reductase
7-dehydrocholesterolCholesterol
25(OH)D
1,25(OH)2D
1,24,25(OH)3D
24,25(OH)2D
Calcitroic acid
11
Calcifediol
Calcifediol, also named calcidiol, is the 25(OH)D metabolite. Calcifediol is more 
hydrophilic, does not require hepatic hydroxylation and binds with higher affinity to its 
binding proteins, when compared to vitamin D3 [29, 30]. As such, supplementation 
with calcifediol is characterized by fast absorption and requires only 1α-hydroxylation 
before becoming biologically active. This supplementation type is especially effective in 
patients with malabsorption syndromes or impaired hepatic function [31]. Hypercalcemia 
is the most common side-effect, though when compared to supplementation with 
calcitriol, it shows a relatively lower risk of hypercalcemic effects. Clinical studies have 
been performed in patient populations where the supplement was well tolerated [32]. 
However, limited data are available on pharmacokinetics of daily supplementation with 
different doses of calcifediol in healthy older adults [33, 34]. 
 
Calcitriol
Calcitriol is the active vitamin D hormone 1,25(OH)2D. A specific indication for 
supplementing with calcitriol, or its 1α-derivatives, involves patients with chronic kidney 
disease as the production of 1,25(OH)2D is diminished, which causes secondary 
hyperparathyroidism. Besides, supplementation with calcitriol might be considered for 
the treatment of postmenopausal osteoporosis in order to correct mineral and bone 
homeostasis [35]. However, supplementation with calcitriol requires careful monitoring 
as direct supplementation with the active metabolite limits the feedback regulation in 
the system and side-effects, like hypercalcemia and hypercalciuria are more likely to 
occur [32].
 
Vitamin D for older adults
Aging is characterized by a gradual decline in muscle mass and bone density, which 
can result in musculoskeletal conditions such as sarcopenia and osteoporosis [36]. 
These conditions are related to an increased risk of falls and fractures, which may 
subsequently lead to disability or institutionalization. As the social and economic 
impact of these events is significant, research is looking for protective factors in these 
conditions [37, 38]. Bone and muscle tissue both act as endocrine organs in which 
vitamin D is suggested to play an integrated role. The main function of vitamin D is to 
stimulate calcium and phosphorus absorption from the intestine, and to interact with 
PTH to mobilize calcium from the skeleton to regulate serum calcium concentrations. 
As such, vitamin D is crucial for the mineralization of bone and the prevention of its 
related conditions; osteomalacia, osteoporosis and fractures [39]. However, vitamin 
D deficiency-related fractures may in part be explained by the observed associations 
with muscle weakness and increased risk of falling. As such, vitamin D presents an 
important regulator in the musculoskeletal health of older adults. 
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Prevalence of vitamin D deficiency
The prevalence of vitamin D deficiency in the older population varies between countries 
and depends on the cut-off levels that are used to define deficiency. Based on the 
serum 25(OH)D cut-off as defined by the Dutch Health Council of 50 nmol/L for older 
adults (≥70 years), the estimated prevalence of vitamin D deficiency among community-
dwelling elderly ranges between 25-50% in Europe [40]. The Longitudinal Aging Study 
Amsterdam (LASA), showed a high prevalence of vitamin D deficiency, with 41% of adults 
(55-65 years) having a serum 25(OH)D status <50 nmol/L [41]. Moreover, the older 
cohort (65-88 years), showed an even higher prevalence of deficiency, with a prevalence 
estimate of 47% [42]. Furthermore, the Maastricht Sarcopenia Study (≥65 years) 
showed that the prevalence of deficiency was higher among sarcopenic seniors, with a 
prevalence of 51% compared to a prevalence of 25% in non-sarcopenic seniors [43]. 
 
Determinants of vitamin D status
Serum 25(OH)D concentrations depend on a number of internal and external factors, 
some of which are specific for the older population. First of all, general factors, like 
latitude, season and skin pigmentation are important determinants of cutaneous vitamin 
D production, and as such of vitamin D status. The Netherlands is located at a latitude 
of 50ºN, and vitamin D can only be synthesized in the months March till October [1]. 
This means that, during the winter months, there is a dependency on dietary vitamin 
D intake, leaving many people deficient at the end of winter season. Other factors 
that contribute to vitamin D status are more behavioral in character, such as the time 
spend outdoors, clothing, sunscreen-use, but also dietary preferences. BMI or body 
fat percentage are also considered important determinants of vitamin D status as 
sequestration in adipose tissue has been described [44, 45]. In the last years, research 
on genetic factors also suggest a considerable heritable role on vitamin D status. A 
genome-wide association study showed that several single nucleotide polymorphisms 
(SNPs) were linked to serum 25(OH)D concentration [46]. 
Older adults, especially frail and institutionalized elderly, are at increased risk of vitamin 
D deficiency due to their limited time spent outdoors and ability to expose themselves to 
sunlight. Moreover, the cutaneous synthesis of vitamin D is suggested to decrease with 
age. Studies show a 30-50% reduced production of 7-dehydrocholesterol, or response 
in serum 25(OH)D concentration after standardized UV-B doses in individuals aged 
60-80 years, compared to 20-30 year-old controls [47, 48]. Besides that, age-related 
declines in the 25-hydroxylation and 1α-hydroxylation capacity might occur due to an 
impaired hepatic or renal functioning [49], but also medication use or chronic diseases 
can interfere with the vitamin D metabolism [50-52]. All in all, vitamin D status is thus 
influenced by a broad scale of factors, however, the extent to which these factors 
contribute to the risk of vitamin D deficiency is not completely understood. 
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Current guidelines and recommendations
Reference values for vitamin D intake and status have been defined by several health 
authorities, however, different views are taken. The IOM recommends to maintain 
serum 25(OH)D concentrations >30-50 nmol/L, which corresponds with an Estimated 
Average Requirement (EAR) of 10 µg/day and Recommended Daily Allowance (RDA) 
of 15 µg/day for those 1-70 years of age. Above the age of 70 years, the EAR and 
RDA are set at 15 and 20 µg/day, respectively [2]. On the other hand, the Endocrine 
Society (ES) defines deficiency as having serum 25(OH)D concentrations <50 nmol/L, 
insufficiency as levels between 50-75 nmol/L, and sufficiency as levels >75 nmol/L, 
recommending supplementation up to 50 µg/day for adults >50 years [53]. The dietary 
reference guidelines of the Dutch Health Council recommend to maintain serum 25(OH)
D concentrations >30 nmol/L for those 4 to 70 years of age, and >50 nmol/L for those 
≥70 years of age. Daily supplementation with 10 µg/day  is advised for women ≥50 years, 
and 20 µg/day for men and women ≥70 years of age [1]. In part, the different approach 
between policies can be explained by the fact that the IOM aims to provide guidance to 
the general population, whereas the ES specifically targets at-risk populations for the 
prevention and treatment of vitamin D deficiency. However, the optimal serum 25(OH)D 
concentration for specific health outcomes is under considerable debate. For example, 
the IOM based its recommendations on the beneficial effect on bone, whereas the ES 
advocates levels >75 nmol/L to maximize the effect of vitamin D on PTH suppression, 
fall risk reduction, and bone and muscle metabolism. All in all, there is controversy in 
these recommendations and what constitutes an ‘optimal vitamin D status’ requires 
further investigation. 
 
Vitamin D and musculoskeletal health
Muscle strength and function are necessary for basic bodily movement and 
increasingly important to remain mobile and independently living when aging. There 
is growing evidence that vitamin D plays an important role in skeletal muscle. Already 
in times when rickets was prevalent, symptoms of myopathy, hypotonia or waddling 
gait were associated with this disease [54]. In adults with osteomalacia or extreme 
vitamin D deficiency, comparable symptoms, like diffuse muscle pain and difficulty in 
rising from a chair are described [55]. Moreover, early case-studies suggest that these 
complaints could be relieved after supplementation with vitamin D [56, 57] and thus, 
provide relevant leads for further research. 
 
Muscle and vitamin D mechanism
While the exact effect of vitamin D on muscle metabolism remains to be elucidated, 
numerous cell-line and animal studies have attempted to address this question. Several 
mechanisms have been proposed, which either relate to systemic endocrine effects via 
mineral homeostasis or regulatory effects through the VDR in muscle tissue (Figure 1.2). 
The 1,25(OH)2D metabolite is suggested to stimulate the accumulation and release of 
calcium from the sarcoplasmic reticulum, thereby influencing calcium influx in muscle 
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cells [58]. Besides, 1,25(OH)2D can support phosphate transport through the cell 
membrane [59], both of which are necessary for muscle contraction [60]. Moreover, 
the identification of the VDR in muscle cells and the local expression of CYP27B1 
and CYP24A1, support a direct role of 1,25(OH)2D in skeletal muscle [61-64]. In the 
target cell, 1,25(OH)2D binds to the VDR and heterodimerizes with the RXR receptor, 
after which the complex will bind to vitamin D response elements (VDREs) on target 
genes to induce gene expression involved in calcium handling, cell proliferation and 
differentiation [65, 66]. The expression of the VDR in muscle cells has been under 
debate as it could be detected by several studies [67-69], although not by all [70]. In 
mice models, ablation of the VDR results in reduced grip strength, abnormal muscle 
development and reduced size of both type I and II muscle fibers [71, 72]. In humans, 
the VDR expression in muscle is reported to decrease with age and supplementation 
with vitamin D appeared to reverse this process [73, 74]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Suggested mechanisms by which vitamin D acts on muscle. 
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Evidence from epidemiological studies
Several observational studies have described associations between vitamin D status 
and measures of physical performance, muscle strength or postural balance, where 
serum 25(OH)D concentrations <50 nmol/L have been associated with poor physical 
performance [75, 76] or muscle strength [77-79]. However, the observed associations 
appear inconsistent. Several studies also observed higher cut-offs of >75 nmol/L 
or >100 nmol/L to be relevant [80, 81], whereas others report no association [82, 
83]. Prospective observations from the LASA cohort showed that serum 25(OH)D 
concentrations <25 nmol/L were associated with an increased risk of losing muscle 
mass and grip strength over a 3 year period [84]. Likewise, an accelerated decline was 
observed over a 2,5 year period in performance on the Timed Up and Go test (TUG) in 
older women with a serum 25(OH)D status <50 nmol/L [85]. 
  
Evidence from intervention studies
A number of randomized trials investigated the effect of vitamin D supplementation on 
physical performance and muscle strength, with some reporting beneficial effects [86-
92], whereas others did not [93-96]. While these studies vary considerably in design, 
several meta-analyses have attempted to pool the results. A meta-analysis in older 
adults with a serum 25(OH)D status <50 nmol/L, concluded that supplementation with 
20-25 µg/day resulted in beneficial effects on the TUG test and balance performance 
[97]. In addition, a meta-analysis studying the effect of vitamin D supplementation on 
lower limb strength, observed a beneficial effect only in those with a serum 25(OH)D 
status <25 nmol/L [98]. A large meta-analysis including 30 studies and all age groups, 
indicated a small significant effect of supplementation on muscle strength, but no effect 
on muscle power or muscle mass [99]. Moreover, the beneficial effect on strength was 
more pronounced in subgroups with serum 25(OH)D status <30 nmol/L or those aged 
≥65 years. In contrast, a recent meta-analysis on the effect of vitamin D supplementation 
in older adults, concluded no improvements on grip strength and observed even a small 
significant deterioration on the TUG test [100]. These meta-analyses indicate that the 
current evidence-base is inconsistent, but point towards a plausible beneficial effect of 
vitamin D supplementation, especially in older populations with low baseline 25(OH)D 
concentrations. When studying the effect of vitamin D supplementation, the goal is to 
correct deficiency and induce a significant increase in serum 25(OH)D concentrations 
towards the targeted therapeutic range. Up until now, most studies supplemented 
with vitamin D3 to increase serum 25(OH)D concentrations. However, in this context, 
calcifediol might offer an effective supplementation strategy as well. The European 
Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis 
(ESCEO) reported in a recent position statement that other vitamin D compounds 
require investigation with respect to their efficacy and safety on extra-skeletal health 
[101]. A previous pilot study (n=20) in postmenopausal women indicated beneficial 
effects of calcifediol on knee-extension strength and gait speed when compared to 
vitamin D3 [102]. However, whether these effects are explained by the rapid increase 
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in serum 25(OH)D concentration, the higher serum 25(OH)D thresholds obtained, or 
other characteristics of this metabolite remains to be determined. Therefore, further 
randomized trials, in placebo-controlled settings, using effective treatment regimens 
and taking into account the baseline 25(OH)D concentration, are needed to investigate 
the potential effect of vitamin D supplementation on muscle function in older adults. 
  
This thesis – rationale and outline
This thesis aimed to address several topics related to vitamin D, with a focus on the 
community-dwelling, or pre-frail and frail older population. First of all, to identify those 
at risk of deficiency, we aimed to get insight in the prevalence and main determinants of 
a low vitamin D status. Next, we assessed how dietary intake and supplementation can 
contribute to prevent or overcome deficiency, and lastly, we studied whether improving 
serum 25(OH)D status might benefit muscle function in vitamin D deficient pre-frail and 
frail older adults. These study questions are addressed in the following chapters: 
In chapter 2, the prevalence of vitamin D deficiency, and the importance of sunlight 
exposure, dietary vitamin D intake and genetic variance for adequate serum 25(OH)
D concentrations is described. Chapter 3 examines the dietary vitamin D intake and 
specific food sources that contribute most to vitamin D status. In chapter 4, a dose-
response study was performed to explore the potential for calcifediol as a valuable 
supplementation strategy in the treatment of vitamin D deficiency. Moreover, chapter 5 
describes the association between serum 25(OH)D status, physical performance and 
frailty, and in chapter 6, a placebo-controlled trial was performed to study the effect 
of vitamin D3 or calcifediol supplementation on muscle function in vitamin D deficient 
older adults. Finally, in chapter 7, the main findings are discussed, providing a critical 
methodological reflection and suggestions for future research.
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ABSTRACT
Background & aims: The prevalence of vitamin D deficiency among seniors is high. 
Whereas sun exposure, vitamin D intake, genes, demographics, and lifestyle have been 
identified as being important determinants of vitamin D status, the impact of these 
factors is expected to differ across populations. To improve current prevention and 
treatment strategies, this study aimed to explore the main determinants of vitamin D 
status and its relative importance in a population of community-dwelling Dutch older 
adults.
 
Methods: Serum 25-hydroxyvitamin D (25(OH)D) was measured in 2857 adults aged 
≥65 years. Sun exposure was assessed with a structured questionnaire (n=1012), 
vitamin D intake using a Food Frequency Questionnaire (n=596), and data on 
genetic variation that may affect 25(OH)D status was obtained for 4 genes, DHCR7 
(rs12785878), CYP2R1 (rs10741657), GC (rs2282679), and CYP24A1 (rs6013897) 
(n=2530).  
Results: Serum 25(OH)D concentrations <50 nmol/L were observed in 45% of the 
population; only 6% of these participants used vitamin D supplements. Sun exposure 
(being outside daily during summer: 66 ± 25 nmol/L versus not being outside daily 
during summer: 58 ± 27 nmol/L, P=0.02) and vitamin D intake (per unit µg/day during 
winter/spring: 3.1 ± 0.75 nmol/L, P<0.0001) were associated with higher 25(OH)D 
concentrations. Major allele carriers of SNPs related to DHCR7, CYP24A1, and GC, 
as well as CYP2R1 minor allele carriers had the highest 25(OH)D concentrations. 
Together, sun (R2=0.29), vitamin D intake (R2=0.24), and genes (R2=0.28) explained 
35% (R2=0.35) of the variation in 25(OH)D concentrations during summer/autumn 
period, when adjusted for age, sex, BMI, education, alcohol consumption, smoking, 
physical activity, and self-rated health status (n=185). 
Conclusion: The investigated determinants explained 35% of 25(OH)D status. Of the 
three main determinants under study, sun exposure still appeared to be an important 
determinant of serum 25(OH)D in older individuals, closely followed by genes, and 
vitamin D intake. Given the low frequency of vitamin D supplement use in this population, 
promoting supplement use may be an inexpensive, easy, and effective strategy to fight 
vitamin D deficiency. 
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INTRODUCTION
In the Netherlands about half of the community-dwelling older people have a vitamin 
D status (25(OH)D) below 50 nmol/L [1] and are classified as having an insufficient 
status according to guidelines of the Institute of Medicine (IOM) [2]. In order to tackle 
this issue of low 25(OH)D concentrations it is important to gain knowledge on its main 
determinants. 
One of the sources of vitamin D is the diet, but only a limited number of foods contain 
vitamin D. Vitamin D is therefore mainly acquired through sunlight exposure, specifically 
ultraviolet-B radiation (UV-B), which activates the cutaneous synthesis of pre-vitamin 
D3 in the skin [3]. The efficiency of sunlight exposure and vitamin D intake to increase 
25(OH)D status depends on a variety of factors, including latitude, season, air pollution, 
sunscreen use, skin pigmentation, age, efficiency of absorption in the gut, liver and 
kidney disease, and medication use [4]. To illustrate this, at higher latitudes (e.g. 
>50˚) the intensity of UV-B during the winter months is too low to activate the vitamin 
D synthesis in the skin [5]. It is also shown that 25(OH)D concentrations decrease 
with age due to a decrease in cutaneous vitamin D synthesis in the skin [6]. Genetic 
make-up has furthermore been associated with vitamin D metabolism and variations in 
25(OH)D concentrations [7]. Thus, 25(OH)D concentrations depend on a broad variety 
of factors ranging from environmental and behavioral factors to genetics. Despite this 
knowledge, vitamin D deficiency is observed worldwide [8-11], of which particularly 
older populations are at increased risk [12]. 
This study is performed to assess the prevalence of vitamin D deficiency, and to 
examine to what extent vitamin D intake, frequency of vitamin D supplement use, sunlight 
exposure habits, and genetic variance are associated with 25(OH)D concentrations in 
a population of Dutch community-dwelling older adults. Identification of the relative 
contribution of these factors to vitamin D status in this particular age category might 
help to pinpoint important determinants in the prevention and treatment of vitamin D 
deficiency.
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METHODS
 
Participants
This cross-sectional study was performed using baseline data of the B-PROOF 
study (B-vitamins for the PRevention Of Osteoporotic Fractures); a randomized, 
double-blind, placebo-controlled trial designed to assess the efficacy of daily oral 
supplementation with vitamin B12 (500 µg) and folic acid (400 µg) on fracture risk in 
mildly hyperhomocysteinemic (plasma homocysteine 12-50 µmol/l) older adults ≥65 
years. Details of this study have been reported elsewhere [13]. Data on 25(OH)D 
concentration were available of 2857 participants. Genetic information on vitamin D 
related genes was obtained from 2530 participants. Sun exposure was assessed 
in 1012 participants, and vitamin D intake in 596 participants. The Medical Ethics 
Committee of Wageningen UR approved the study protocol and the Medical Ethics 
Committees of VUmc and Erasmus MC confirmed local feasibility. All participants gave 
their written informed consent.
 
Dietary assessment
Dieticians at the division of Human Nutrition at Wageningen University developed 
a 190-item Food Frequency Questionnaire (FFQ) to measure vitamin D intake and 
vitamin D supplement use. The questionnaire was developed based on two validated 
FFQs [14, 15], which was updated to include vitamin D intake by means of the Dutch 
FFQ-TOOL™. Specifically, food items contributing to ≥0.1% of total vitamin D intake 
were included, which was estimated to cover 80% of total vitamin D intake based on 
the Dutch National Food Consumption Survey of 1998 [16]. 
 
Sunlight exposure
Habitual sunlight exposure was assessed using a questionnaire, which was 
administered on the day of blood sampling, thus throughout the year depending on 
date of inclusion. Data were collected on the amount of time spent outdoors and in the 
sun during summer, use of sun protection and solariums, type of clothing worn during 
summer, and holidays with a sunny destination during the past three months. 
 
Genotyping
DNA was isolated from buffy coats. Samples were genotyped for about 700,000 
SNPs using the Illumina Omni-express array, covering >90% of all common variations 
in the genome. SNPs selected for this study were based on a genome-wide association 
study on relations between genes and serum 25(OH)D concentrations, and included 
rs12785878 (DHCR7), rs6013897 (CYP24A1), rs10741657 (CYP2R1), and rs2282679 
(GC) [7].
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Biochemical analyses
Blood samples were drawn throughout the year, and always in the morning, when 
participants were fasting or had consumed a restricted breakfast. Samples were 
stored at -80 ˚C until determination. Measurement of serum 25(OH)D occurred by 
releasing it from its binding protein(s) and by adding a denaturised internal standard IS: 
25(OH)D3-d6. Subsequently, serum 25(OH)D was measured by isotope dilution-online 
solid phase extraction liquid chromatography-tandem mass spectrometry (ID-XLC-MS/
MS) [17]. Inter-assay coefficient of variation was 9% at a level of 25 nmol/L and 6% at 
a level of 62 nmol/l. Analyses were performed at the Endocrine Laboratory of the VU 
University Medical Centre. 
 
Covariates
Body height was measured at baseline with a stadiometer to the nearest 0.1 cm. Body 
weight was measured to the nearest 0.5 kg with a calibrated analogue scale, while 
wearing light clothes. Body Mass Index (BMI) was calculated as weight/height2. Data 
on educational level (years), smoking status (never, current, former), physical activity 
(kcal/day) [18], and alcohol consumption (no and light, moderate, high and excessive) 
[19] were collected by means of questionnaires. Self-rated health was obtained from the 
Short-Form Health Survey (SF-12) [20]. Season of blood collection was dichotomized 
into summer/autumn (June-November) and winter/spring (December-May) [21].
 
Statistical Analyses
Participants characteristics are reported as mean with standard deviation (SD), or 
percentages. To compare baseline characteristics of participants having inadequate 
serum 25(OH)D concentrations (<50 nmol/L) with participants having adequate 
serum 25(OH)D concentrations (≥50 nmol/L), chi-squared tests were performed for 
categorical variables and independent t-tests for continuous variables. To assess 
the association between total vitamin D intake and serum 25(OH)D status, multiple 
linear regression analyses were conducted with adjustment for age, sex, BMI, years of 
education, alcohol consumption, smoking, physical activity, and self-rated health status, 
and stratified by season. Stratification for season was applied as we assumed that the 
impact of vitamin D intake may be higher during winter/spring than during summer/
autumn, specifically larger effects of vitamin D supplementation are expected when 
25(OH)D concentrations are lower. Analysis of Covariance (ANCOVA) was used to 
explore associations between sunlight exposure variables and 25(OH)D status with 
adjustment for age, sex and BMI, and stratified by season. Associations between 
vitamin D related genetic make-up and 25(OH)D status were tested using ANOVA, 
stratified by season. In order to further investigate the importance of summer sunlight 
exposure, vitamin D intake, and genes for serum 25(OH)D concentrations all three 
factors were individually and simultaneously added to the multiple linear regression 
model, and age, sex, BMI, years of education, alcohol consumption, smoking, physical 
activity, and self-rated health status were included as covariates. As at higher latitudes 
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the impact of sun exposure on 25(OH)D status is expected to be small during winter/
spring, only data obtained during summer/autumn - and only for those with complete 
data of the determinants under study - were included in this model (n=185). Missing 
data were not imputed. All tests were two-sided (P<0.05). Analyses were performed 
using the statistical package SPSS, version 21.0 (SPSS Inc., Chicago, IL, USA). 
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RESULTS
Descriptive data of the population are shown in Table 2.1. In this population of older 
individuals, 45% had serum 25(OH)D concentrations <50 nmol/L, 28% had serum 
25(OH)D concentrations <40 nmol/L, and 14% had serum 25(OH)D concentrations 
<30 nmol/L. As expected, stratification for season showed that the prevalence of vitamin 
D deficiency was higher during the winter/spring (63%) than during the summer/autumn 
(37%). Participants with vitamin D deficiency were more likely to be women, older, have 
a higher BMI, have a lower vitamin D intake, and were more likely to be included during 
the winter/spring (P<0.0001). As depicted in Figure 2.1-A, a clear seasonal fluctuation 
in serum 25(OH)D was observed; Figure 2.1-B confirms the expected age-dependent 
differences in serum 25(OH)D.
 
Sunlight exposure
ANCOVA showed that all sunlight measures were significantly associated with 
serum 25(OH)D in participants who were enrolled during the summer/autumn months 
after adjustment for age, sex, and BMI, including “daily outside 2 weeks prior to blood 
sampling” (F633=5.6, P=0.02), “daily outside during summer” (F633=4.9, P=0.03), 
“clothing” (F621=19.5, P<0.0001), “sun holiday” (F631=18.9, P<0.0001), “sun lamps” 
(F628=13.6, P<0.0001), and “sun cream use” (F631=5.8, P<0.01) (Table 2.2) (n=1012). 
Associations for “daily outside 2 weeks prior to blood sampling” (F362=4.1, P=0.04) 
and “sun lamp use” (F360=11.0, P<0.01) with serum 25(OH)D were less strong, but still 
significant, in participants that were included during the winter/spring months. Other 
components were not significant anymore when participants were enrolled during the 
winter/spring months.
 
Vitamin D intake
Mean total vitamin D intake was 4.9 ± 2.9 µg per day. Vitamin D intake was significantly 
associated with serum 25(OH)D; stratification for season revealed that the association 
between vitamin D intake and 25(OH)D status was more pronounced during winter 
months (β 3.1 ± 0.8, P<0.0001) than during summer/autumn months (β 1.0 ± 0.4, 
P=0.02). These linear regression coefficients suggest that every µg increase in vitamin 
D intake increases serum 25(OH)D with about 3.1 nmol/L during winter/spring months 
and with 1.0 nmol/L during summer/autumn months. 
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Table 2.1 Descriptive statistics of 2857 Dutch men and women aged ≥65 years.
 
 
Figure 2.1 Serum 25(OH)D distribution (mean ± SEM) per month (A) and per age 
category (B) in Dutch men and women aged ≥65 years.
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 25(OH)D 
<50 nmol/L 
25(OH)D 
≥50 nmol/L 
P-value n 
25(OH)D, nmol/L 34 ± 10 74 ± 18 <0.0001 2857 
Age, years  75.1 ± 7.1 73.2 ± 5.9 <0.0001 2857 
Sex, n (% men) 597 (42) 831 (58) <0.0001 2857 
BMI, kg/m2 27.5 ± 4.3 26.8 ± 3.6 <0.0001 2842 
Physical activity level (kcal/day) 598 ± 440 691 ± 502 <0.0001 2842 
Years of education 9.8 ± 3.9 10.3 ± 4.0 0.11 2855 
Smoking 
   Never 
   Current 
   Former 
 
459 (36) 
142 (11) 
690 (53) 
 
510 (32) 
135 (9) 
921 (59) 
0.01 2857 
Alcohol consumption 
   Light 
   Moderate 
   Excessive 
 
925 (72) 
318 (25) 
46 (3) 
 
998 (64) 
505 (32) 
63 (4) 
<0.0001 2855 
Self-experienced health 
   Excellent 
   Very good 
   Good 
   Mediocre 
   Poor 
 
79 (6) 
230 (18) 
787 (61) 
183 (14) 
11 (1) 
 
130 (8) 
386 (25) 
874 (56) 
170 (11) 
5 (0) 
<0.0001 2855 
Blood sampling 
   December until May 
   June until November 
 
813 (63) 
478 (37) 
 
543 (35) 
1023 (65) 
<0.0001 2857 
Vitamin D supplement use, n (%) 174 (6) 411 (14) <0.0001 2857 
Total vitamin D intake, µg/day 4.2 ± 2.1 5.2 ± 3.2 <0.0001   596 
Vitamin D intake from foods, µg/day 4.0 ± 1.9 4.5 ± 2.1 0.002   596 
Values are expressed as mean ± SD, median (IQR), or n (%). 
 
 
 
 
Figure 2.1 Serum 25(OH)D distribution (mean ± SEM) per month (A) and per age category (B) in Dutch men and 
women aged ≥65 years. 
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Table 2.2 Associations between sun exposure and serum 25(OH)D of 1012 Dutch 
men and women aged ≥65 years stratified for season.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitamin D related genetic make-up
Vitamin D status varied significantly between allele carriers for all genes under study, 
except for the CYP24A1 gene (Figure 2.2). As expected, there were differences in 
25(OH)D concentrations between summer/autumn and winter/spring, but differences 
between alleles were comparable. The gene GC, which encodes for the protein related 
to vitamin D transport in the circulation, was most strongly associated with 25(OH)D 
status (P<0.0001), indicating that during summer/autumn, minor allele carriers have the 
lowest 25(OH)D concentrations (53 ± 20 nmol/L) and major allele carriers the highest 
25(OH)D concentrations (68 ± 25 nmol/L) (Figure 2.2). 
 
Sunlight, vitamin D intake and vitamin D related genetic make-up combined 
Finally, after considering individual associations of sunlight exposure, vitamin D 
intake, and vitamin D related genetic make-up with 25(OH)D concentrations, a multiple 
linear regression model was built using data of participants that were included during 
summer/autumn and had complete data of the determinants under study (n=185). 
Individually, vitamin D intake - while also taking into account age, sex, BMI, education, 
alcohol consumption, smoking, physical activity, and self-rated health status - explained 
24% of the variance in 25(OH)D status, sunlight exposure 29%, and genes 28%. All 
together these factors explained 35% of the variance in 25(OH)D status, as reflected 
by an R2 of 0.35 (adjusted R2: 0.27) (Table 2.3 and Figure 2.3). 
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 Summer/Autumn Winter/spring 
 25(OH)D  Fdf, P-value 25(OH)D  Fdf, P-value 
Daily outside 2 weeks before blood sampling 
   No 
   Yes 
 
58 ± 27 
66 ± 25 
F633=5.6, 0.02  
41 ± 19 
47 ± 21 
F362=4.1, 0.04 
Daily outside during summer  
   No 
   Yes 
 
57 ± 25 
66 ± 25 
F633=4.9, 0.03  
42 ± 20 
46 ± 21 
F359=1.0, 0.32 
Clothing 
   Long sleeved 
   Short sleeved 
 
51 ± 27 
66 ± 25 
F621=19.5, <0.0001 
 
 
42 ± 22 
47 ± 20 
F355=3.0, 0.09 
Sun holiday 3 months before blood sampling 
   No 
   Yes 
 
62 ± 25 
73 ± 23 
F631=18.9, <0.0001  
44 ± 21 
51 ± 18 
F358=4.0, 0.05 
Use of sunlamps 
   No 
   Yes 
 
64 ± 26 
78 ± 20 
F628=13.6, <0.0001  
44 ± 20 
59 ± 27 
F360=11.0, 0.01 
Sun cream use 
   Always 
   Sometimes 
   Never  
 
69 ± 24 
67 ± 26 
60 ± 25 
F631=5.8, <0.01  
51 ± 22 
45 ± 18 
43 ± 22 
F359=3.0, 0.05 
Serum 25(OH)D levels (nmol/L) are displayed as mean ± SD. Models are adjusted for age, sex, BMI.  
 
Vitamin D related genetic make-up 
Vitamin D status varied significantly between allele carriers for all genes under study, except for the 
CYP24A1 gene (Figure 2.2). As expected, there were differen es in 25(OH)D concentrations between 
summer/autumn and winter/spring, but differences between alleles were comparable. The gene GC, 
which encodes for the protein related to vitamin D transport in the circulation, was most strongly 
associated with 25(OH)D status (P<0.0001), indicating that during summer/autumn, minor allele 
carriers have the lowest 25(OH)D concentrations (53 ± 20 nm l/L) and major allel  carri rs the 
highest 25(OH)D concentrations (68 ± 25 nmol/L) (Figure 2.2).  
 
Sunlight, vitamin D intake, vitamin D related genetic make-up combined and serum 25(OH)  
Finally, after considering individual associations of sunlight exposure, vitamin D intake, and vitamin 
D related genetic make-up with 25(OH)D concentrations, a multiple linear regression model was built 
using data of participants that were included during summer/autumn and had complete data of the 
determinants nder study (n=185). Individually, vitamin D intake - while also taking into account age, 
sex, BMI, education, alcohol consumption, smoking, physical activity, and self-rated health status - 
explained 24% of the variance in 25(OH)D status, sunlight exposure 29%, and genes 28%. All 
together these factors explained 35% of the variance in 25(OH)D status, as reflected by an R2 of 0.35 
(adjusted R2: 0.27) (Table 2.3 and Figure 2.3).  
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Figure 2.2 Associations between vitamin D related genetic make-up and serum 
25(OH)D. 
Analyzed using ANOVA in 2530 Dutch men and women aged ≥65 years, stratified by season of blood sampling. 
A) Summer/autumn: Bonferroni post hoc tests indicate significant differences for DHCR7 [heterozygotes vs. 
major], CYP2R1 [minor vs. major], and GC [minor vs. heterozygotes, heterozygotes vs. major, minor vs. major]. 
B) Winter/spring: Bonferroni post hoc tests indicate significant differences for DHCR7 [minor vs. major], 
CYP2R1 [heterozygotes vs. major], and GC [minor vs. heterozygotes, heterozygotes vs. major, minor vs. major]. 
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Table 2.3 Estimates of the relative importance of vitamin D intake, sunlight exposure, 
and vitamin D related genetic make-up using data of Dutch men and women aged ≥65 
years that were included during the summer/autumn months (n=185).
 
 
 
Figure 2.3 Explained variance per component. 
 
Using data of the participants that were included during the summer/autumn months and had complete 
data of all determinants under study (n=185), adjusted for age, sex, BMI, years of education, alcohol 
consumption, smoking, physical activity, and self-rated health status.  
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 β  SE sβ  P-value 
(Constant) 147.7 34.1 - <0.0001 
CYP24A1 4.1 3.1 0.09 0.18 
GC  7.4 2.6 0.18 0.005 
DHCR7  2.5 2.9 0.06 0.39 
CYP2R1  -4.2 2.3 -0.12 0.07 
Outside past 2 weeks 15.6 6.2 0.24 0.01 
Outside past summer -9.2 6.5 -0.14 0.16 
Clothing worn 2.4 6.7 0.03 0.72 
Sun cream use -2.2 2.6 -0.06 0.41 
Sunlamp use 12.7 5.7 0.14 0.03 
Sun holiday 3.7 4.4 0.06 0.40 
Vitamin D intake 0.4 0.5 0.06 0.38 
Model was adjusted for age (sβ -0.21, P=0.003), sex (sβ -0.15, P=0.06), BMI (sβ -0.21, 
P=0.004), years of education (sβ -0.12, P=0.08), smoking (sβ -0.03, P=0.66), alcohol 
consumption (sβ 0.11, P=0.12), physical activity level (sβ 0.05, P=0.45), self-experienced 
health (sβ -0.09, P=0.24). sβ=standardized beta. 
 
 
 
Figure 2.3 Explained variance per component. 
Using data of the particip nts that were included d ring the 
summer/autumn months and had complete data of all determinants under 
study (n=185), adjusted for age, sex, BMI, years of education, alcohol 
consumption, smoking, physical activity, and self-rated health status.  
 
R2=0.29
adjR2=0.23
R2=0.35
adjR2=0.27
R2=0.24
adjR2=0.20
R2=0.28
adjR2=0.23
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DISCUSSION
In this Dutch community-dwelling older population, living at a latitude of 52˚N, 45% of 
the participants had 25(OH)D concentrations below 50 nmol/L. Total vitamin D intake 
was far below the recommended level of 20 µg/day as set by the Dutch Health Council 
for adults ≥70 years [22]; supplement use was reported by only 20% of the participants. 
Total vitamin D intake, sunlight exposure, and vitamin D related genetic make-up were 
all significantly associated with serum 25(OH)D. When exploring the contribution of the 
three factors to serum 25(OH)D status, vitamin D intake explained 24% of the variance, 
sunlight exposure 29%, and vitamin D related genetic make-up 28%. Including these 
three factors simultaneously, while accounting for other known relevant covariates, 
resulted in a 35% explained variance in serum 25(OH)D.
 
Methodological considerations
In order to appreciate these findings, several methodological issues of this study 
warrant further discussion. To the best of our knowledge, this is the first study examining 
the relative contribution of habitual sunlight exposure, vitamin D intake, and genetic 
make-up to the variation in serum 25(OH)D in a community-dwelling older population, 
while taking into account many potential important covariates. As participants were 
included throughout the year, we had the possibility to study the influence of sun 
exposure, vitamin D intake, and genetic make-up in association to serum 25(OH)D 
in winter/spring and summer/autumn. Unfortunately, we could not account for the 
potential role of diseases known to alter the absorption and metabolism of vitamin D. 
Another possible limitation is the use of a non-validated Food Frequency Questionnaire 
(FFQ). The FFQ used, however, was very detailed, composed using a validated method, 
and covered 80% of the total vitamin D intake according to the Dutch National Food 
Consumption Survey of 1998. In addition, our vitamin D intake data are in line with 
recent vitamin D intake data of this age group that were obtained from the Dutch Food 
Consumption Survey of 2013 [23]. This suggests that the reported vitamin D intake 
estimates were reasonably accurate. In both studies, however, vitamin D intake may be 
underestimated as evidence indicates that certain foods may contain 25(OH)D, while 
food consumption tables do not yet account for this [24]. Taking into account 25(OH)D 
in animal-based foods may result in vitamin D intake estimates that are about 1.7-2.9 µg/
day higher than current estimates [24]. Finally, the assessment of habitual sun exposure 
can be considered suboptimal, which probably resulted in an underestimation of the 
explained variation in 25(OH)D concentrations resulting from UV-B exposure. For 
instance, sunlight questions did not account for time of day at which a participant was 
exposed to sunlight, while it has been shown that during summer ultraviolet-B is most 
efficient in producing vitamin D3 between approximately 10 a.m. and 2 p.m. [25]. Using 
dosimeters might have resulted in more accurate UV-B exposure estimates [26]. 
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Vitamin D deficiency
The high prevalence of deficient 25(OH)D concentrations observed in this population 
is in line with reports on 25(OH)D deficiency in other countries [8, 9]. Serum 25(OH)D 
concentrations of 50 nmol/L or higher are considered sufficient in order to prevent 
disturbances in calcium metabolism [2]. Recent insights also indicate that 25(OH)D 
may relate to cardiovascular problems, glucose homeostasis, inflammation, muscle 
strength, and cognitive function [9, 27-30]; where future well-designed large RCTs are 
needed to establish whether these links are actually causal. Thus, the low 25(OH)D 
concentrations in this older population are alarming and more knowledge on the 
determinants of 25(OH)D may help to steer guidelines. 
 
Sunlight exposure and 25(OH)D concentrations
Despite the fact that the role of sunlight exposure to maintain serum 25(OH)D 
concentrations decreases with age [6], we observed significant associations between 
surrogate markers of habitual sun exposure and 25(OH)D status in this older population. 
This finding is in line with a study by Holick et al. (2007) that showed that exposing 
nursing home residents to 0.75 MED whole body exposure, using a tanning bed three 
times a week for five weeks, increased 25(OH)D concentrations up to 150% of its 
baseline concentration [25]. Interestingly, in our population, serum 25(OH)D was higher 
among participants reporting use of sun cream; Hyppönen and colleagues (2007) 
reported a similar finding when studying a nationwide cohort of British adults [21]. It 
may be that participants exposing themselves more abundantly to sunlight were more 
aware of their increased risk of for instance skin cancer and as such felt the necessity 
to use sun cream. As a result of their overall higher exposure to sunlight, these people 
were still the ones with the highest 25(OH)D concentrations. 
 
Vitamin D intake and 25(OH)D concentrations
Total vitamin D intake - including both dietary intake and supplement use - in this 
population was on average 4.9 ± 2.9 µg/day. Vitamin D supplement use was reported 
by 20% of the population of which 6% still had a 25(OH)D deficient status. Studies 
in southern European countries as well as Australia have reported vitamin D intakes 
ranging from 1.2 to 1.4 µg/day [31-33]. In Scandinavian countries, where vitamin D 
fortified products are more common, substantially higher vitamin D intake levels have 
been observed, ranging from 6 to 8 µg/day [34, 35]. The vitamin D intake in this 
Dutch population is far from adequate [22], which can be explained by the fact that 
the Dutch diet does not contain many foods that are naturally rich in vitamin D, and 
fortified products are hardly available. Therefore, Dutch men and women ≥70 years 
are recommended to use 20 µg vitamin D daily via supplements [22]. However, based 
on our data and data from the Dutch Food Consumption Survey 2013 [23], it can be 
concluded that compliance to this recommendation is low. This suggests that more 
actively promoting the vitamin D recommendation may be important to reduce the 
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prevalence of 25(OH)D deficiency, particularly during winter months. When analyzing 
the dose-response relation between vitamin D intake and serum 25(OH)D levels in this 
study, data suggested a 1.0 nmol/L (summer/autumn) and 3.1 nmol/L (winter/spring) 
increase in 25(OH)D status with every unit increase in vitamin D intake. This finding 
is in line with previous studies that showed that dietary vitamin D intake was positively 
associated with 25(OH)D status during winter, but not in summer [32, 35-37]. 
 
Vitamin D related genetic make-up and 25(OH)D concentrations
In this population, three out of four investigated genes in the pathway of vitamin D 
metabolism (i.e. DHCR7, CYP2R1, and GC) were significantly associated with serum 
25(OH)D concentrations. These results are in line with the findings of a large genome-
wide association study by Wang and colleagues [7], and several smaller studies [38-40]. 
Our data suggest that major allele carriers of the DHCR7 gene have higher 25(OH)D 
concentrations. DHCR7 encodes for the enzyme 7-dehydrocholesterol reductase. 
This enzyme catalyzes the conversion of 7-dehydrocholesterol into cholesterol in the 
skin, and thus prevents that 7-dehydrocholesterol is metabolized into vitamin D. The 
minor allele of CYP2R1 was associated with higher 25(OH)D concentrations. CYP2R1 
encodes for the hepatic enzyme 25-hydroxylase that converts vitamin D into 25(OH)D. 
Carriers of the major CYP24A1 and GC alleles were shown to have higher 25(OH)D 
concentrations. CYP24A1 encodes for an enzyme that initiates the degradation of 
25(OH)D and 1,25(OH)D into calcitroic acid. GC is the major transport protein of 
vitamin D metabolites, such as 25(OH)D, to different target organs, tissues and cells 
[7]. 
 
Important determinants of serum 25(OH)D 
Previous estimations indicate that sunlight accounts for 70-90% of the 25(OH)D 
supply of the body [4]. In this study, habitual summer sun exposure also explained most 
of the variance (29%) in serum 25(OH)D, closely followed by genetic make-up (28%), 
and vitamin D intake (24%), while taking into account other relevant covariates. Larger 
differences were expected regarding the importance of sun exposure and vitamin D 
intake. Assessing sun exposure habits, however, is challenging and measurement 
error is very likely to have occurred. The three factors, together with potential relevant 
covariates, explained 35% of the variance in serum 25(OH)D. When extending our 
findings to other studies that also calculated R2 in order to identify determinants of 
serum 25(OH)D, we conclude that there are substantial differences with respect to 
predictors included in the models. To the best of our knowledge, this is the first study 
taking into account genetic factors in a population of community dwelling seniors. The 
explained variance in 25(OH)D status of our final model is in line with a comparable study 
in postmenopausal women, published by Engelman and colleagues, who accounted 
for 29% of the variation in the model when taking into account vitamin D intake, waist 
circumference, season, self-reported sun exposure, cholesterol, and genetic profile 
[41]. On the other hand Gilbert and colleagues did consider taking genetic information 
Sun, vitamin D intake, genes and vitamin D status
CHAPTER 2
41
into account, but concluded that this information did not improve the fit of the 
prediction score in their data, which explained 28% of the variation in 25(OH)D when 
sun exposure, vitamin D intake, anthropometrics, clinical factors, demographics, age, 
season, study center, and batch assay were included in the model [42]. Other previous 
studies that included vitamin D intake, a measure of UV-B exposure, demographic, 
and environmental factors have explained between 21 up to 33% of the variation in 
25(OH)D status [33, 43, 44]. Studies considering vitamin D intake, demographic and 
environmental factors and season of blood sampling have shown an explained variation 
in 25(OH)D ranging from 19-28% [45-47]. All in all, based up on the current literature, 
our data do suggest that taking genetic factors into account does contribute to a better 
understanding of the variance in 25(OH)D concentrations.
 
Conclusion
In summary, the findings of this study acknowledge the previously reported inadequate 
vitamin D intake and the relatively high prevalence of 25(OH)D deficiency in the older 
population. Moreover, it was shown that UV-B exposure, vitamin D intake and vitamin 
D-related genetic make-up all substantially contribute to the variability in 25(OH)D 
concentrations. The high prevalence of vitamin D deficiency as well as the low intake 
of vitamin D supplements imply that more effort should be undertaken to encourage 
the use of vitamin D supplements in order to optimize the 25(OH)D concentrations 
in the Dutch older population. Moreover, given the suggested importance of genes 
involved in vitamin D metabolism, in combination with the on-going question on whether 
the associations found between 25(OH)D concentrations and non-skeletal health are 
causal [28-30, 48], these results plea for studies examining associations between 
vitamin D related genetic make-up and the health outcomes under debate, and large 
well-designed RCTs in populations with low vitamin D concentrations. 
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ABSTRACT
Background & aims: Various populations are at increased risk of developing a low 
vitamin D status, in particular older adults. Whereas sun exposure is considered the 
main source of vitamin D, especially during summer, dietary contributions should not 
be underestimated. This study aims to identify food sources of vitamin D that associate 
most strongly with serum vitamin D concentration. 
Methods: Data of 595 Dutch adults, aged ≥65 years, were analysed. Vitamin D intake 
was assessed with a food frequency questionnaire and 25-hydroxyvitamin D (25(OH)
D) was determined in serum. Associations of total vitamin D intake and vitamin D intake 
from specific food groups with serum 25(OH)D status were examined by P-for trend 
analyses over tertiles of vitamin D intake, prevalence ratios (PRs), and spline regression. 
Results: The prevalence of vitamin D deficiency was high, with 36% of the 
participants having a 25(OH)D status <50 nmol/L. Participants with adequate 25(OH)
D concentrations were more likely to be men and more likely to be younger than 
participants with vitamin D deficiency. Total median vitamin D intake was 4.3 µg/day, 
of which 4.0 µg/day was provided by foods. Butter and margarine were the leading 
contributors to total vitamin D intake with 1.8 µg/day, followed by the intake of fish and 
shellfish with 0.56 µg/day. Participants with higher intakes of butter and margarine were 
21% more likely to have a sufficient 25(OH)D status after adjustment for covariates 
(T1 vs. T3: PR 1.0 vs. 1.21 (95% CI: 1.03-1.42), P-for trend 0.02). None of the other 
food groups showed a significant association with the probability of having a sufficient 
25(OH)D status. 
Conclusion: This study shows that vitamin D intake was positively associated with total 
serum 25(OH)D concentration, with butter and margarine being the most important 
contributors to total vitamin D intake. 
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INTRODUCTION
Various populations are at increased risk of developing a low vitamin D status, in 
particular older adults [1]. Recent studies show adverse associations between 
25-hydroxyvitamin D (25(OH)D) deficiency and a broad range of health outcomes, 
e.g. cardiovascular and autoimmune function, neuropsychiatric health, diabetes and 
muscle function [2]. While more studies are needed to investigate the causality of 
these vitamin D-health associations, the effect on bone homeostasis is considered 
established [3]. Based on these classical effects of vitamin D on bone health, current 
dietary guidelines emphasize the need to prevent low serum 25(OH)D concentrations. 
Although vitamin D is primarily synthesized after sun exposure, particularly during 
summer months [4], dietary vitamin D intake can significantly contribute to higher 
serum 25(OH)D concentrations [5-8]. As such, the Institute of Medicine (IOM) and 
the Health Council of the Netherlands recommend a vitamin D intake between 10-20 
µg/day to maintain serum 25(OH)D levels above a target value of 50 nmol/L [9, 10]. 
Vitamin D can be obtained as ergocalciferol (vitamin D2) and cholecalciferol (vitamin 
D3). Limited amounts of ergocalciferol are obtained via UV-irradiated mushrooms, 
milk, and butter [11, 12]. Cholecalciferol is mainly obtained from fatty fish (e.g. salmon, 
mackerel, herring) and in lesser quantities via meat, egg yolks, milk and butter [13]. 
Nevertheless, dietary vitamin D intakes are far below the recommended reference 
intake in many countries [14-16]. To prevent these observed low dietary intakes, several 
countries fortify specific foods with vitamin D. Fortification of milk products in the USA, 
and the fortification of milk and fat spreads in Canada are mandatory [17]. In addition, 
many countries also fortify other foods, such as cereals and fruit juices. In Europe, 
fortification policies differ between countries, where fat spreads and some cereals 
are the most commonly fortified products; milk fortification is not customary, with the 
exception of Finland, Norway and Sweden [18]. Currently, in the Netherlands, vitamin 
D food fortification is not common practice, with the exception of margarines. Vitamin 
D intake data from the Dutch National Food Consumption Survey (DNFCS) published 
in 2013 show mean vitamin D intakes of 4.1 µg/day in a population ≥70 years [19]. This 
average is far below the current dietary recommendation for the older adults and while 
specific supplementation advice is in order, only 22% of the older adults reports to use 
a vitamin D supplement [19]. Therefore, the importance of an adequate dietary intake 
should not be underestimated, especially in case of modest vitamin D inadequacy. For 
that reason, the aims of this study were I) to investigate which food source contributes 
most to total vitamin D intake, and II) to examine which food source contributes most to 
higher serum 25(OH)D status and adequacy in older Dutch adults.
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METHODS
 
Study population
Cross-sectional analyses were conducted using baseline data of the B-PROOF study, 
which is a multi-center, placebo-controlled, double-blind, randomized trial performed by 
three study centers in the Netherlands (Wageningen University, Erasmus MC and VUmc). 
The primary aim of this study was to investigate the effect of supplementation with folic 
acid and vitamin B-12 to prevent osteoporotic fractures in mildly hyperhomocysteinemic 
adults, aged 65 years or older. Participants were recruited between August 2008 and 
March 2011. Main exclusion criteria were: a low or high plasma homocysteine status 
(<12 µmol/L or >50 µmol/L), the use of vitamin-B supplements or injections in the 
past 4 months, being diagnosed with cancer in the past 5 years, renal dysfunction 
or being bed bound. Dietary intake was only measured in the Wageningen cohort of 
which reliable data on vitamin D intake and 25(OH)D status were available for 595 
participants. More specific information on the research protocol and study population 
have been described elsewhere [20]. The study protocol was approved by the Medical 
Ethics Committees of Wageningen UR and VUmc and the medical ethics committee 
of Erasmus MC confirmed local feasibility. All participants gave their written informed 
consent. The study was registered at ClinicalTrials.gov as NCT00696514 since June 
9, 2008.
 
Dietary assessment
To estimate dietary vitamin D intake, an extensive Food Frequency Questionnaire 
(FFQ) was used of which the methods are previously described [21]. FFQ food items 
were categorized as total vitamin D intake, and the vitamin D intake from meat, fish and 
shellfish, eggs, butter and margarine, total dairy, and dairy subgroups i.e. milk, yogurt, 
cheese. In addition, the FFQ included questions on vitamin D supplement use, and the 
type, dose and frequency of the supplement.
 
Biochemical analyses
Blood was drawn in the morning and participants were requested to remain fasted 
or only take a light breakfast (according provided instructions). Serum 25(OH)D 
concentrations were analyzed by tandem mass spectrometry (ID-XLC-MS/MS) at the 
VU University Medical Centre [22]. Inter-assay coefficient of variation was 9 and 6% at 
a serum 25(OH)D level of 25 and 62 nmol/L, respectively. 
 
Covariates
Weight was measured with a calibrated analogue scale to the nearest 0.5 kg. Height 
was measured to the nearest 0.1 cm, using a stadiometer. Body Mass Index (BMI) was 
reported as kg/m2. Furthermore, each participant filled out a questionnaire to report 
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data on education level (primary, secondary, higher), smoking (non, current, former), 
alcohol intake (light, moderate, excessive) [23], and physical activity (min/day) [24]. 
Date of blood collection was used to define a covariate for season (summer: June-
November and winter: December-May).
 
Data analyses 
General characteristics and dietary intake of the population are presented as mean 
(SD), median (25-75th percentile) or n (%) by subgroups. Subgroups were created 
based on serum 25(OH)D status (inadequate <50 nmol/L versus adequate ≥50 
nmol/L) and age (<70 versus ≥70 years). Potential differences between subgroups 
were tested by ANOVA or Kruskal-Wallis test in case of continuous variables or the 
Chi-square test in case of categorical variables. ANCOVA analyses were used to 
calculate adjusted means (95% CI) per tertile of vitamin D intake from the total diet and 
specific food categories. P-for trend analysis was performed to analyze the association 
between vitamin D intake and serum 25(OH)D status across these tertiles. Additionally, 
Prevalence Ratios (PR) for serum 25(OH)D levels ≥50 nmol/L were determined by Cox 
proportional hazards regression with robust error variance and tertile 1 as a reference 
group. The hazard ratio obtained from this analysis is presented as a PR because a 
constant risk period was assigned to all study subjects [25]. All models were adjusted 
for appropriate covariates. The PRs were further investigated by restricted cubic spline 
regression, with knots set at the 1st, 5th and 9th decile of intake. Analyses were executed 
using SAS, version 9.2 statistical software (SAS Institute Inc., Cary, NC, USA) and a 
P-value of ≤0.05 (two-sided) was determined to be statistically significant. 
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RESULTS
Table 3.1 presents the participant characteristics of the study population. The mean 
age of the total study population was 72 ± 5 years and 58% were men. Mean (SD) 
BMI was 26.9 ± 3.6 kg/m2, serum 25(OH)D was 61 ± 26 nmol/L, and 40% of the 
participants were included during winter/spring. Participants with an adequate serum 
25(OH)D concentration (64%) were more likely to be men (62% versus 52%) and more 
likely to be younger (71 ± 5 versus 73 ± 6 years), compared to participants with an 
inadequate serum 25(OH)D status (<50 nmol/L). Participants included in the higher 
age category (≥70 years) had significantly lower serum 25(OH)D concentrations (59 ± 
25 versus 64 ± 27 nmol/L) compared to those in the younger age category (<70 years). 
Table 3.2 describes the dietary intake of the total study population stratified by serum 
25(OH)D status and age. The study population had a mean fat intake of 36 ± 6 En%, 
protein intake of 15 ± 2, carbohydrate intake of 44 ± 7, and fiber intake of 24 ± 7 (data 
not shown in tables). Total median (25-75th percentile) vitamin D intake was 4.3 (3.2-
5.8) µg/day, of which 4.0 (3.0-5.4) µg/day from foods. When the different food sources 
of vitamin D were examined, butter and margarine were the main contributors to total 
dietary vitamin D intake, with a median of 1.8 (0.9-2.9) µg/day (comprising 45% of dietary 
vitamin D intake). Fish and shellfish intake was the second most contributing dietary 
vitamin D source, with a median intake of 0.56 (0.22-1.04) µg/day, followed by meat 
intake, with a median intake of 0.40 (0.27-0.52) µg/day. Furthermore, participants with 
adequate serum 25(OH)D concentrations (≥50 nmol/L) had significantly higher vitamin 
D intakes compared to participants with inadequate serum 25(OH)D concentrations 
(<50 nmol/L), with a median vitamin D intake of 4.7 (3.4-6.3) versus 3.8 (3.0-5.2) µg/
day. No significant differences were observed between age categories in total vitamin 
D intake or supplement use. 
Table 3.3 and Table 3.4 show the associations of serum 25(OH)D concentrations 
by tertiles of total vitamin D intake or intake from specific food sources. A significant 
association was observed between total vitamin D intake and serum 25(OH)D status, 
with a 10 nmol/L difference in serum 25(OH)D concentration between the lowest 
(<3.55 µg/day) and highest (≥5.32 µg/day) tertile of vitamin D intake (Table 3.3). In 
line with the data indicating butter and margarine as the main contributors to vitamin D 
intake, these data show that there is also a significant association between butter and 
margarine and serum 25(OH)D status. Participants with higher butter and margarine 
intakes (T1 vs. T3: PR 1.0 vs. 1.21 (95%CI: 1.03-1.42), P-for trend 0.02) have a 21% 
higher probability of having an adequate serum 25(OH)D status after adjustment for 
covariates, compared to participants with lower butter and margarine intakes (Table 
3.4). Associations between total vitamin D intake from foods and vitamin D intake from 
55CHAPTER 3
Food sources of vitamin D and vitamin D status
butter and margarine (modelled continuously) with 25(OH)D adequacy (<50 vs. ≥50 
nmol/L) are visualized in Figure 3.1. None of the other vitamin D-food sources were 
significantly associated with 25(OH)D status. 
 
Table 3.1 Participant characteristics (n=595).
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 Total 25(OH)D  Age 
  <50 nmol/L ≥50 nmol/L <70 years ≥70 years 
N 595 212 383 225 370 
Sex, n men (%)  346 (58) 110 (52) 236 (62)# 132 (59) 214 (58) 
Age, years 72 ± 5 73 ± 6 71 ± 5# 67 ± 2 75 ± 4# 
BMI, kg/m2 26.9 ± 3.6 26.9 ± 3.9 26.9 ± 3.4 26.9 ± 3.7 26.9 ± 3.6 
Education, n (%) 
   Primary 251 (42) 99 (47) 152 (40) 94 (42) 157 (42) 
   Secondary 144 (24) 52 (25) 92 (24) 56 (25) 88 (24) 
   Higher 200 (34) 61 (29) 139 (36) 75 (33) 125 (34) 
Smoking, n (%) 
   Non-smoker 184 (31) 61 (29) 123 (32) 76 (34) 108 (29) 
   Smoker 62 (10) 27 (13) 35 (9) 27 (12) 35 (10) 
   Former    
   Smoker 
349 (59) 124 (58) 225 (59) 122 (54) 227 (61) 
Alcohol intake, n (%) 
   Light 379 (64) 156 (74) 223 (58)# 135 (60) 244 (66) 
   Moderate   198 (33) 48 (23) 150 (39) 80 (36) 118 (32) 
   Excessive  18 (3) 8 (4) 10 (3) 10 (4) 8 (2) 
Physical activity, min/day 128  
(84-193) 
123  
(83-193) 
131  
(85-193) 
127  
(81-194) 
129  
(85-191) 
Serum 25(OH)D, nmol/L 61 ± 26 35 ± 11 75 ± 20# 64 ± 27 59 ± 25# 
Winter/Spring, n (%) 235 (40) 114 (54) 121 (32) 74 (33) 161 (44) 
BMI, Body Mass Index; 25(OH)D, 25-hydroxyvitamin D. Values represent mean ± SD, or medians (25-
75th percentile). #Significant difference between groups P≤0.05. 
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Table 3.2 Total vitamin D intake and vitamin D intake from specific food sources in a 
population of older Dutch adults (n=595).
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 Total 25(OH)D  Age 
  <50 nmol/L ≥50 nmol/L <70 years ≥70 years 
N  595 212 383 225 370 
Energy intake, kcal/day 2005 ± 475 1933 ± 425 2044 ± 496# 2016 ± 452 1998 ± 488 
Total vitamin D intake, 
µg/day 
4.3 (3.2-5.8) 3.8 (3.0-5.2) 4.7 (3.4-6.3)# 4.3 (3.0-5.9) 4.4 (3.3-5.8) 
Vitamin D supplements, 
µg/day 
0 (0-0)  0 (0-0) 0 (0-0)  0 (0-0) 0 (0-0) 
 
Vitamin D from food sources 
Total foods, µg/day 4.0 (3.0-5.4) 3.7 (2.8-4.8) 4.3 (3.0-5.7)# 3.9 (2.8-5.5) 4.1 (3.1-5.3) 
Meat, µg/day 0.40  
(0.27-0.52) 
0.38  
(0.25-0.49) 
0.42  
(0.28-0.53)# 
0.43  
(0.29-0.54) 
0.39  
(0.26-0.51)# 
Fish and shellfish, µg/day 0.56  
(0.22-1.04) 
0.52  
(0.16-0.97) 
0.58  
(0.28-1.06) 
0.58  
(0.26-1.11) 
0.56  
(0.19-1.01) 
Eggs, µg/day 0.25  
(0.13-0.25) 
0.25  
(0.13-0.25) 
0.25  
(0.13-0.38)# 
0.25  
(0.13-0.25) 
0.25 
(0.13-0.38) 
Dairy, µg/day 0.29  
(0.20-0.41) 
0.29  
(0.18-0.41) 
0.29  
(0.20-0.41) 
0.31  
(0.20-0.41) 
0.27  
(0.18-0.41) 
   Milk, µg/day 0.04  
(0.01-0.09) 
0.04  
(0.01-0.08) 
0.04  
(0.02-0.09) 
0.04  
(0.02-0.08) 
0.04  
(0.01-0.09) 
   Yogurt, µg/day 0.02  
(0.00-0.05) 
0.01  
(0.00-0.05) 
0.02  
(0.00-0.05) 
0.02  
(0.00-0.05) 
0.02  
(0.00-0.05) 
   Cheese, µg/day 0.14  
(0.09-0.24) 
0.14  
(0.08-0.21) 
0.15  
(0.09-0.24) 
0.16  
(0.10-0.25) 
0.14  
(0.08-0.22)# 
Butter and margarine, 
µg/day 
1.8  
(0.9-2.9) 
1.6  
(0.7-2.6) 
1.9  
(1.0-3.1)# 
1.7  
(0.8-2.9) 
1.8  
(0.9-2.8) 
Values represent mean ± SD, or medians (25-75th percentile). #Significant difference between groups P≤0.05.  
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Table 3.3 The association between vitamin D intake from different food sources and 
serum 25-hydroxyvitamin D status in older Dutch adults.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52	
	
 
 
Tertile 1 Tertile 2 Tertile 3 P for trend 
Total vitamin D intake, µg/day <3.55 3.55-5.31 ≥5.32  
   Serum 25(OH)D, nmol/L 57 (48 ; 65) 61 (53 ; 69) 67 (59 ; 76) 0.0004 
Meat  
   Total intake, g/day 44 ± 23 88 ± 16 122 ± 26  
   Vitamin D intake, µg/day <0.32 0.32-0.47 ≥0.48  
   Serum 25(OH)D, nmol/L 60 (52 ; 69) 61 (53 ; 69) 62 (54 ; 71) 0.73 
Fish and shellfish 
   Total intake, g/day 5 ± 6 14 ± 5 33 ± 24  
   Vitamin D intake, µg/day <0.34 0.34-0.83 ≥0.84  
   Serum 25(OH)D, nmol/L 59 (50 ; 67) 63 (54 ; 71) 63 (54 ; 71) 0.17 
Eggs 
   Total intake, g/day 3 ± 2 11 ± 3 33 ± 16  
   Vitamin D intake , µg/day <0.13 0.13-0.24 ≥0.25  
   Serum 25(OH)D, nmol/L 61 (52 ; 69) 61 (53 ; 69) 61 (52 ; 70) 0.66 
Dairy     
   Total intake, g/day 251 ± 147 342 ± 151 402 ± 176  
   Vitamin D intake, µg/day <0.23 0.23-0.36 ≥0.36  
   Serum 25(OH)D, nmol/L 61 (53 ; 70) 63 (55 ; 71) 59 (51 ; 68) 0.32 
Milk 
   Total intake, g/day 65 ± 100 146 ± 90 294 ± 123  
   Vitamin D intake , µg/day <0.02 0.02-0.05 ≥0.06  
   Serum 25(OH)D, nmol/L 62 (53 ; 70) 61 (52 ; 69) 62 (53 ; 70) 0.89 
Yogurt 
   Total intake, g/day 66 ± 75 77 ± 71 160 ± 87  
   Vitamin D intake, µg/day 0 0.01-0.03 ≥0.04  
   Serum 25(OH), nmol/L 58 (50 ; 66) 64 (56 ; 73) 64 (56 ; 73) 0.02 
Cheese 
   Total intake, g/day 16 ± 10 31 ± 10 62 ± 26  
   Vitamin D intake, µg/day <0.11 0.11-0.19 ≥0.20  
   Serum 25(OH)D, nmol/L 60 (62 ; 69) 62 (53 ; 70) 62 (54 ; 70) 0.84 
Butter and margarine 
   Total intake, g/day 13 ± 11 27 ± 16 47 ± 15  
   Vitamin D intake, µg/day <1.16 1.16-2.50 ≥2.51  
   Serum 25(OH)D, nmol/L 58 (50 ; 66) 59 (51 ; 68) 66 (57 ; 74) 0.01 
25(OH)D, 25-hydroxyvitamin D. Values represent adjusted means (95% CIs) calculated by ANCOVA, 
adjusted for age, sex, BMI, smoking, alcohol intake, education, physical activity level, season, energy intake 
and vitamin D intake from other food categories. Values for total food group intakes represent mean ± SD.  
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Table 3.4 Prevalence ratios (95% CIs) for vitamin D adequacy (25(OH)D ≥50 nmol/L) 
by tertiles of vitamin D food sources.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
53	
	
 25-hydroxyvitamin D ≥50 nmol/L (n=383) 
Food sources of vitamin D Model 1 Model 2 Model 3 
Total vitamin D intake, µg/day 
   <3.55 1 (ref) 1 (ref) 1 (ref) 
   3.55-5.31 1.14 (0.96-1.34) 1.13 (0.97-1.32) 1.13 (0.97-1.32) 
   ≥5.32 1.35 (1.16-1.57) 1.31 (1.13-1.52) 1.31 (1.13-1.52) 
   P for trend <0.0001 0.0002 0.0004 
Vitamin D intake from meat, µg/day 
   <0.32 1 (ref) 1 (ref) 1 (ref) 
   0.32-0.47 0.98 (0.84-1.15) 1.01 (0.87-1.18) 0.98 (0.83-1.14) 
   ≥0.48 1.13 (0.98-1.31) 1.14 (0.99-1.32) 1.09 (0.94-1.27) 
   P for trend 0.08 0.06 0.23 
Vitamin D intake from fish and shellfish, µg/day 
   <0.34 1 (ref) 1 (ref) 1 (ref) 
   0.34-0.83 1.06 (0.92-1.24) 1.02 (0.88-1.18) 1.03 (0.89-1.20) 
   ≥0.84 1.10 (0.95-1.28) 1.05 (0.91-1.22) 1.06 (0.92-1.23) 
   P for trend  0.20 0.50 0.42 
Vitamin D intake from eggs, µg/day 
   <0.13 1 (ref) 1 (ref) 1 (ref) 
   0.13-0.24 1.14 (0.96-1.36) 1.09 (0.92-1.29) 1.08 (0.91-1.27) 
   ≥0.25 1.17 (0.96-1.41) 1.11 (0.92-1.35) 1.11 (0.92-1.34) 
   P for trend 0.15 0.31 0.31 
Vitamin D intake from dairy, µg/day 
   <0.23 1 (ref) 1 (ref) 1 (ref) 
   0.23-0.36 1.01 (0.88-1.17) 1.00 (0.87-1.15) 1.00 (0.86-1.16) 
   ≥0.36 1.00 (0.87-1.16) 0.99 (0.85-1.14) 0.96 (0.82-1.13) 
   P for trend 0.98 0.95 0.88 
Vitamin D intake from milk, µg/day 
   <0.02 1 (ref) 1 (ref) 1 (ref) 
   0.02-0.05 1.00 (0.87-1.16) 1.03 (0.89-1.18) 1.01 (0.88-1.17) 
   ≥0.06 1.02 (0.88-1.18) 1.04 (0.91-1.19) 1.02 (0.88-1.17) 
   P for trend 0.79 0.58 0.83 
Vitamin D intake from yogurt, µg/day 
   0 1 (ref) 1 (ref) 1 (ref) 
   0.01-0.03 1.11 (0.96-1.29) 1.13 (0.98-1.30) 1.13 (0.98-1.30) 
   ≥0.04 1.12 (0.96-1.29) 1.12 (0.97-1.29) 1.14 (0.98-1.31) 
   P for trend  0.19 0.17 0.12 
Vitamin D intake from cheese, µg/day 
   <0.11 1 (ref) 1 (ref) 1 (ref) 
   0.11-0.19 1.02 (0.88-1.18) 1.01 (0.87-1.17) 1.01 (0.87-1.17) 
   ≥0.20 1.05 (0.91-1.22) 1.01 (0.88-1.16) 1.01 (0.87-1.17) 
   P for trend 0.46 0.93 0.93 
Vitamin D intake from butter and margarine, µg/day 
   <1.16 1 (ref) 1 (ref) 1 (ref) 
   1.16-2.50 1.09 (0.93-1.27) 1.09 (0.93-1.27) 1.08 (0.93-1.26) 
   ≥2.51 1.20 (1.03-1.39) 1.22 (1.05-1.42) 1.21 (1.03-1.42) 
   P for trend 0.02 0.007 0.02 
Model 1:  incl. covariates for age and sex. Model 2: incl. covariates of model 1 plus BMI, smoking alcohol 
intake, education, physical activity level, and season. Model 3: incl. covariates of model 1 and 2 plus energy 
intake and vitamin D intake from other food categories. 
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Figure 3.1 Associations between vitamin D-intake and serum 25-hydroxyvitamin D 
concentrations ≥50 nmol/L (i.e. defined as adequate vitamin D status). 
 
Graphs represent Prevalence Ratios incl. 95% CIs. Models incl. covariates for age, sex, BMI, smoking, 
alcohol intake, education, physical activity level, season, energy intake and vitamin D intake from other food 
categories. A: P for non-linearity 0.37. B: P for non-linearity 0.59.
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DISCUSSION
Our analyses showed that mainly butter and margarine contributed to the total vitamin 
D intake in this Dutch community-dwelling older population. Fish and shellfish intake 
was the second most important contributor to the total vitamin D intake, although 
comprising less than half the amount of vitamin D obtained from butter and margarine. 
Both total vitamin D intake as well as vitamin D intake from butter and margarine were 
positively associated with higher serum 25(OH)D concentrations after full adjustment 
for potential covariates. 
Several methodological considerations should be addressed before further 
discussing these findings. Although the FFQ used in this study was not validated to 
estimate vitamin D intake, the method to compose the FFQ was validated [26, 27]. As 
our estimated vitamin D intakes are in agreement with data obtained by two 24-hour 
recalls of the Dutch Food Consumption Survey 2013, we assume an accurate estimate 
of total vitamin D intake [19]. A strength of our study includes the opportunity to not only 
analyze intake data, but also to link these data to serum 25(OH)D concentrations, while 
accounting for a broad set of potential covariates.
This study shows a high prevalence of inadequate vitamin D intake (median intake: 4.3 
µg/day) in older Dutch adults. Of the total vitamin D intake reported in this study, 4.0 µg/
day originated from the diet. This daily intake is intermediate in comparison to the intake 
of European countries, with intakes ranging between 2-15 µg/day [28]. The NHANES 
cohort showed total vitamin D intakes of 10.7 µg/day and 10.0 µg/day in American 
men and women aged >71y, respectively [29]. When vitamin D from supplements was 
excluded, mean vitamin D intakes were still higher compared to our population, that is 
4.5 µg/day in women and 5.6 µg/day in men. Additionally, a Canadian cross-sectional 
study showed total vitamin D intakes of 8.2 µg/day and 13.6 µg/day in men and women, 
respectively [30]. Also in this study, higher vitamin D intakes predominantly related to 
higher supplemental vitamin D intakes. Specifically, supplements accounted for 56% 
of the total vitamin D intake, with 45% of women and 17% of men using a supplement. 
In our study population, only 12% of the population used a vitamin D supplement. 
Moreover, higher vitamin D intakes in the US and Canada may also be explained by 
higher intakes of fortified products. In the US and Canada, dairy products, especially 
fortified milk, are considered the main food source of vitamin D intake, followed by meat 
and fish [30-32]. 
Despite relatively low vitamin D intakes in our population total vitamin D intake was 
significantly associated with vitamin D status. Our data also indicated that butters 
or margarines are the most important sources to increase serum 25(OH)D status. 
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Participants in the highest tertile of butter and margarine intake, representing an intake 
of 47 g/day (equalling 4 sandwiches with fat spread), had a 21% higher probability 
of having a sufficient vitamin D status. Although fish intake was the second major 
contributor to dietary vitamin D intake, higher fish intake was not significantly associated 
with higher serum 25(OH)D levels. A recent meta-analysis published by Lehman et 
al. investigated the effect of fish intake on serum 25(OH)D concentrations [33]. The 
authors showed that the consumption of ± 300 g fish/week over a period of at least 4 
weeks, was associated with a significant increase in serum 25(OH)D concentrations. 
The non-significant association observed in this study may relate to the relatively low 
intake of fish in this study group (median 13 (25 -75th percentile: 7-21) g fish/day).
In the presence of adequate cutaneous vitamin D synthesis, adequate vitamin D 
supplement intake, and consumption of fortified foods, the importance of vitamin D 
intake from foods is likely to be diminished. However, according to our data, the use 
of supplements and fortified products is limited among older Dutch adults. As such, 
the total vitamin D intake lies far below the Dutch dietary reference value, currently 
set at an Adequate Intake (AI) of 10 µg/day for adults <70 years, and Recommended 
Dietary Allowance (RDA) of 20 µg/day for adults ≥70 years (based on the assumption 
of insufficient sunlight exposure) [9]. In our population, only 4 participants consumed at 
least 10µg vitamin D day. Since 2007, the Dutch commodities act allows the addition 
of vitamin D to food products other than margarine (to 4.5 µg/100 kcal of product). 
However, food fortification is currently hardly practiced. A recent report by the National 
Institute for Public Health and the Environment (RIVM) shows that the fortification 
strategies in the Netherlands could be optimized without exceeding the tolerable upper 
intake level in the general Dutch population [34]. The scenario analysis indicated that the 
Dietary Reference Intake (DRI) could be met by >80% of the older Dutch adults when 5 
µg of vitamin D would be added per 100 g of milk or yogurt, and 25 µg would be added 
per 100 g of margarines. Thus, food fortification in combination with the promotion of 
vitamin D supplement use may substantially improve the 25(OH)D status in older Dutch 
adults. However, as shown by our data, regular intake of foods high in vitamin D could 
also support an increase in vitamin D status across the general population, particularly 
in case of modest 25(OH)D insufficiency. Also the observed low fish/shellfish intake 
shows room for improving the dietary vitamin D intake. Nevertheless, for the older 
adults with more severe 25(OH)D deficiency, the habitual diet will not suffice in the total 
amount of vitamin D needed to meet the recommendations. Therefore, policies should 
focus on health messages regarding food fortification and vitamin D supplementation 
specifically targeted to this age group.
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ABSTRACT
Background & aims: Oral supplementation with vitamin D is recommended for older 
adults to maintain a sufficient 25-hydroxyvitamin D (25(OH)D) status throughout the 
year. While supplementation with vitamin D2 or D3 is most common, alternative treatment 
regimens exist which require further investigation with respect to increasing 25(OH)D 
concentration. We investigated the dose-response effects of supplementation with 
calcifediol compared to vitamin D3 and assessed the dose which results in mean serum 
25(OH)D3 concentrations between 75–100 nmol/L.
Methods: This randomized, double-blind intervention study included men and women 
aged ≥65 years (n=59). Participants received either 5, 10 or 15 µg calcifediol or 20 
µg vitamin D3 per day, for a period of 24 weeks. Blood samples were collected every 
four weeks to assess response profiles of vitamin D related metabolites; serum vitamin 
D3, 25(OH)D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 24,25-dihydroxyvitamin 
D3 (24,25(OH)2D3). Further, serum calcium, plasma parathyroid hormone, and urinary 
calcium were evaluated.
Results: Supplementation with 20 µg vitamin D3 increased 25(OH)D3 concentrations 
towards 70 nmol/L within 16 weeks. Supplementation with 10 or 15 µg calcifediol 
increased 25(OH)D3 levels >75 nmol/L in 8 and 4 weeks, respectively. Steady state 
was achieved from week 12 onwards with serum 25(OH)D3 levels stabilizing between 
84-89 nmol/L in the 10 µg calcifediol group. A significant association was observed 
between the changes in 25(OH)D3 and 24,25(OH)2D3 (R
2=0.83, P<0.01), but not 
between 25(OH)D3 and 1,25(OH)2D3 (R
2=0.04, P=0.18). No cases of hypercalcemia 
occurred in any treatment during the study period.
Conclusions: Calcifediol supplementation rapidly and safely elevates serum 
25(OH)D3 concentrations to improve vitamin D status in older adults. A daily dose of 
10 µg calcifediol allows serum 25(OH)D3 concentrations to be maintained between 
75–100 nmol/L.
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INTRODUCTION
Vitamin D deficiency is common worldwide, and particularly prevalent in the elderly 
[1-4]. A deficiency can be caused by environmental and age-related factors, affecting 
vitamin D uptake or metabolism. Vitamin D can be obtained from the diet as vitamin D2 
(ergocalciferol) or D3 (cholecalciferol). However, relatively few foods contain vitamin 
D, and therefore the dietary intake is considered low. As such, vitamin D3 is mainly 
acquired after sun exposure, as it can be synthesized from 7-dehydrocholestrol after 
cutaneous exposure to ultraviolet-B radiation [5]. However, production of vitamin D3 
is often limited to the summer months [6], and depends on many behavioral factors, 
such as outdoor activities and clothing [7], as well as the capacity of the skin to 
synthesize vitamin D3, which is suggested to be decreased in older adults [8, 9]. 
To be biologically active, vitamin D is hydroxylated by the liver into the prehormone 
25-hydroxyvitamin D (25(OH)D) and converted primarily in the kidney to the active 
hormone 1,25-dihydroxyvitamin D (1,25(OH)2D), which acts upon a broad variety of cells 
in the body. These metabolites can be further hydroxylated in the kidney into the inactive 
metabolite 24,25-dihydroxyvitamin D (24,25(OH)2D) and as such regulate the available 
pool and synthesis of 25(OH)D and 1,25(OH)2D. However, several factors such as, 
a declined hepatic or renal function [10, 11] can affect the metabolism of vitamin D 
and can increase the risk of vitamin D deficiency. Current recommendations show no 
consensus with regard to the optimal vitamin D status, with the Institute of Medicine 
(IOM) defining serum 25(OH)D levels of 50 nmol/L as adequate and others advocating 
a threshold of 75 nmol/L [12-14]. However, all agree that vitamin D supplements are 
needed to meet requirements in the older population. Supplementation with vitamin 
D2 or D3 is currently most common. However, supplementation with calcifediol, the 
25(OH)D3 metabolite, might be considered as well. As calcifediol is more hydrophilic 
and already hydroxylated, it can present an effective supplementation strategy in cases 
of malabsorption or impaired hepatic function [15]. Previous studies have demonstrated 
that calcifediol is more potent in increasing serum 25(OH)D3 status compared to native 
vitamin D3 [15-19]. This makes it an interesting alternative to be considered in the older 
population. However, additional clinical trials are needed to establish the appropriate 
dosing and safety of calcifediol supplementation in this population. Therefore, we 
investigated the dose-response effects of calcifediol compared to vitamin D3 on serum 
25(OH)D3 and its metabolites in people aged 65 years or older.
CHAPTER 4
Dose-response effects of calcifediol supplementation
70
METHODS
 
Trial design
This study was a double-blind trial including subjects randomly assigned to either 5, 
10 or 15 µg calcifediol or 20 µg vitamin D3 per day. The full study covered a screening 
visit and a 24 week intervention period including monthly visits to measure vitamin 
D metabolites and to monitor safety parameters. Randomization was carried out by 
an independent researcher using SAS software 9.20, with stratification on BMI (20–
29, 30–35 kg/m2) and permuted blocks of 4. All subjects and researchers remained 
blinded to treatment assignment until data collection and analyses were completed. The 
study was carried out in Wageningen, the Netherlands (latitude 51ºN), between 26th of 
August 2013 and 30th of April 2014. The study protocol was approved by the Medical 
Ethics Committee of Wageningen UR and written informed consent was provided by all 
participants. The study was registered at clinicaltrials.gov as NCT01868945 and was 
performed according to ICH-GCP.
 
Participants
Subjects were recruited via registries of municipalities and invited for a screening visit 
to measure eligibility according inclusion and exclusion criteria. Subjects were included 
if they were 65 years or older, had a serum 25(OH)D3 concentration between 25 and 
50 nmol/L and a body mass index between 20 and 35 kg/m2. Exclusion criteria were a 
serum calcium level >2.6 mmol/L, diagnosis with kidney stones in the past 10 years, 
renal insufficiency, liver failure, malabsorption syndromes, sarcoidosis and primary 
hyperparathyroidism. Use of medication that might interfere with vitamin D metabolism 
led to exclusion (e.g. thiazides, parathyroid hormone, bisphosphonates). In addition, 
subjects were excluded if they consumed >3 alcoholic beverages per day, used vitamin 
D supplements in the three months prior to the screening visit, were not willing to stop 
the use of multivitamins during the study, were expected to increase sun exposure (e.g. 
planned holiday to a sunny resort), were blood donor or had a surgery planned. 
 
Intervention
Study supplements were hard gelatin capsules that were identical in appearance and 
taste. DSM Nutritional Products Ltd. provided calcifediol or vitamin D3 in spray-dried 
form, and supplements were manufactured by Fisher Clinical Services GmbH. The 
Analytical Research Centre of DSM Nutritional Products tested the capsules using 
high performance liquid chromatography analysis (HPLC). The actual content of the 
capsules was: 5.1, 10.3 and 15.3 µg calcifediol or 22.3 µg vitamin D3. At the start 
of the study, subjects were instructed to consume one capsule per day at breakfast. 
Compliance was assessed by capsule count every two months. Subjects were 
considered compliant when ≥80% of the supplements were taken during the intervention. 
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Measurements 
Laboratory analyses
All blood samples were collected in a fasted state in the morning and stored at -80 ˚C 
until analysis. At screening, serum 25(OH)D3 samples were analyzed using isotope 
dilution-online solid phase extraction liquid chromatography-tandem mass spectrometry 
(ID-XLC-MS/MS) (VU Medical Centre, Amsterdam, the Netherlands) [20]. At baseline 
and every 4 weeks during the intervention period, a more comprehensive analysis was 
performed. Serum albumin and calcium were measured by colorimetric analysis to 
monitor albumin-corrected calcium [21]. EDTA blood samples were used to measure 
intact PTH by sandwich chemiluminescence immunoassay. In addition, morning spot-
urine was collected to monitor urinary calcium levels (expressed as calcium/creatinine 
ratio) (SHO laboratory, Velp, the Netherlands). Vitamin D metabolites, i.e. serum vitamin 
D3, 25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3 were analyzed at the end of the study using 
LC/MS/MS (Analytical Research Center, DSM Nutritional Products, Kaiseraugst, 
Switzerland). The inter-assay and intra-assay CVs were ≤15%. Due to sensitivity reasons, 
the Lower Limit of Quantitation (LLQ) for the baseline measurement of vitamin D3 had to 
be increased from 1.3 to 2.6 nmol/L in 56 out of 59 baseline blood samples. Besides, 
analysis of vitamin D3 and 1,25(OH)2D3 showed several laboratory values below the 
calibration point, these values are set at the LLQ for data interpretation. The method of 
analysis lacked sensitivity to accurately measure low concentrations of 25(OH)D2 as 
37 out of 59 samples were below the detection limit at baseline. Therefore, we restrict 
our analysis to the reporting of D3-related metabolites. All laboratory analyses were 
performed blinded to treatment allocation.
 
Questionnaires
Participants filled out a comprehensive questionnaire during the screening visit. 
Medical history, medication, dietary supplement use, alcohol consumption (number of 
alcoholic drinks per week) and smoking habits (current, former, never) were assessed. 
During the intervention phase, subjects filled out a questionnaire every 4 weeks to 
monitor changes in health status or medication use. Dietary vitamin D and calcium 
intake were recorded using a Food Frequency Questionnaire (FFQ) at baseline. This 
FFQ was developed using validated FFQs that were updated to facilitate the reporting 
of habitual vitamin D and calcium intake [22-24].
 
Anthropometrics
Weight was measured during each study visit, using a calibrated analogue scale and 
without wearing heavy clothing. Weight was reported to the nearest 0.5 kg. Height was 
measured at screening, baseline and at the end of the study. Height was measured 
using a stadiometer and reported to the nearest 0.1 cm. Body mass index (BMI) was 
reported as weight/height2. 
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Statistical methods
Sample size was based on a publication by Cashman et al., 2012, of 56 adults, aged 
≥50 years who completed a 10-week intervention receiving either 20 µg vitamin D3, 
7 or 20 µg calcifediol or a placebo [17]. From this publication, we derived the serum 
25(OH)D response per µg calcifediol to estimate the mean response after 10 weeks 
with doses of 5, 10 and 15 µg calcifediol. The primary study objective was to determine 
which of these doses would result in mean serum 25(OH)D concentrations between 
75–100 nmol/L. For a calcifediol dose of 10 µg/day, a mean ± SD serum 25(OH)D level 
of 84 ± 18 nmol/L was predicted. When including 14 subjects per group, the expected 
standard error of the mean was therefore 4.8 nmol/L (95% CI of ± 10 nmol/L). This was 
considered an acceptable degree of uncertainty and 60 subjects were randomized. 
Baseline characteristics were described as mean, SD or percent of categorical class 
and compared between treatment groups using one-way ANOVA or Chi-Square test. 
Linear regression was used to quantify the association between variables. Analyses 
of the dose-response in vitamin D metabolites were performed as pre-specified in the 
study protocol, i.e. by using subjects who completed the trial and had no major protocol 
deviations (per-protocol). Safety parameters were analyzed with all available data 
(intention-to-treat). Response profiles of each outcome variable were analyzed using 
mixed model analysis. Fixed effects were treatment, time (week) and the interaction of 
treatment x time. All models included a random effect for subject. The baseline level of 
the response variable and BMI were included as covariates in all models. Results were 
expressed as model predicted means including 95% CIs. In addition, steady state of 
serum 25(OH)D3 concentration was examined in each group by ANOVA contrasts, 
comparing each time point versus the final time point by Bonferroni post-hoc tests, 
using 5 contrasts. Steady state was determined by the last non-significant contrast. 
Statistical tests were all two-sided and carried out at the 5% level of significance. Data 
analyses were performed using SPSS (version 19) and graphs by using Graphpad 
Prism (version 5).
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RESULTS
In total, 481 subjects were screened for study participation and 60 subjects 
were randomized (Figure 4.1). However, one of these randomized subjects did not 
receive treatment due to violation of eligibility criteria and thus 59 subjects started 
the intervention. After enrolment, 5 subjects discontinued their participation and 54 
subjects completed the study. In addition, 3 subjects were excluded from the per-
protocol analysis due to major protocol deviations (Figure 4.1). 
 
 
Figure 4.1 Flow-chart of subjects.
 
*Non-compliant: <80% of the supplements were taken during the intervention. ITT, intention-to-treat; PP, per-protocol.
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Analysis 
 
CHAPTER 4
74
 
69 
 
 
Table 4.1 Baseline characteristics by treatment group.1 
 Vitamin D3 
20  µg/d  
(n= 14) 
Calcifediol 
5  µg/d  
(n= 14) 
Calcifediol 
10  µg /d 
(n= 15) 
Calcifediol 
15 µg/d 
(n= 16) 
Total 
(n= 59) 
P 2  
Demographics 
Age (y) 78 (7.7) 3 80 (7.3) 79 (7.0) 80 (7.0) 79 (7.1) 0.81 
Gender (M), % (n) 36 (5) 57 (8) 60 (9) 56 (9) 53 (31) 0.55 
Weight (kg) 78 (11.1) 74 (11.8) 74 (11.0) 76 (10.7) 76 (11.0) 0.73 
BMI (kg/m2) 27.6 (3.5) 26.0 (4.4) 26.6 (3.7) 26.8 (3.9) 26.8 (3.8) 0.74 
Alcohol intake, % (n)4 
   Light 71 (10) 79 (11) 93 (14) 75 (12) 80 (47) 
0.47    Moderate 29 (4) 21 (3) 7 (1) 25 (4) 20 (12) 
   Excessive - - - - - 
Smoking 
   Non-smokers 43 (6) 36 (5) 40 (6) 31 (5) 37 (22) 
0.68    Current smokers 7 (1) - - - 2 (1) 
   Ex-smokers 50 (7) 64 (9) 60 (9) 69 (11) 61 (36) 
Laboratory parameters 
Vitamin D3 (nmol/L)5 <LLQ <LLQ <LLQ <LLQ <LLQ  
25(OH)D3 (nmol/L) 37.7 (7.0) 43.4 (15.8) 38.3 (10.5) 38.6 (12.9) 39.4 (11.9) 0.56 
1,25(OH)2D3 (pmol/L)  79.3 (17.2)6 68.0 (19.2)7 77.5 (22.2)6 79.4 (19.6)6 76.2 (19.7) 0.36 
24,25(OH)2D3 (nmol/L) 5.5 (2.1) 7.9 (3.8) 6.2 (3.0) 6.6 (2.8) 6.5 (3.0) 0.20 
PTH (pmol/L) 5.2 (1.9) 5.7 (1.7) 4.9 (1.3) 4.9 (1.8) 5.2 (1.7) 0.55 
Calcium (mmol/L)8 2.2 (0.1) 2.2 (0.1) 2.2 (0.1) 2.2 (0.1) 2.2 (0.1) 0.92 
UCa/Cr ratio (mmol/mmol) 0.5 (0.3) 0.3 (0.2) 0.3 (0.2) 0.4 (0.2) 0.4 (0.2) 0.29 
Dietary intake 
Vitamin D  (µg/day) 3.7 (1.2) 4.2 (1.6) 3.3 (1.3) 3.5 (1.5) 3.6 (1.4) 0.36 
Calcium  (mg/day) 985 (438) 1204 (487) 1041 (293) 1111 (386) 1087 (402) 0.53 
1LLQ, Lower Limit of Quantitation; UCa/Cr, Urinary Calcium/Creatinine. 2Between group differences explored by one-way ANOVA or 
chi-square test. 3Mean; SD in parentheses (all such values). 4Light: ≤7 drinks, moderate: 8-21 drinks, severe >21 drinks per week. 5All 
measured laboratory values were below the calibration point of 1.3 nmol/L (or 2.6 nmol/L for samples with sensitivity issues). 
6Laboratory value of 1 subject was below the calibration point, and this value was set at the LLQ of 48 pmol/L for data interpretation. 
7Laboratory values of 2 subjects were below the calibration point, and thus these values were set at the LLQ of 48 pmol/L for data 
interpretation. 8Serum albumin-corrected calcium by the formula (plasma Ca-(0.02x[Alb-40]).  
 
Changes in serum 25(OH)D3 concentration 
Figure 4.2-A presents the changes in serum 25(OH)D3 status by treatment group throughout the 24 
week intervention period. On average, all treatments resulted in an increase of serum 25(OH)D3 levels 
>50 nmol/L with a significant treatment x time interaction (P=0.00). One month of supplementation 
already showed large differences in achieved serum 25(OH)D3 levels, with a mean of 52.4 nmol/L (CI 
44.4, 60.5), 67.9 nmol/L (CI 60.5, 75.3), 84.8 nmol/L (CI 77.4, 92.1) and 58.7 nmol/L (CI 50.2, 67.1) 
in the 5 µg, 10 µg, 15 µg calcifediol and 20 µg vitamin D3 group, respectively. Thereafter, serum 
25(OH)D3 levels continued to rise in the 10 µg and 15 µg calcifediol group and 20 µg vitamin D3 
group, while the group receiving 5 µg of calcifediol did not show significant changes over subsequent 
time points, with an average between 52 and 55 nmol/L. The other treatments all plateaued from week 
12 onwards with serum 25(OH)D3 stabilizing between 69 and 72 nmol/L in the 20 µg vitamin D3 
group, between 84 and 89 nmol/L in the 10 µg calcifediol group and between 106 and 110 nmol/L in 
the 15 µg calcifediol group over subsequent time points. 
 
Table 4.1 shows the population characteristics per treatment group. The mean age 
of the total study population was 79 ± 7.1 years and 53% were men. Mean baseline 
serum 25(OH)D3 concentration was 39.4 ± 11.9 nmol/L and there were no significant 
differences in baseline 25(OH)D3 concentration between treatment groups (P=0.56). 
Mean dietary vitamin D and calcium intakes were 3.6 ± 1.4 µg/day and 1087 ± 402 mg/
day, respectively. Average compliance of the study population was 97%, 58 subjects 
had a compliance of 80% or higher. 
  
Table 4.1 Baseline characteristics by treatment group.1
 
 
 
 
Changes in serum 25(OH)D3 concentration
Figure 4.2-A presents the changes in serum 25(OH)D3 status by treatment group 
throughout the 24 week intervention period. On average, all treatments resulted in 
an increase of serum 25(OH)D3 levels >50 nmol/L with a significant treatment x time 
interaction (P=0.00). One month of supplementation already showed large differences 
in achieved seru  25 OH)D3 levels, with a mean of 52.4 nmol/L (CI 44.4, 6 .5), 67.9 
nmol/L (CI 60.5, 75.3), 84.8 nmol/L (CI 77.4, 92.1) and 58.7 nmol/L (CI 50.2, 67.1) in 
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the 5 µg, 10 µg, 15 µg calcifediol and 20 µg vitamin D3 group, respectively. Thereafter, 
serum 25(OH)D3 levels continued to rise in the 10 µg and 15 µg calcifediol group and 
20 µg vitamin D3 group, while the group receiving 5 µg of calcifediol did not show 
significant changes over subsequent time points, with an average between 52 and 
55 nmol/L. The other treatments all plateaued from week 12 onwards with serum 
25(OH)D3 stabilizing between 69 and 72 nmol/L in the 20 µg vitamin D3 group, between 
84 and 89 nmol/L in the 10 µg calcifediol group and between 106 and 110 nmol/L in 
the 15 µg calcifediol group over subsequent time points.
 
Changes in vitamin D related metabolites and PTH
By the end of the study, significantly higher serum vitamin D3 concentrations were 
observed in the vitamin D3 group compared to the calcifediol groups, confirming 
treatment allocation (Table 4.2). During the study, serum 1,25(OH)2D3 levels fluctuated 
in all treatment groups with a gradual increase towards a peak concentration in week 
20 (Figure 4.2-B). By the end of the study, there were no significant differences 
between groups in serum 1,25(OH)2D3 concentration (Table 4.2). Serum 24,25(OH)2D3 
concentrations increased over time, with a significant treatment x time interaction 
(P=0.00) (Figure 4.2-C). There was a significant association between the change in 
25(OH)D3 and 24,25(OH)2D3 (R
2=0.83, P<0.01), but not between 25(OH)D3 and 
1,25(OH)2D3 (R
2=0.04, P=0.18). During the study, plasma PTH levels fluctuated in 
all treatment groups, with no significant treatment x time interaction (P=0.39) (Figure 
4.2-D). By the end of the study, plasma PTH levels were significantly lower in the 15 µg 
versus 5 µg calcifediol group (Table 4.2). 
 
Safety results and adverse events
Serum calcium concentrations remained below the reference value of 2.6 mmol/L 
and no cases of hypercalcemia occurred in any treatment during the study period. 
Furthermore, there were no significant differences in serum calcium levels or urinary 
calcium/ creatinine ratios between groups after 24 weeks of supplementation (Table 
4.2). A total of 76 adverse events (AEs) occurred in 39 subjects and 8 serious adverse 
events (SAEs) occurred in 6 subjects. The number of AEs and SAEs did not differ 
significantly between groups. None of the AEs or SAEs led to discontinuation of the 
study or changes in supplementation regimen. All SAEs were reviewed by the Ethics 
Committee and were not related to the study products. 
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Figure 4.2 Serum concentration time curves of vitamin D metabolites and PTH. 
Graph represents unadjusted baseline and model predicted means including 95% CIs (per-protocol). 
Models are adjusted for BMI and baseline value of the response variable. A) Mean serum 25(OH)D3 
(nmol/L). Grey dashed lines indicate the reference at 75 and 100 nmol/L. B) Mean serum 1,25(OH)2D3 
(pmol/L). 4% of the laboratory results were below the calibration point, and thus these values were set at 
the LLQ of 48 pmol/L for data interpretation. C) Mean serum 24,25(OH)2D3 (nmol/L). D) Mean plasma PTH 
(pmol/L).
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Table 4.2 End-of-study comparison of laboratory values between groups.1  
 Vitamin D3 
20  µg/d  
Calcifediol 
5  µg/d  
Calcifediol 
10  µg /d 
Calcifediol 
15 µg/d 
Vitamin D3 (nmol/L) 7.0 (6.4-7.6)
 2, 3 <LLQ4 <LLQ4 <LLQ4 
25(OH)D3 (nmol/L) 71.6 (63.2-80.0)
a 52.2 (44.4-60.2)b 88.7 (81.4-96.1)c 109.9 (102.5-117.2)d 
1,25(OH)2D3 (pmol/L)
  92.4 (81.1-103.7)a 85.8 (75.0-93.6)a, 5 79.3 (69.3-89.3)a 92.0 (82.1-102.0)a 
24,25(OH)2D3 (nmol/L) 15.4 (12.8-17.0)
a 9.5 (7.0-12.1)b 18.6 (16.3-20.9)a 27.2 (24.9-29.5)c 
PTH (pmol/L) 4.7 (4.1-5.2)a, b 5.1 (4.6-5.6)a 4.8 (4.3-5.3)a, b 3.9 (3.4-4.4)b 
Calcium (mmol/L)6 2.3 (2.3-2.3)a 2.3 (2.3-2.3)a 2.3 (2.3-2.3)a 2.3 (2.3-2.3)a 
UCa/Cr ratio 
(mmol/mmol) 
0.4 (0.3-0.5)a 0.4 (0.3-0.5)a 0.5 (0.4-0.6)a  0.5 (0.4-0.6)a 
1LLQ, Lower Limit of Quantitation; UCa/Cr, Urinary Calcium/Creatinine. 2Model predicted means; 95% CIs in 
parentheses (all such values). 3Laboratory value of one subject was below the calibration point, and this value was set 
at the LLQ of 1.3 nmol/L for data interpretation. 4Laboratory values of all subjects were below the calibration point of 
1.3 nmol/L. a, b, c, dValues that have no superscript letter in common are significantly different, P<0.05 (Bonferroni-
adjusted tests). 5Laboratory values of 2 subjects were below the calibration point, and thus these values were set at the 
LLQ of 48 pmol/L for data interpretation. 6 Serum albumin-corrected calcium by the formula (plasma Ca-(0.02x[Alb-
40]).  
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Discussion
This study shows clear differences in response to supplementation with three different 
dosages of calcifediol. First of all, supplementation with 10 or 15 µg calcifediol resulted 
in a prompt increase in 25(OH)D3 concentrations, with serum levels increasing above 
the threshold of 75 nmol/L after 8 and 4 weeks, respectively. In contrast, a significant 
longer period (16 weeks) was needed to increase status levels towards 70 nmol/L 
with 20 µg vitamin D3, whereby mean concentrations of 75 nmol/L were not achieved. 
Overall, these data support the results of previous studies with repeated dosing of 
calcifediol, showing a fast increase in serum 25(OH)D early in the supplementation 
phase [16, 17, 25]. Supplementation with 5 µg calcifediol appeared to be insufficient 
to reverse deficiency, as about 50% of the subjects remained below the 50 nmol/L 
threshold throughout the intervention period. Nevertheless, as the study was mainly 
performed in the winter months, during which 25(OH)D3 status normally decreases 
due to insufficient UV-B exposure, the 5 µg calcifediol dose might have compensated 
at least this expected seasonal decrease in 25(OH)D3 status.
Steady state attainment is an important aspect of dose determination when aiming 
at achieving certain serum concentrations. In a study published by Cashman et al., 
older adults were supplemented with 7 or 20 µg calcifediol per day over a period of 10 
weeks [17]. Serum 25(OH)D concentration increased with 28 nmol/L and 96 nmol/L, 
respectively. Besides, in a study published by Bischoff-Ferrari et al., postmenopausal 
women were supplemented with 20 µg calcifediol per day or 140 µg calcifediol per 
week over a period of 16 weeks [16]. Dose-response effects were comparable for 
both the daily and weekly supplementation strategy, and results of the calcifediol 
groups were combined. In this study, serum 25(OH)D concentration increased with 
143 nmol/L after supplementation with calcifediol. However, both studies could not 
confirm a steady state in serum 25(OH)D3 concentrations, which might relate to the 
shorter study duration and higher doses of calcifediol (20 µg). In our study, daily 
supplementation with 10 µg or 15 µg calcifediol, increased status levels with 50 nmol/L 
and 71 nmol/L, respectively. Average steady state was tested aiming at serum 25(OH)D3 
concentrations between 75–100 nmol/L. Steady state was reached at 12 weeks of 
supplementation in both the 20 µg vitamin D3 as in the 10 and 15 µg calcifediol group. 
However, only the 10 µg calcifediol group plateaued within the target range of 75–100 
nmol/L. Treatment with 20 µg vitamin D3 plateaued at 72 nmol/L and 15 µg calcifediol 
exceeded the upper reference of 100 nmol/L after 8 weeks.
As suggested by a recent report from the European Society for Clinical and Economic 
Aspects of Osteoporosis (ESCEO) and the International Osteoporosis Foundation 
(IOF), equipotent doses of calcifediol and vitamin D3 should be tested to allow 
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comparison of target level effectiveness [26]. When describing the relative potency 
of calcifediol compared to vitamin D3, Cashman et al. reported conversion factors 
between 1.4 and 5.0 based on results of previous studies [17]. Because of variability 
in study design, baseline levels and dosing regimens, direct comparison of these 
conversion factors should be perceived with caution. Nevertheless, when considering 
the effective doses of 10 and 15 µg calcifediol in the current study, conversion factors 
were 2.8 and 3.0, indicating that, per microgram supplemented, calcifediol was about 3 
times more effective to increase serum 25(OH)D3 status when compared to vitamin D3. 
Furthermore, Zittermann et al. published a formula to calculate the expected increase 
in serum 25(OH)D concentration when supplementing with vitamin D while taking into 
account the age, baseline 25(OH)D status and body weight of the study population 
[27]. Using this formula, the predicted increase in serum 25(OH)D concentration when 
supplementing with 20 µg vitamin D3, was in line with the actual increase as observed in 
our study (34 nmol/L actual increase versus 40 nmol/L predicted increase). Moreover, 
this formula indicates that much higher doses, of about 40 µg and 125 µg vitamin 
D3, would be required to establish the increase in serum 25(OH)D concentration as 
observed in the 10 µg and 15 µg calcifediol groups. Along with its higher potency, our 
study shows that the calcifediol doses appeared to be safe for use over a 24-week 
period as no cases of hypercalcemia occurred. Nevertheless, this safety evaluation is 
limited to the timeframe under study and further research is needed to investigate the 
long-term daily use of calcifediol. 
Serum 25(OH)D is currently considered the best biomarker to reflect vitamin D status, 
as it has a longer half-life and correlates better with PTH suppression compared to 
the active hormone 1,25(OH)2D [28]. Nevertheless, recent studies suggest that other 
metabolites might also provide clinically relevant information [29]. Serum 1,25(OH)2D 
is under tight homeostatic control by PTH and serum concentrations of calcium and 
phosphorus. Our study shows no association between the change in 25(OH)D3 and 
1,25(OH)2D3 concentrations after supplementation with either form of supplementation. 
This is consistent with findings of previous randomized trials supplementing with either 
vitamin D3 or calcifediol [25, 30]. Serum 24,25(OH)2D is suggested as an index of 
vitamin D deficiency and catabolism. Our study showed a strong positive correlation 
between the change in 25(OH)D3 and 24,25(OH)2D3 after supplementation. Serum 
24,25(OH)2D3 showed similar dose-response patterns as serum 25(OH)D3, which 
suggests stimulation of the catabolic pathway to regulate 1,25(OH)2D3 [29]. 
Strengths of this study are the monthly measurements of multiple vitamin D metabolites, 
providing comprehensive data on vitamin D status and repletion. Besides, all vitamin 
D metabolites were measured using chromatography-based techniques, which are 
now considered the research gold standard [31]. Other strengths are the high subject 
compliance and good adherence to the study visits which resulted in few missing 
data. Our study also has limitations. First of all, results in this study were restricted 
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to the reporting of  D3-related metabolites to accurately reflect serum 25(OH)D3 
dose-response relationships. However, total serum 25(OH)D status is mostly used for 
clinical diagnosis of deficiency. Nevertheless, the contribution of serum 25(OH)D2 to 
total serum 25(OH)D status in our study is expected to be low, as indicated by the high 
number of samples with undetectable values. Furthermore, the study started in late 
summer which might induce confounding due to endogenous generation of vitamin D 
in all treatment arms. However, the main study period fell within the season of minimal 
endogenous vitamin D synthesis (October-April when latitudes above 40ºN) which 
might limit this confounding [32]. Period of inclusion was considered as a covariate 
in the dose-response models but did not affect the study results. Lastly, the findings 
may not be generalizable to patients with an impaired renal functioning, as those 
were excluded from participation. An impaired renal functioning is known to affect 
vitamin D metabolism and can alter the regulation of calcium and phosphorus levels 
[33]. Therefore, the efficacy and safety of calcifediol supplementation in this specific 
population requires further research.
Scientific findings of the possible biologic actions of vitamin D and epidemiological 
studies linking vitamin D to a broad spectra of diseases have led to guidelines to 
increase the recommended status levels. For example, the Endocrine Society suggests 
serum 25(OH)D concentrations >75 nmol/L for at risk populations, including the 
elderly, to support the possible effect on bone and muscle metabolism [13]. Although 
the optimal serum 25(OH)D status remains a subject of ongoing debate and needs 
further investigation, higher target ranges require higher doses of vitamin D3 per day. 
Therefore, calcifediol might be a potential strategy to rapidly increase serum 25(OH)D 
levels towards desired levels. 
To conclude, this study adds to the characterization of dose-response effects with 
calcifediol in an older population. Our results show that a dose of 10 µg/day resulted in 
sustained serum 25(OH)D3 concentrations between 75–100 nmol/L. 
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ABSTRACT
Background & aims: Sufficient 25-hydroxyvitamin D (25(OH)D) concentrations 
might prevent a decline in physical performance, and are considered important for 
the prevention of frailty. This study investigates the association of serum 25(OH)D 
concentration with physical performance and frailty status in Dutch older adults. 
Methods: This cross-sectional study included 756 men and women, aged ≥65 years. 
Serum 25(OH)D) concentration and frailty status (Fried criteria) were assessed in the 
total population. Screening for frailty status included functional tests of gait speed and 
hand grip strength. In a subgroup (n=494), the Timed-Up and Go test (TUG) and 
knee-extension strength were measured. Associations of serum 25(OH)D status with 
physical performance were examined by multiple linear regression. Prevalence ratios 
(PR) were used to quantify associations between serum 25(OH)D deficiency (<50 
nmol/L) and frailty. 
Results: In total, 45% of the participants were vitamin D deficient. Participants with 
vitamin D status <50 nmol/L and 50-75 nmol/L had significantly lower scores on the 
TUG and gait speed test, compared to participants with vitamin D status >75 nmol/L. 
No significant associations with serum 25(OH)D concentrations were observed for 
handgrip strength or knee-extension strength. Participants with serum 25(OH)D status 
<50 nmol/L were about 2 times more likely to be frail compared to participants with 
serum 25(OH)D status ≥50 nmol/L. 
Conclusion: In this study, serum 25(OH)D concentrations were significantly 
associated with frailty status and measures of physical performance, including gait 
speed and TUG, but not with strength related outcomes. 
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INTRODUCTION
Frailty is a geriatric syndrome associated with adverse health outcomes, such as 
physical disability, increased risk of falls, institutionalization, hospitalization and mortality 
[1]. To identify older people at risk, Fried et al. proposed a characterization of a frail 
state, using a clinical phenotype [2]. The definition consists of five physical components 
(weakness, slow walking speed, exhaustion, physical inactivity, and unintentional 
weight loss) and is now commonly applied in clinical research. The prevalence of frailty 
is relatively high among community-dwelling elderly, with 44% of seniors being pre-frail, 
and 10% being frail [3]. In view of the ageing population, the prevalence of the frailty 
syndrome will increase, which in turn will result in higher rates of hospitalization, and 
considerably burden the public health care costs [4]. As such, the need for interventions, 
supporting older people to remain healthy and independent, increases. One of the key 
features of frailty is profound muscle weakness and a decline in functional capabilities 
[2]. The cause of this loss in strength and function is multifactorial, and a low vitamin 
D status is suggested to be one of the risk factors [5, 6]. Vitamin D stimulates calcium 
absorption in the intestine and is responsible for the mineralization of bone and general 
functioning of cells throughout the body [7]. Deficient vitamin D concentrations (serum 
25(OH)D <50 nmol/L) [8] are common in frail older adults, with a prevalence reported 
up to 62% [9]. Low vitamin D concentrations have been associated with an impaired 
muscle function and an increased risk of being frail [9-11]. However, the strength and 
shape of these associations, and the ability to control for confounding factors differs 
between studies. Further characterization of the association between serum 25(OH)D 
concentration and frailty, but also the closely related functional parameters, might help 
to define consensus about the optimal vitamin D status for these health outcomes. 
Therefore, the aim of this study was to determine the association of serum 25(OH)D 
concentrations with physical performance and frailty status. 
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METHODS
 
Study sample
In this study, we report data of 756 older adults that attended a screening visit for 
participation in the D-DOSE or D-FIT trial (clinicaltrial.gov registration: NCT01868945 
or NCT02349282). These studies used similar recruitment strategies, inclusion criteria 
and measurement protocols, which allowed combining of datasets. Both studies were 
performed by the Division of Human Nutrition, Wageningen University, the Netherlands. 
Recruitment took place via the university database, or municipality registers of 
Wageningen and surroundings. Participants were invited to the screening visit if 
they were 65 years or older. Visits took place between May 2013 and April 2015. All 
participants provided data on general characteristics, serum 25(OH)D status and frailty 
criteria (gait speed, handgrip strength, physical activity, weight loss and self-reported 
exhaustion). Additional measures of muscle strength and physical performance were 
performed in a subgroup of 494 participants. Before screening, all participants signed 
informed consent and study protocols were approved by the ethical committee of 
Wageningen University. 
 
Serum 25-hydroxyvitamin D
Serum blood samples were collected to measure 25(OH)D concentration. Samples 
were centrifuged, stored at -80 ºC and thereafter analyzed using LC-MS/MS. Samples 
collected for the D-DOSE study (n=259) were analyzed at the Endocrine Laboratory 
of the VU University Medical Centre, Amsterdam, the Netherlands [12]. The intra-
assay and inter-assay coefficients of variation were below 6% and 8%, respectively. 
Serum 25(OH)D samples collected for the D-FIT study (n=497) were analyzed at 
the Department of Clinical Chemistry, Canisius Wilhelmina Hospital, Nijmegen, the 
Netherlands. The intra-assay and inter-assay coefficients of variation were below 
4% and 7.5%, respectively [13]. Both laboratories are DEQAS-certified and the 
comparability of the LC-MS/MS methods between these two laboratories has been 
published previously, which indicated good agreement between methods [14].  
 
Physical performance
Handgrip strength (HGS) was measured on the dominant hand by taking the mean 
of 3 attempts (Jamar® hydraulic hand-held dynamometer, Patterson Medical, IL, USA). 
Mean gait speed was assessed by taking the average time, of 2 attempts, to walk a 
course of 15 feet. In a subgroup (n=494), the Timed Up and Go test (TUG) and maximal 
isometric knee- extension strength were assessed. The TUG test is a test of functional 
ability to rise from a chair, walk 3 meters, make a turn, and walk back to the chair to sit 
down again. The average time to complete this test, out of 2 attempts, was recorded. 
Knee-extension strength was measured using the MicroFET hand-held dynamometer 
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(Hoggan Health Inc., West Jordan, UT, USA). Participants were asked to sit upright 
with their knees in a 90˚ angle. Maximal strength (Newton) was measured 3 times per 
leg with 5 seconds of muscle contraction and 60-seconds of rest between repetitions. 
The average muscle strength of the right leg was used for analysis. All measurements 
were performed by examiners trained to regularly perform these tests according study 
protocol and standardized verbal encouragement was provided.  
 
Fried frailty criteria
Frailty status was assessed using the criteria published by Fried et al. [2]. These 
consist of the following five criteria: unintentional weight loss (in the past year, by 
questionnaire), self-reported exhaustion (CES-D questionnaire) [15], weakness 
(handgrip strength), slow walking speed (gait speed), and low physical activity levels 
(Short version of the Minnesota questionnaire) [16]. According the frailty definition of 
Fried et al., a participant scores non-frail when no criteria are present, pre-frail when 
one or two criteria are present and frail when three or more criteria are present [2].
 
Covariates
Questionnaires were used to record general participant characteristics such as, 
age, sex, ethnicity (caucasian, other), physical activity (short version of the Minnesota 
questionnaire) [16], vitamin D supplement use, smoking status, alcohol intake, and the 
number of chronic diseases (including heart failure, hypertension, diabetes mellitus, 
renal insufficiency, liver disease or cancer). A stadiometer was used to measure the 
height of the participants, and a calibrated analog scale was used to measure their 
weight. BMI was calculated as kg/m2. In addition, laboratory site and season of blood 
collection (winter: December-February, spring: March-May, summer: June-August, 
autumn: September-November) were recorded.  
 
Statistical analyses 
Characteristics of the study population are described as mean (SD), median (25 – 
75th percentile) or number (%) of categorical class. Serum 25(OH)D concentrations 
<50 nmol/L are generally considered deficient [8, 17], and a status between 50-75 
nmol/L or >75 nmol/L is suggested for optimal muscle health and physical performance 
[18, 19]. Serum 25(OH)D was categorized accordingly, with the latter (>75 nmol/L) 
being the reference category. Differences between categories of serum 25(OH)D 
concentration were examined by One-way ANOVA for continuous variables, Kruskal-
Wallis test in case of skewed variables and Chi-square tests for categorical variables. 
The association between serum 25(OH)D concentration and measures of physical 
performance (TUG and gait speed) and muscle strength (handgrip strength and knee-
extension strength) were explored for nonlinearity by restricted cubic spline regression. 
As associations with TUG and hand grip strength tended to be nonlinear, all outcomes 
were further explored across categories of serum 25(OH)D. Multiple linear regression 
models were adjusted for factors known to be related to both serum 25(OH)D 
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and physical performance. Model 1 was adjusted for age, sex and laboratory site. 
Model 2 was additionally adjusted for BMI and season of blood collection, and model 
3 was additionally adjusted for ethnicity, physical activity, alcohol intake, smoking and 
number of diseases. A Cox Proportional Hazards analysis with robust error variance 
was performed to calculate Prevalence Ratios (PR) of participants being pre-frail or 
frail across categories of serum 25(OH)D status. By assigning a constant risk period 
to all participants, the obtained hazard ratio can be considered a PR [20]. Models 
including frailty as dependent variable were not corrected for physical activity, as this 
measure is also included in the definition of frailty status. Previous studies identified 
sex as a possible effect modifier in the association between vitamin D and physical 
performance [21]. Therefore, interaction terms including sex were added to the final 
models. A P-value of ≤0.1 was considered significant to retain an interaction term in the 
model. All analyses were performed using statistical software package SAS version 9.2 
(SAS Institute Inc., Cary, NC, USA) or using the R software package version 3.3.1 (R 
Foundation for Statistical Computing, Vienna, Austria). A two-sided P-value of ≤0.05 
was considered statistically significant. 
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RESULTS
Table 5.1 shows the general characteristics of the study population in total, and by 
categories of serum 25(OH)D status. The mean ± SD age of the study population 
was 74 ± 6 years and 55% were men. Mean BMI was 27.1 ± 3.5 kg/m2 and median 
serum 25(OH)D status was 54 (38-72) nmol/L, irrespective of season. Participants in 
the deficient serum 25(OH)D category (<50 nmol/L) were more likely to be men and 
more likely to have a higher BMI compared to participants in the higher categories of 
serum 25(OH)D status. Season of blood collection was significantly different between 
the vitamin D categories, with 81% of the vitamin D deficient participants measured in 
the winter/ spring. Of all participants, 12% reported to use a vitamin D supplement. 
A significant difference was observed in the number of supplement users across 
categories, with 4% in the deficient category and 18% and 19% in the two higher 
categories. Most participants scored non-frail according the Fried criteria, namely 
57%, followed by 39% scoring pre-frail and 4% scoring frail. 
Table 5.2 shows the association between serum 25(OH)D concentration and 
measures of physical performance. There was an inverse association between serum 
25(OH)D and TUG test scores, which remained significant after full adjustment for 
confounders. Compared with the reference category (>75 nmol/L), participants with 
serum 25(OH)D concentrations <50 nmol/L (β 0.73, 95% CI 0.14; 1.32) and 50-75 
nmol/L (β 0.83, 95% CI 0.21; 1.45) had significantly higher TUG scores, indicating 
more time needed to complete the test. Likewise, participants with serum 25(OH)D 
status <50 nmol/L (β -0.04, 95% CI -0.08; -0.01) and status between 50-75 nmol/L 
(β -0.04, 95% CI -0.07; -0.01) had significantly lower gait speed scores, compared 
with the reference category. Serum 25(OH)D categories were not associated with 
handgrip strength and knee-extension strength. The effect of vitamin D supplement use 
was explored but did not change the interpretation of results. Furthermore, interaction 
analyses did not suggest significant modification of the associations by sex.
Table 5.3 shows the association between serum 25(OH)D concentrations and 
frailty status. As only 2 participants scored frail in the >75 nmol/L category,  the 50-75 
nmol/L and >75 nmol/L categories were combined to further explore the association 
between serum 25(OH)D and frailty status. Participants with serum 25(OH)D status 
<50 nmol/L were about 2 times more likely to be frail (PR=2.30, 95% CI 1.11; 4.76, 
P=0.02), compared to participants with serum 25(OH)D status ≥50 nmol/L. The effect 
of vitamin D supplement use was explored, which attenuated the prevalence ratio but 
the association remained significant (PR=2.16, 95% CI 1.04; 4.52, P=0.04). When 
comparing non-frail versus pre-frail older adults (or pre-frail and frail combined), no 
significant associations were observed with serum 25(OH)D status.
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Table 5.1 Participant characteristics.
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Table 5.1 Participant characteristics  
  Serum 25-hydroxyvitamin D 
 
 
 Total 
n=756 
< 50 nmol/L 
n=340 
50-75 nmol/L 
n=254 
> 75 nmol/L 
n=162 
P 
value 
Men, n (%) 416 (55) 217 (64) 125 (49) 76 (46) 0.00 
Age, y 73.8 ± 6.4 74.1 ± 6.6 74.0 ± 6.2 72.9 ± 5.9 0.08 
BMI, kg/m2 27.1 ± 3.5 27.5 ± 3.7 27.0 ± 3.3 26.2 ± 3.1 0.00 
Caucasian, n (%) 736 (98) 327 (97) 250 (98) 159 (98) 0.49 
Independent living, n (%)a, § 723 (96) 320 (95) 243 (96) 160 (99) 0.10 
Non-smokers, n (%)a 705 (94) 311 (92) 239 (94) 155 (96) 0.31 
Alcohol consumers, n (%)a  598 (79) 269 (80) 197 (78) 132 (82) 0.61 
25(OH)D, nmol/L 54 (38-72) 36 (29-42) 62 (58-67) 91 (84-100) 0.00 
VitD suppl. users, n (%)b 88 (12)  13 (4) 45 (18) 30 (19) 0.00 
Season, n (%)†  
0.00   Summer  - autumn 259 (34) 64 (19) 101 (40) 94 (58) 
  Winter - spring 497 (66) 276 (81) 153 (60) 68 (42) 
Number of diseases, n (%)c      
   0 380 (51) 159 (47) 130 (52) 91 (56) 0.36 
   1-2 353 (47) 167 (50) 117 (46) 69 (43)  
   ≥ 3 17 (2) 10 (3) 5 (2) 2 (1)  
Physical activity, MJ/wk d 8.4 (4.5-13.0) 7.8 (4.5-13.1) 8.5 (4.3-12.0) 9.6 (5.4-15.1) 0.11 
TUG, s#, d 9.8 ± 2.4 9.9 ± 2.5 9.9 ± 2.3 9.1 ± 2.2 0.04 
Gait, m/se 1.06 ± 0.20 1.05 ± 0.21 1.05 ± 0.19 1.10 ± 0.20 0.03 
Knee-extension, N# 328 ± 104 336 ± 103 324 ± 104 301 ± 106 0.04 
HGS, kgf 28.9 ± 9.5 29.4 ± 9.3 28.1 ± 9.6 28.9 ± 9.7 0.23 
Frailty, n (%)g  
0.16   Non-frail 425 (57) 183 (55) 142 (57) 100 (62) 
  Pre-frail 289 (39) 131 (39) 98 (39) 60 (37) 
  Frail 33 (4) 20 (6) 11 (4) 2 (1) 
25(OH)D, 25-hydroxyvitamin D; BMI, Body Mass Index; VitD suppl. users, vitamin D supplement users; 
TUG, Timed Up and Go; HGS, Hand grip strength; N, Newton. Values presented are mean ± SD or median 
(25th-75th percentile). a3 missing values. b5 missing values. c6 missing values. d1 missing value. e7 missing 
values. f4 missing values. g9 missing values. §Assisted living includes: home care or service flat. †Winter-
spring: Dec-May, summer-autumn: Jun-Nov. #Subgroup n=494. 
 
  
< . 1
< . 1
< . 1
< . 1
< . 1
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Table 5.2 Association between serum 25-hydroxyvitamin D status and physical 
performance. 
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Table 5.3 Prevalence ratios (PR) and 95% CIs for frailty status of participants with 
serum 25-hydroxyvitamin D concentrations <50 nmol/L versus  ≥50 nmol/L  
           Serum 25-hydroxyvitamin D 
 
 < 50 nmol/L ≥ 50 nmol/L 
 
 PR (95% CI)  Reference group n 
Frail vs. non-frail     
Model 1 2.24 (1.06; 4.75)* 1 (ref) 458 
Model 2 2.07 (1.02; 4.20)* 1 (ref) 458 
Model 3 2.30 (1.11; 4.76)* 1 (ref) 453 
Pre-frail vs. non-frail 
Model 1 1.10 (0.91; 1.32) 1 (ref) 714 
Model 2 1.08 (0.90; 1.29) 1 (ref) 714 
Model 3 1.06 (0.88; 1.26) 1 (ref) 711 
Pre-frail or frail vs. non-frail 
Model 1 1.14 (0.97; 1.35) 1 (ref) 747 
Model 2 1.13 (0.96; 1.32) 1 (ref) 747 
Model 3 1.10 (0.93; 1.29) 1 (ref) 742 
*P<0.05. Model 1: adjusted for age, sex and laboratory site. Model 2: adjusted for 
age, sex, laboratory site, BMI and season. Model 3: adjusted for age, sex, 
laboratory site, BMI, season, ethnicity, alcohol, smoking and number of diseases. 
Models are not corrected for physical activity, as this measure is also included in 
frailty status. 
 
Table 5.2 Association between serum 25-hydroxyvitamin D status and physical performance 
 Serum 25-hydroxyvitamin D 
 
 < 50 nmol/L 50-75 nmol/L > 75 nmol/L 
 β (95% CI) β (95% CI) Reference group n 
TUG, s 
Model 1 0.85 (0.24; 1.45)** 0.83 (0.19; 1.47)* 0 (ref) 493 
Model 2 0.77 (0.18; 1.36)* 0.84 (0.22; 1.47)** 0 (ref) 493 
Model 3 0.73 (0.14; 1.32)* 0.83 (0.21; 1.45)** 0 (ref) 488 
Gait, m/s 
Model 1 -0.06 (-0.10; -0.02)** -0.05 (-0.09; -0.01)** 0 (ref) 749 
Model 2 -0.05 (-0.09; -0.01)** -0.04 (-0.08; -0.01)* 0 (ref) 749 
Model 3 -0.04 (-0.08; -0.01)* -0.04 (-0.07; -0.01)* 0 (ref) 745 
HGS, kg 
Model 1 -0.93 (-2.25; 0.38) -0.71 (-2.02; 0.61) 0 (ref) 752 
Model 2 -1.06 (-2.38; 0.26) -0.84 (-2.15; 0.47) 0 (ref) 752 
Model 3 -0.92 (-2.25; 0.40) -0.78 (-2.10; 0.53) 0 (ref) 748 
Knee-extension, N 
Model 1 7.74 (-15.03; 30.50) 12.23 (-11.95; 36.42) 0 (ref) 494 
Model 2 7.70 (-15.10; 30.50) 13.09 (-11.11; 37.29) 0 (ref) 494 
Model 3 9.89 (-12.82; 32.60) 12.71 (-11.37; 36.80) 0 (ref) 489 
**P<0.01, *P<0.05. Model 1: adjusted for age, sex and laboratory site. Model 2: adjusted for age, sex, 
laboratory site, BMI and season. Model 3: adjusted for age, sex, laboratory site, BMI, season, ethnicity, 
physical activity, alcohol, smoking and number of diseases. TUG, Timed Up and Go; HGS, Hand grip 
strength; N, Newton. 
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Discussion
In this study, serum 25(OH)D concentrations were significantly associated with 
physical performance and frailty status in a population of community-dwelling older 
adults. To date, no generally accepted recommendation on the optimal serum 25(OH)D 
status for muscle function is present, with the IOM proposing concentrations of 30-50 
nmol/L for older adults [8], and others supporting thresholds of 75 nmol/L or higher [18, 
19]. Our results indicated that serum 25(OH)D status <50 nmol/L, but also between 
50-75 nmol/L, were associated with lower functioning on TUG and gait speed tests, 
when compared to serum 25(OH)D status >75 nmol/L. Similar associations were 
observed in two large cohorts, where low serum 25(OH)D was associated with physical 
performance, and the strongest associations were observed on walking tests [22, 23]. 
In addition, comparable effect estimates were reported in a study of older adults at-
risk of disability, with slower walking speed (mean difference 0.04 m/s) in vitamin D 
deficient older adults (<50 nmol/L) compared to those with a sufficient status [24]. The 
association with TUG was also observed in previous studies, where higher vitamin D 
concentrations were associated with a faster performance on the TUG test  [21, 25]. 
In a study by van Dam et al., women with serum 25(OH)D concentrations ≤80 nmol/L 
showed slower TUG scores (mean difference 0.77 sec) than those who had a serum 
25(OH)D status ≥115 nmol/L, and the lower 25(OH)D category appeared predictive 
of a greater decline in function over a period of 2.5 years [21]. In addition, several 
studies report an association between vitamin D deficiency and reduced handgrip 
strength [23, 26], or leg extension strength [27, 28], albeit not all [29]. In our study, 
no significant association was observed between serum 25(OH)D concentration and 
measures of muscle strength. Mechanistically, the link between vitamin D and muscle 
function is explained via the regulation of calcium and phosphate, necessary for muscle 
contraction, or via the activation of the vitamin D receptor (VDR) in muscle cells [30]. 
However, the presence of the VDR is also observed in neurons and glial cells in several 
regions of the brain, which suggests a role of vitamin D in the neuromuscular system 
[31, 32]. Vitamin D deficiency is associated with an increased postural sway and greater 
risk of falling [33]. Moreover, a previous trial showed that vitamin D supplementation 
improved balance with 9% in vitamin D deficient older adults [34]. It is thus plausible 
that vitamin D status is more strongly associated with complex functional parameters 
rather than muscle strength due to its suggested role in neurological processes of 
motor performance. However, more research is needed in this field. 
Vitamin D deficient participants (<50 nmol/L) were ~2 times as likely to score frail, 
compared to those with sufficient serum 25(OH)D concentrations. This is in line with 
most previous studies investigating this association [9, 35, 36]. In the Longitudinal 
Aging Study Amsterdam (LASA), participants with 25(OH)D status between 25-50 
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nmol/L were 1.7 times as likely to be frail, and those with serum status below 25 nmol/L 
were 2.6 times as likely to be frail compared to the reference group with vitamin D 
status >50 nmol/L [37]. Likewise, in the NHANES III study, older adults with vitamin 
D deficiency (<37 nmol/L) were 3.7 times as likely to score frail on the Fried criteria 
compared to the reference group (≥75 nmol/L) [11]. In our study, serum 25(OH)D 
concentrations were not associated with the pre-frail state. However, a prospective 
study reported that serum 25(OH)D status ≥50 nmol/L tended to prevent a decline 
from the pre-frail to frail state over a period of 3 to 6 years [38], which might indicate 
that prevention of vitamin D deficiency is also relevant in this stage. Furthermore, sex 
has been reported as an effect modifier in the association between 25(OH)D and 
frailty [39]. In our study, the prevalence of frailty was relatively low (4%), limiting reliable 
testing of effect modification across such a small sample of cases.
Overall, the association between vitamin D status and frailty appears to be consistent, 
with lower serum 25(OH)D status associated with an increased likelihood of being 
frail. However, the causality of the association remains to be determined, given the 
cross-sectional design of these reported associations. An important determinant of 
vitamin D status is sun-exposure, which closely relates to being outdoors and physically 
active. As frail older adults might stay more indoors, reverse causation is plausible. 
Autier et al. recently discussed that the serum 25(OH)D status might not be a cause 
of adverse health outcomes, but a marker of ill health [40]. While we controlled for a 
broad range of lifestyle and health related factors, correcting for confounding remains 
challenging. While we used questionnaires to estimate physical activity status and 
season to correct for sun-exposure, residual confounding cannot be excluded. Besides 
the factors inherent to the cross-sectional design of this study, other limitations should 
be noted. The prevalence of frailty was relatively low when compared to the reported 
prevalence of 10% for physical frailty in community-dwelling older adults [3]. The low 
prevalence might relate to the fact that this population consists of older adults that 
were willing to participate in an intervention trial and had likely a better health status 
or were more mobile compared to the general population, limiting the generalizability 
of the study findings. Also, parathyroid hormone (PTH), could potentially mediate the 
association between serum 25(OH)D status and physical performance or frailty, but 
was not measured in this study. Nevertheless, Pabst et al. investigated the mediating 
effect of PTH on frailty, but the attenuation of the odds ratio was small, suggesting 
an independent association with 25(OH)D [36]. Strengths of this study include the 
broad range of vitamin D concentrations measured in this population, the relatively 
high prevalence of vitamin D deficiency, and the fact that, besides the measurement 
of frailty, we included measures of lower extremity strength and TUG to reflect overall 
body function and strength.
With only 12% of the participants using a vitamin D supplement, 45% of our 
study population was vitamin D deficient. Identifying older adults at risk of vitamin D 
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deficiency might be important given the possible predisposed risk of frailty. In this 
study, associations were observed between 25(OH)D status and the performance on 
the TUG and gait speed test. Both tests represent the ability of motor performance and 
balance control, supporting the plausible modulatory role of vitamin D in fall prevention 
[41]. Although the observed associations represent only small clinically meaningful 
changes [42, 43], if causal, these findings might be relevant for public health. 
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ABSTRACT
Objectives: Vitamin D supplementation is proposed as a potential treatment strategy 
to counteract functional decline in older adults. However, data from randomized trials are 
either limited or inconsistent. This study investigates the effect of daily supplementation 
with calcifediol or vitamin D3 on muscle strength and physical performance in older 
adults.
Design: A randomized, double-blind, placebo-controlled trial of 6 months.
Setting and participants: Seventy-eight pre-frail or frail, community-dwelling older 
adults, aged 65 years or older, with a baseline 25-hydroxyvitamin D (25(OH)D) status 
between 20-50 nmol/L.
Intervention: 10 µg calcifediol, 20 µg vitamin D3 or a placebo capsule per day.
Measurements: Serum 25(OH)D was measured by liquid chromatography-mass 
spectrometry (LC-MS/MS). Outcome measures included: maximal isometric knee-
extension and knee-flexion strength (Biodex System 4), hand grip strength, Short-
Physical Performance Battery (SPPB), Timed Up and Go (TUG), postural sway, muscle 
mass (DXA) and muscle fiber type and size. 
Results: Mean baseline serum 25(OH)D concentrations were 37.7 nmol/L (95% CI 
35.4 to 39.9). After 6 months of supplementation, status levels increased towards 98.7 
nmol/L (95% CI 93.1 to 104.4) in the calcifediol group, and to 72.0 nmol/L (95% 
CI 66.1 to 77.8) in the vitamin D3 group, compared to 47.5 nmol/L (95% CI 41.8 to 
53.3) in the placebo group. Knee-extension strength did not significantly change in the 
calcifediol group (5.9 Nm; 95% CI -6.2 to 18.0), nor in the vitamin D3 group (5.5 Nm; 
95% CI -6.8 to 17.8), or placebo group (1.8 Nm; 95% CI -10.7 to 14.4) (treatment x 
time interaction P=0.74). Further, no significant differences were observed in the mean 
change on physical performance tests, muscle mass, or muscle fiber type and size 
between groups. 
Conclusion: Improving serum 25(OH)D concentration over a period of 6 months did 
not significantly change muscle strength and physical performance in pre-frail and frail 
older adults.  
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INTRODUCTION
Aging is characterized by a gradual decline in skeletal muscle mass and muscle 
strength, which increases the risk of falls, disability, and frailty [1]. Vitamin D is 
suggested to be one of the factors that can moderate the age-related decline in muscle 
function. Low vitamin D levels have been linked to an impaired physical performance, 
and vitamin D deficiency is highly prevalent in frail older adults [2]. Therefore, frail 
elderly might represent an important target group for interventions including vitamin D 
supplementation.  
Vitamin D is a prohormone that plays a key role in the regulation of calcium and 
phosphate for the maintenance of bone tissue [3]. The hypothesis that vitamin D 
plays a role in muscle function originates from early case reports of proximal muscle 
weakness and complaints of muscle pain in patients with severe vitamin D deficiency 
[4]. Treatment with vitamin D appeared to relief these symptoms [5, 6]. The mechanism 
by which vitamin D acts on muscle tissue is suggested to work either direct, by binding 
the active metabolite 1,25-dihydroxyvitamin D to the vitamin D receptor (VDR) in muscle 
cells, or indirect, through its effect on intracellular calcium and phosphate handling [7]. 
In the last decade, observational studies have shown that low serum 25-hydroxyvitamin 
D (25(OH)D) levels (<50 nmol/L) are associated with impaired physical performance 
[8]. In addition, several prospective studies reported that adequate serum 25(OH)
D levels are associated with reduced risks of functional limitations [9-11]. As such, 
supplementation is proposed as a potential treatment strategy to counteract functional 
decline. Several randomized trials showed positive effects of vitamin D supplementation 
on lower extremity strength, balance and physical performance in older adults [12-17], 
however, the evidence is inconsistent, as a number of studies also reported null-findings 
[18-21]. 
Besides supplementation with vitamin D3, calcifediol might provide an alternative 
supplementation strategy. Previous studies have shown that, compared to vitamin 
D3, calcifediol has a higher potency in raising serum 25(OH)D towards desired 
concentrations [22-24]. Interestingly, a pilot study in postmenopausal women showed 
beneficial effects of calcifediol over vitamin D3 on knee extension strength and gait 
speed after 4 months of supplementation [25, 26]. This study, however, had a small 
sample size and did not include a placebo arm. 
More evidence from placebo-controlled trials is needed to further define the causality 
and determine the magnitude of the effect of vitamin D on muscle function. Therefore, 
the aim of this study was to evaluate the effect of supplementation with either vitamin D3 
or calcifediol on muscle strength and physical performance in pre-frail and frail, vitamin 
D deficient older adults.
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METHODS
 
Study design and objectives
This study was a six-month, double-blind, placebo-controlled trial, including subjects 
randomly allocated to a treatment, receiving supplements with either 10 µg calcifediol 
(CAL), 20 µg vitamin D3 (VD3) or a placebo (PLA) capsule per day. The primary outcome 
measure was change in knee-extension strength. Secondary outcome measures 
included change in knee-flexion strength and hand grip strength, physical performance 
(Timed Up and Go test, TUG; Short Physical Performance Battery, SPPB; and postural 
balance), muscle mass (Dual-energy X-ray Absorptiometry, DXA), muscle fiber type and 
size (muscle biopsy). Measurements were performed at baseline, after 3 months, and 
6 months of intervention, with the exception of the DXA scans and muscle biopsies, 
which were performed at baseline and after 6 months only. The study was carried out 
at Wageningen University and Hospital Gelderse Vallei, Ede, the Netherlands (latitude 
51ºN), between December 2014 and December 2015. The Medical Ethics Committee 
of Wageningen UR approved the study protocol and hospital Gelderse Vallei approved 
local feasibility. All participants gave their written informed consent. The study was 
registered at clinicaltrials.gov as NCT02349282.
 
Study population 
Participants were recruited via registries of municipalities in Wageningen and 
surroundings. A total of 78 men and women volunteered to partake in this study. 
Participants were included if they were ≥65 years of age, had a serum 25(OH)D 
level between 20-50 nmol/L, a BMI between 18.5 and 35 kg/m2 and were pre-frail 
or frail based on the frailty criteria of Fried et al. [27]. Exclusion criteria were: a serum 
calcium level >2.6 nmol/L or uncontrolled hypocalcaemia, diagnosed malabsorption 
disorders, sarcoidosis, lymphoma, primary hyperparathyroidism, kidney stones (in past 
10 years), renal insufficiency, cancer or the use of medication that may influence vitamin 
D metabolism (e.g. bisphosphonates, PTH treatment, tuberculostatica, anti-epileptica, 
bile acid sequestrate or lipase inhibitors). Furthermore, participants were excluded if 
they consumed >21 alcoholic beverages per week, were not willing or able to stop the 
use of vitamin D containing supplements during the study, were expected to increase 
their sun exposure (e.g. planned holiday) or had a surgery planned.
 
Intervention
An independent investigator randomly allocated subjects to one of the 3 intervention 
groups by a computer-generated list (SAS software 9.20). Randomization was carried 
out in permuted blocks (block size 3) and stratified by sex and BMI (18.5-29.9, 30-35 
kg/m2). The 3 groups received supplements with either 10 µg/day CAL, 20 µg/day VD3 
or PLA. Both the participants and investigators were blinded to treatment allocation, and 
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study supplements were identical in appearance and taste. DSM Nutritional Products 
Ltd. provided CAL (calcifediol 0.25% SD/S), VD3 or placebo (microcrystalline cellulose, 
Avicel PH-102) in spray-dried form. Capsules were manufactured by Fisher Clinical 
Services GmbH. The actual content of the CAL capsules was 9.9 µg, which was tested 
using High-Performance Liquid Chromatography (HPLC). The actual content of the 
VD3 capsules was 22.9 µg, which was tested using Liquid Chromatography-Mass 
Spectrometry (LC-MS/MS) (Analytical Research Centre of DSM Nutritional Products). 
Participants were instructed to consume one capsule per day at breakfast. Treatment 
compliance was reported at 3 and 6 months by capsule count of returned capsules, 
taking into account the number of days active in the study. Participants were considered 
compliant when ≥80% of the study supplements were taken. 
 
Measurements
Strength tests and physical performance
Lower extremity strength was measured as maximal knee-extension and knee-flexion 
(Nm) using the Biodex System 4 dynamometer (Biodex Medical Systems, Shirley, 
NY, USA). Subjects were seated upright with their chest and waist secured by belts. 
The lateral epicondyle of the femur was aligned with the rotation axis of the lever arm 
and the ankle was secured in the ankle attachment. Experiments were performed 
with knee angle of 60⁰ and hip angle of 90⁰. Subjects performed 3 maximal voluntary 
isometric contractions for five seconds, with 30 seconds of rest between trials and 
five minutes of rest between knee-extension and knee-flexion trials. Researchers 
provided standardized verbal encouragement during the strength tests. Upper 
extremity strength was determined by hand-held dynamometer (Jamar) and recorded 
to the nearest 1.0 kg as the mean hand grip strength of 3 consecutive trials with the 
dominant hand. The TUG-test and SPPB were performed to include a measure of 
functional mobility. For the TUG-test, subjects had to rise from a chair of standardized 
height, walk a distance of 3 meters in normal speed, turn, walk back to the chair, and 
sit down again [28]. The average of two trials was recorded. The SPPB consists of 3 
components: balance, gait speed and chair rise time [29]. Each of the components 
was scored on its test-specific scale and on a 0 to 4 point scale, resulting in a total 
score between 0-12. In addition, postural body sway was measured using a force plate 
(AMTI Accusway Plus Balance Platform, Version 2.02.01). Subjects were asked to 
stand as still as possible for 30 seconds on the force plate under four conditions; 
with their feet together (closed base) and eyes open (CBEO), feet together and eyes 
closed (CBEC), feet hip-width apart (open base) and eyes open (OBEO), feet hip-width 
apart and eyes closed (OBEC). Each stand was performed twice and the average 
area ellipse was used as a measure of sway. The area ellipse represents 95% of the 
center of pressure points distributed in both the x-axis and y-axis. Higher values indicate 
increased sway and as such poorer balance. If a participant was unable to complete the 
stand (by stepping off the force plate or touching the handles), the test was stopped. 
 
112
Vitamin D supplementation and muscle function
CHAPTER 6
Blood samples
Blood samples were collected in a fasting state in the morning and stored at -80 ⁰C 
until analysis. At screening, serum 25(OH)D was measured by LC-MS/MS at the 
Department of Clinical Chemistry, Canisius Hospital, Nijmegen, the Netherlands 
(DEQAS-certified laboratory). During the intervention, intact plasma parathyroid 
hormone (PTH) was measured in EDTA blood by sandwich chemiluminescence 
immunoassay. To monitor calcium concentrations, serum calcium and albumin were 
measured by colorimetric analysis, and morning spot-urine was collected to monitor 
urinary calcium levels (expressed as calcium/creatinine ratio) (SHO laboratory, Velp, the 
Netherlands) [30]. Serum 25(OH)D concentration during the intervention was analyzed 
using LC-MS/MS (Analytical Research Center, DSM Nutritional Products, Kaiseraugst, 
Switzerland). Serum 25(OH)D concentration reflects the sum of serum 25(OH)D2 and 
25(OH)D3. The analysis of serum 25(OH)D2 showed several laboratory values below 
the Lower Limit of Quantitation (LLQ) of 1.2 nmol/L, and these values were set at the 
detection limit for data interpretation. To assess laboratory performance of the method, 
dedicated standard and quality control samples were analyzed daily to ensure the 
accuracy and precision of the method (inter-assay and intra-assay CVs were ≤15 % and 
accuracy 85 - 115 % according FDA and EMEA guidelines). 
 
Biopsy samples
Muscle biopsies were collected from a subgroup (n=35) as subjects taking 
anticoagulant medication (except platelet inhibitors) or subjects not willing to undergo 
the biopsy were excluded from this procedure. Biopsies were collected from the middle 
region of the vastus lateralis muscle by percutaneous needle biopsy technique, as 
described previously [31]. Muscle biopsies were carefully freed from any visible fat 
and blood and embedded in Tissue-Tek (Sakura Finetek Europe BV, the Netherlands) 
and frozen in liquid nitrogen cooled isopentane. Samples were stored at -80 ⁰C until 
analysis.
 
Immunohistochemistry
Frozen muscle biopsies were cut into 5 µm thick cryosections using a cryostat at 
−20 ˚C. Histochemical methods are previously described in more detail [32]. In brief, 
muscle cross sections were stained with antibodies against laminin (polyclonal rabbit 
antilaminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and myosin heavy chain 
(MHC)-I (A4.840, dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA, 
USA). Secondary antibodies were goat anti-rabbit IgG Alexa555 and goat anti-mouse 
IgM Alexa488 (dilution 1:500 and 1:400, respectively; Molecular Probes, Invitrogen, 
Breda, the Netherlands). Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI, 
0.238 µM; Molecular Probes). Imaging was performed with 10x magnification using 
an Olympus BX51WI spinning disk confocal fluorescence microscope coupled to a 
Hamamatsu EM-CCD C9100 digital camera. Micromanager 1.4 software was used for 
image acquisition [33] and ImageJ software (version 1.50b, National Institute of Health, 
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MD) for quantitative analyses [34]. To assess fiber cross-sectional area (CSA), laminin 
was used to (semi)automatically detect the outline of the individual muscle fibers; 
corrections were made by hand where necessary. Based on these indications, fiber 
size was measured for each muscle fiber to calculate mean type I and type II muscle 
fiber size. Mean (SD) number of muscle fibers analyzed was 264 ± 146 and 328 ± 179 
at baseline and after 6 months, respectively.
 
Body composition 
At baseline, weight was measured using an analogue scale and reported to the 
nearest 0.5 kg. Height was measured using a stadiometer and reported to the nearest 
0.1 cm. BMI was reported as weight/height2. Body composition was assessed by DXA 
(Lunar Prodigy Advance; GE-Healthcare, Madison, WI, USA) scan and Appendicular 
Lean Mass (ALM) was calculated as the lean mass of arms and legs [35]. In 7 subjects, 
the specific regions of interest (ROI) for ALM could not be accurately defined due to 
overlap of upper limbs and trunk. 
 
Questionnaires
Participants filled out a comprehensive questionnaire during the screening visit. 
Medical history, medication, and dietary supplement use were assessed. During the 
intervention phase, subjects filled out a questionnaire to monitor changes in health 
status or medication use. Dietary intake of vitamin D and calcium were assessed by a 
Food Frequency Questionnaire (FFQ), as described previously [36-38]. 
 
Statistical methods
The sample size was based on a previous trial studying the effect of CAL or VD3 
supplementation on knee extension strength [25]. Based on the effect size of 47.6 N 
(P-value 0.03), the corresponding variability was calculated as the pooled estimate 
of the SD (49.0 N) [39]. Considering a power of 80% and an alpha level of 0.05, 
54 subjects were needed. Taking into account a drop-out rate of 30%, 78 subjects 
were included. Baseline characteristics were described as mean, SD or percent of 
categorical class and compared between treatment groups using one-way ANOVA for 
continuous variables and Chi-Square test or Fisher’s Exact test in case of categorical 
variables. Changes in study outcomes between groups over time were analyzed using 
linear mixed models. Models included fixed effects of treatment, time, and the interaction 
between treatment and time, with subject defined as random effect. Covariates (age, 
sex, BMI) were included based on model fit. Model assumptions were checked by visual 
inspection of residual plots and the TUG time and chair rise time were log-transformed. 
Results are described as model adjusted means and mean changes over time including 
95% confidence intervals. Log-transformed variables were transformed back to their 
original scale using the anti-log to present the geometric means at baseline, and ratios 
of geometric means to describe changes over time (baseline set as a reference 1.0). 
Analyses were performed based on the intention to treat principle. Statistical tests 
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were all two-sided and carried out at the 5% level of significance. Data analyses were 
performed using SPSS (version 22, IBM Corp., Armonk, NY, USA) and Graphpad 
Prism (version 5).
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RESULTS
Figure 6.1 presents the participant flow from recruitment and randomization to 
study completion. In total, 500 subjects were screened for study participation and 
78 subjects were randomized. After baseline, 3 subjects withdrew and 75 subjects 
completed the study. Two subjects withdrew due to a serious adverse event not related 
to study treatment and one subject because of personal reasons. Overall compliance 
to treatment was ≥80% in all participants, with an average compliance of 98%. At 
baseline, the mean age of the study population was 74 ± 6 years, and 55% were men 
(Table 6.1). Participants scored predominantly pre-frail on the Fried criteria (91%) and 
had a mean serum 25(OH)D concentration of 37.7 nmol/L (CI 35.4 to 39.9), with no 
baseline differences between groups (P=0.69). Figure 6.2 illustrates the change in 
serum 25(OH)D concentration over time, which was significantly different between 
all groups (treatment x time interaction P<0.01). After 6 months of supplementation, 
mean serum 25(OH)D concentration had increased with 60.6 nmol/L (CI 53.7 to 
67.5), 35.7 nmol/L (CI 28.6 to 42.7) and 8.9 nmol/L (CI 2.0 to 15.9) in the CAL, VD3 
and PLA group, respectively (Table 6.2). Furthermore, PTH concentrations were not 
significantly different between groups at baseline (P=0.28). However, during the study, 
PTH concentrations decreased significantly in both the CAL (-1.7 pmol/L, CI -2.5 to 
-0.9) and VD3 (-1.4 pmol/L, CI -2.2 to -0.6) group, compared to placebo (0.3 pmol/L, 
CI -0.5 to 1.1) (treatment x time interaction P<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Flowchart of recruitment and inclusion of study participants. 
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Table 6.1 Participant characteristics.
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Changes in serum 25-hydroxyvitamin D concentration per treatment group. 
 
Graph represents mean and 95% confidence intervals. Grey dashed line indicates the reference at 50 
nmol/L. To convert 25(OH)D to ng/mL divide by 2.496.
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Table 6.1 Participant characteristics. 
 Calcifediol, 
10µg/d 
(n=26) 
Vitamin D3, 
20µg/d 
(n=26) 
Placebo 
 
(n=26) 
 
P-value† 
Demographics 
Sex, male  54 (14) 58 (15) 54 (14) 0.95 
Age, y 73.1 ± 6.0 74.8 ± 6.7  73.7 ± 6.2 0.64 
Height, cm 167.8 ± 9.6  167.7 ± 7.9  167.5 ± 9.2  0.99 
Weight, kg 77.9 ± 12.8  77.0 ± 12.0  78.2 ± 13.6  0.94 
BMI, kg/m2 27.6 ± 3.5 27.4 ± 3.6 27.8 ±  3.7 0.92 
Frailty status 
   Pre-frail 81 (21) 96 (25) 96 (25) 
0.20 
   Frail 19 (5) 4 (1) 4 (1) 
Dietary intake 
Vitamin D, µg/d 3.5 ± 1.6 3.6 ± 1.1 3.6 ± 1.5 0.97 
Calcium, mg/d 1105 ± 481 985 ± 304 1014 ± 555 0.62 
Values are mean ± SD or % (n). † Between group differences were analyzed by one-
way ANOVA, Chi-Square test, or Fisher’s Exact test. 
 
 
 
 
 
 
Figure 6.2 Changes in serum 25-hydroxyvitamin D concentration per treatment group.  
Graph represents mean and 95% confidence intervals. Grey dashed line indicates the 
reference at 50 nmol/L. To convert 25(OH)D to ng/L divide by 2.496.  
  
Month
S
er
um
 2
5(
O
H
)D
 (n
m
ol
/L
)
0
0
25
50
75
100
125
3
Calcifediol, 10µg/d
Vitamin D3, 20 µg/d
Placebo 
6
117CHAPTER 6
Vitamin D supplementation and muscle function
Muscle strength and physical performance
Results on muscle strength and physical performance tests are described in Table 
6.3. At baseline, there was no significant difference in knee-extension strength 
between treatment groups (P=0.67). Over time, knee-extension strength did not 
significantly change in the calcifediol group (5.9 Nm, CI -6.2 to 18.0), the vitamin D3 
group (5.5 Nm, CI -6.8 to 17.8) or placebo group (1.8 Nm, CI -10.7 to 14.4) (treatment 
x time interaction P=0.74). Likewise, no significant treatment x time interactions were 
observed for other strength measures (knee-flexion strength or hand grip strength). 
Baseline SPPB scores did not differ between groups (P=0.68), with an average score 
of 10.6 points. The SPPB score decreased on average during the intervention period 
(time effect P<0.003), with no differential change between groups (treatment x time 
interaction P=0.23). The time to complete the TUG test increased on average during 
the intervention period (time effect P=0.02), with no differences in mean change among 
the treatment groups (treatment x time interaction P=0.94). Likewise, no significant 
treatment x time interactions were observed on the gait speed and chair stand tests. 
Results on postural sway of the foot positions CBEC and OBEC are presented as 
these conditions are most distinctive for balance performance. At baseline, balance 
performance did not significantly differ between groups (P>0.05 for all stands), and the 
degree of postural sway did not change differently between groups over time.
 
Table 6.2 Laboratory results at baseline and changes after 3 and 6 months per 
treatment group.
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Muscle strength and physical performance 
Results on muscle strength and physical performance tests are described in Table 6.3. At baseline, 
there was no significant difference in knee-extension strength between treatment groups (P=0.67). 
Over time, knee-extension strength did not significantly change in the calcifediol group (5.9 Nm, CI -
6.2 to 18.0), the vitamin D3 group (5.5 Nm, CI -6.8 to 17.8) or placebo group (1.8 Nm, CI -10.7 to
14.4) (treatment x time interaction P=0.74). Likewise, no significant treatment x time interactions 
were observed for other strength measures (knee-flexion strength or hand grip strength). Baseline 
SPPB scores did not differ between groups (P=0.68), with an average score of 10.6 points. The SPPB 
score decreased on average during the intervention period (time effect P<0.003), with o differential 
change between groups (treatment x time interaction P=0.23). The time to complete the TUG test 
increased on average during the intervention period (time effect P=0.02), with no differences in mean 
change among the treatment groups (treatment x time interaction P=0.94). Likewise, no significant 
treatment x time interactions were observed on the gait speed and chair stand tests. Results on postural 
sway of the fo t positions CBEC and OBEC are presented as these conditions are most di ti ctive for
balance performance. At baseline, balance performance did not significantly differ between groups 
(P>0.05 for all stands), and the degree of postural sway did not change differently between groups 
over time. 
 
 Calcifediol, 10µg/d Vitamin D3, 20µg/d   Placebo   
 Mean (95% CI) Mean (95% CI) Mean (95% CI) P-value* 
25(OH)D (nmol/L) 
   Baseline 38.1 (32.5; 43.8) 36.3 (30.6; 42.0) 38.1 (32.5; 43.8) 0.00 
   Δ 3 months 54.0 (47.1; 60.8) 31.8 (24.8; 38.9) 9.6   (2.6; 16.5) 
   Δ 6 months 60.6 (53.7; 67.5) 35.7 (28.6; 42.7) 8.9   (2.0; 15.9)  
PTH (pmol/L) 
   Baseline 7.5 (6.6; 8.4) 7.6 (6.7; 8.5) 6.5 (5.6; 7.4) 0.00 
   Δ 3 months -2.0 (-2.8; -1.2) -1.0 (-1.8; -0.2) 0.1 (-0.7; 0.9) 
   Δ 6 months -1.7 (-2.5; -0.9) -1.4 (-2.2; -0.6) 0.3 (-0.5; 1.1) 
Calcium (mmol/L)†, § 
   Baseline 2.35 (2.32; 2.38) 2.32 (2.29; 2.35) 2.34 (2.31; 2.37) 0.39 
   Δ 3 months 0.04 (0.00; 0.07) 0.02 (-0.02; 0.05) 0.00 (-0.03; 0.04) 
   Δ 6 months 0.00 (-0.03; 0.04) 0.02 (-0.02; 0.05) -0.03 (-0.06; 0.00) 
UCa/Cr ratio (mmol/mmol)‡, || 
   Baseline 0.31 (0.23; 0.40) 0.39 (0.27; 0.44) 0.38 (0.30; 0.46) 0.07 
   Δ 3 months 0.12 (0.04; 0.21) 0.04 (-0.04; 0.13) 0.03 (-0.06; 0.11) 
   Δ 6 months 0.10 (0.02; 0.07) -0.03 (-0.12; 0.16) -0.01 (-0.10; 0.07) 
Values are model adjusted means and 95% confidence intervals, including all three treatments and time points. 
*P-values represent the treatment x time interaction. †Adjusted for BMI. ‡Adjusted for BMI and sex. §Values are 
corrected for albumin according the following formula (plasma Ca-(0.02x[Alb-40]). ||Urinary Calcium/ Creatinine 
ratio. To convert 25(OH)D to ng/L divide by 2.496.  
 
 
mL divide by 2.496.
< . 1
< . 1
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Table 6.3 Muscle strength and physical performance results at baseline and changes 
after 3 and 6 months per treatment group.
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Table 6.3 Muscle strength and physical performance results at baseline and changes after 3 and 6 months per 
treatment group. 
 
 Calcifediol, 10µg/d Vitamin D3, 20µg/d Placebo  
 Mean (95% CI) Mean (95% CI) Mean (95% CI) P-value* 
Knee-extension strength (Nm) ‡ 
   Baseline 134.9 (121.5; 148.4) 127.1 (113.6; 140.6) 126.1 (112.6; 139.5) 0.74 
   Δ 3 months -4.0 (-15.9; 8.0) -1.9 (-14.1; 10.2) 1.7 (-10.7; 14.0) 
   Δ 6 months 5.9 (-6.2; 18.0) 5.5 (-6.8; 17.8) 1.8 (-10.7; 14.4) 
Knee-flexion strength (Nm) ‡ 
   Baseline 67.7 (61.8; 73.7) 62.1 (56.1; 68.0) 62.7 (56.8; 68.7) 0.22 
   Δ 3 months 2.8 (-2.3; 7.9) -0.6 (-5.7; 4.6) 1.6 (-3.6; 6.9) 
   Δ 6 months 4.0 (-1.2; 9.1) -3.3 (-8.7; 2.0) 0.3 (-5.0; 5.6) 
SPPB total (points 0-12) § 
   Baseline 10.4 (9.6; 11.2) 11.0 (10.4; 11.8) 10.5 (9.7; 11.3) 0.23 
   Δ 3 months -0.1 (-0.6; 0.4) 0.1 (-0.5; 0.6) -0.6 (-1.2; -0.1) 
   Δ 6 months -0.3 (-0.9; 0.2) -0.4 (-0.9; 0.2) -0.6 (-1.2; -0.1) 
Timed Up and Go test (sec) †, § 
   Baseline 10.4 (9.6; 11.3) 9.5 (8.7; 10.3) 10.4 (9.5; 11.3) 0.94 
   Δ 3 months 1.04 (0.98; 1.11) 1.02 (0.95; 1.08) 1.03 (0.97; 1.10) 
   Δ 6 months 1.06 (0.98; 1.13) 1.06 (0.99; 1.11) 1.04 (0.98; 1.12) 
Gait speed, (m/sec) § 
   Baseline 1.02 (0.95; 1.09) 1.08 (1.00; 1.15) 1.05 (0.98; 1.13) 0.32 
   Δ 3 months -0.05 (-0.13; 0.02) -0.06 (-0.13; 0.02) -0.13 (-0.20; -0.06) 
   Δ 6 months -0.10 (-0.17; -0.03) -0.11 (-0.19; -0.04) -0.12 (-0.19; -0.04) 
Chair rise, 5 stands (sec) †, § 
   Baseline 12.5 (11.4; 13.8) 11.9 (10.7; 13.1) 12.2 (11.0; 13.4) 0.33 
   Δ 3 months 1.0 (0.91; 1.09) 0.98 (0.90; 1.08) 1.06 (0.97; 1.16) 
   Δ 6 months 1.0 (0.92; 1.10) 1.06 (0.97; 1.16) 1.07 (0.98; 1.17) 
Hand grip strength (kg) ‡ 
   Baseline 25.8 (23.3; 28.2) 25.5 (23.1; 27.9) 24.0 (21.6; 26.4) 0.99 
   Δ 3 months 0.9 (-0.4; 2.3) 0.7 (-0.7; 2.1) 0.7 (-0.7; 2.1) 
   Δ 6 months 1.1 (-0.3; 2.4) 1.1 (-0.3; 2.5) 1.3 (-0.1; 2.7) 
95% area ellipse, OBEC (cm2) ‡ 
   Baseline 4.24 (3.16; 5.32) 3.33 (2.26; 4.40) 3.53 (2.46; 4.61) 0.32 
   Δ 3 months -0.68 (-1.85; 0.48) 0.16 (-1.01; 1.34) 0.06 (-1.15; 1.26) 
   Δ 6 months -0.75 (-1.93; 0.43) 0.61 (-0.59; 1.80) 0.45 (-0.74; 1.63) 
95% area ellipse, CBEO (cm2) ‡ 
   Baseline 3.92 (3.13; 4.71) 3.61 (2.84; 4.38) 3.68 (2.90; 4.46) 0.95 
   Δ 3 months -0.39 (-1.20; 0.42) -0.43 (-1.25; 0.39) -0.18 (-1.02; 0.65) 
   Δ 6 months -0.42 (-1.24; 0.39) -0.65 (-1.47; 0.17) -0.30 (-1.12; 0.53) 
Values are model adjusted means and 95% confidence intervals, including all three treatments and time points. 
*P-values represent the treatment x time interaction. †Values were log-transformed and represent geometric 
means at baseline, and ratios of geometric means to describe changes over time (baseline set as a reference 
1.0). ‡Adjusted for age and sex. §Adjusted for age. Nm, Newton meter; SPPB, Short Physical Performance 
Battery; OBEC, Open Base Eyes Closed; CBEO , Closed Base Eyes Open.  
 
 
Muscle mass, muscle fiber type and size 
Muscle mass and muscle fiber type characteristics are presented in Table 6.4. At baseline, no 
significant differences were observed in total lean mass (P=0.97) or ALM between groups (P=0.89). 
0 96 (0.91; 1.09)
0 (0.92; .10)
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Muscle mass, muscle fiber type and size
Muscle mass and muscle fiber type characteristics are presented in Table 6.4. At 
baseline, no significant differences were observed in total lean mass (P=0.97) or ALM 
between groups (P=0.89). The total lean mass and ALM decreased on average during 
the intervention period (time effect P≤0.01). However, the changes in lean mass or 
ALM did not significantly differ between groups (treatment x time interaction P>0.05). 
At baseline, no significant differences were observed in muscle fiber type distribution 
(P=0.20) or muscle fiber size (type I fiber CSA: P=0.42, type II fiber CSA: P=0.92) 
between groups. Overall, subjects showed specific type II muscle fiber atrophy, with 
smaller type II versus type I fiber size (P=0.03). However, over time, there were no 
differences in mean change between groups in muscle fiber type distribution (treatment 
x time interaction P=0.19) or muscle fiber size (treatment x time interaction P>0.05). 
 
Table 6.4 Body composition and biopsy results at baseline and changes after 6 months 
per treatment group.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety evaluation
During the intervention, serum calcium concentrations remained below the reference 
value of 2.6 mmol/L, except for one subject in the CAL group, who had a serum calcium 
level of 2.61 mmol/L at 3 months. However, these values normalized by the end of the 
study. No cases of hypercalcemia occurred during the study period and changes in 
serum calcium did not significantly differ between groups (treatment x time interaction 
P=0.39) (Table 6.2). Urinary calcium/ creatinine ratios tended to increase in the CAL 
group compared to VD3 and PLA (treatment x time interaction P=0.07), however 
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The total lean mass and ALM decreased on average during the intervention period (time effect 
P≤0.01). However, the changes in lean mass or ALM did not significantly differ between groups 
(treatment x time interaction P>0.05). At baseline, no signific nt differences were observed in muscle 
fiber type distribution (P=0.20) or muscle fiber size (type I fiber CSA: P=0.42, type II fiber CSA: 
P=0.92) between groups. Overall, subjects showed specific type II muscle fiber atrophy, with smaller 
type II versus type I fiber size (P=0.03). However, over time, there were no differences in mean 
change between groups in muscle fiber type distribution (treatment x time interaction P=0.19) or 
muscle fiber size (treatment x time interaction P>0.05).  
 
Table 6.4 Body composition and biopsy results at baseline and changes after 6 months per treatment group. 
 Calcifediol, 10µg/d 
 
Vitamin D3, 20µg/d   Placebo 
  
 
P-value* 
 Mean (95% CI) Mean (95% CI) Mean (95% CI) 
Total lean mass (kg)† 
   Baseline 49.2 (47.1; 51.2) 48.2 (46.2; 50.3) 49.0 (47.0; 51.1) 0.10 
   Δ 6 months -0.35 (-0.88; 0.18) -1.18 (-1.73; -0.63) -0.68 (-1.22; -0.14) 
ALM (kg)†  
   Baseline 21.0 (20.0; 22.0)a 20.3 (19.4; 21.3)b 21.0 (20.0; 22.0)c 0.43 
   Δ 6 months -0.27 (-0.56; 0.03) -0.36 (-0.68; -0.05) -0.08 (-0.38; 0.25) 
Fiber type distribution (% type II fibers)‡, §, || 
   Baseline 62 (52; 72) 49 (40; 59) 53 (43; 62) 0.19 
   Δ 6 months 1 (-8; 10) 1 (-8; 9) 11 (2; 19) 
Type I muscle fiber CSA (µm2)‡, § 
   Baseline 6595 (5523; 7667) 6476 (5490; 7463) 5717 (4645; 6789) 0.80 
   Δ 6 months 284 (-670; 1238) -138 (-1016; 740) 105 (-849; 1059) 
Type II muscle fiber CSA (µm2)‡, § 
   Baseline 5223 (3672; 6775) 5404 (3978; 6832) 4993 (3442; 6545) 0.22 
    Δ 6 months 615 (-344; 1573) -375 (-1457; 507) 598 (-361; 1557) 
Values are model adjusted means and 95% confidence intervals, including all three treatments and time points. *P-values 
represent the treatment x time interaction. †Adjusted for sex and BMI. ‡Adjusted for sex. a1 missing, b2 missing, c4 missing. 
§Biopsy measures were performed in a subgroup of n=11 CAL, n=13 VD3, n=11 PLA. ||Percent type I fibers is the inverse of 
percentage shown in the table. CSA, Cross-sectional Area. 
 
 
Safety evaluation 
During the intervention, serum calcium concentrations remained below the reference value of 2.6 
mmol/L, except for one subject in the CAL group, who had a serum calcium level of 2.61 mmol/L at 3 
months. However, these values nor alized by the end of the study. No cases of hypercalcemia 
occurred during the study period and changes in serum calcium did not significantly differ between 
groups (treatment x time interaction P=0.39) (Table 6.2). Urinary calcium/ creatinine ratios tended to 
increase in the CAL group compared to VD3 and PLA (treatment x time interaction P=0.07), however 
remained below 1.0 in all groups [40]. In total, 43 participants reported one or more adverse events 
(AE), with 39% occurring in the VD3 group, 30% in the CAL group, and 30% in the PLA group. The 
type of reported AE were not related to a specific treatment (P=0.44). 
120
Vitamin D supplementation and muscle function
CHAPTER 6
remained below 1.0 in all groups [40]. In total, 43 participants reported one or more 
adverse events (AE), with 39% occurring in the VD3 group, 30% in the CAL group, and 
30% in the PLA group. The type of reported AE were not related to a specific treatment 
(P=0.44).
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DISCUSSION
In this study, 6 months of daily supplementation with either 10 µg CAL or 20 µg VD3 
increased serum 25(OH)D concentration towards status levels of 97 nmol/L and 71 
nmol/L respectively, whereas the PLA group remained on average below the 50 nmol/L 
threshold during the entire study period. Despite these significant contrasts in serum 
25(OH)D levels achieved, no significant differential effects were observed on muscle 
strength or physical performance.
These findings are in line with several previous studies [18-21], though conflict with a 
comparable number of studies that did establish a beneficial effect on muscle strength 
after vitamin D supplementation [14-17, 25]. The broad variation in study designs, 
treatment comparator, baseline 25(OH)D levels and study measures, may in part explain 
these inconclusive results. Therefore, we aimed to include participants who were pre-
frail or frail, and vitamin D deficient at baseline (20-50 nmol/L), as those might benefit 
most from supplementation [41]. Moreover, we used a broad battery of functional tests 
and included the Biodex System, which is considered the gold standard in assessing 
muscle strength [42]. 
In this study, one treatment arm was supplemented with CAL as it can rapidly restore 
serum 25(OH)D levels. Similar to previous trials, CAL was ~3 times more potent (per 
microgram supplemented) in raising serum 25(OH)D levels compared to native VD3 
[22]. To date, only two previous trials have examined the effect of CAL on muscle 
function [18, 25]. The first trial was a pilot study among 20 postmenopausal women, 
supplemented with either CAL (20 µg/d or 140 µg/wk) or VD3 (20 µg/d) for 16 weeks, 
increasing serum 25(OH)D levels from an average of 30-35 nmol/L to 173 nmol/L in the 
CAL group and to 77 nmol/L in the VD3 group [25]. In that study, CAL supplementation 
resulted in a significant 17% improvement in knee extension strength compared to 
supplementation with VD3. The superior effect of CAL over VD3 could not be confirmed 
in our study, which might relate to the lower dose and status levels achieved. However, 
previous studies have also indicated a possible U-shaped distribution, where higher 
status levels not always equal positive results [43]. This was observed in a recent 
trial among 200 older adults, comparing a low monthly dose (600 µg VD3) with high 
monthly doses of either VD3 (1500 µg) or VD3 plus CAL (600 µg VD3 + 300 µg CAL) 
[33]. One year supplementation did not improve physical performance, but reduced the 
number of falls at the lower 25(OH)D threshold of 53 to 76 nmol/L, while an increased 
risk of falls was observed in the highest 25(OH)D quartile, reaching status levels 
between 112-247 nmol/L. 
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The optimal serum 25(OH)D concentration for muscle health is a matter of ongoing 
debate. Although the IOM recommends serum 25(OH)D levels between 30-50 nmol/L 
based on bone health [44], higher thresholds are suggested for muscle function. 
Observational studies suggest that physical performance and strength outcomes tend 
to increase with serum 25(OH)D concentrations between 60-115 nmol/L [11, 45-47]. 
A recent one-year trial, supplementing a daily dose of 20 µg VD3 and high monthly 
dose of 1250 µg VD3 compared with PLA, achieved status levels ≥50 nmol/L and 
≥75 nmol/L with daily and monthly treatment, respectively [34]. Although participants 
were not vitamin D deficient at baseline, this study showed that increasing status 
levels up to these specific thresholds did not improve functional parameters. In our 
study, comparable status levels were achieved after 6 months of supplementation with 
VD3 (72 nmol/L) or CAL (99 nmol/L) and the study duration allowed serum 25(OH)
D concentrations to reach a plateau, along with significant suppression of PTH levels. 
Nevertheless, it is plausible that profound vitamin D deficiency must exist to elicit an 
effect of supplementation on muscle function. Two meta-analyses indeed reported that 
subjects with serum 25(OH)D levels <25-30 nmol/L show greater improvements in 
muscle strength than older adults with baseline levels above these thresholds [41, 48]. 
In our study, it was considered unethical to randomize and include participants with 
severe vitamin D deficiency. Therefore, subjects with serum 25(OH)D levels <20 nmol/L 
were excluded from participation and mean baseline 25(OH)D status was 38 nmol/L. 
In addition, although we screened according the Fried criteria [27], participants were in 
general good health, and physical performance levels were relatively high, indicated by 
average SPPB scores between 10.4 and 11.0 points. As such, participants might have 
been less likely to show improvements in strength and functioning.
Myopathy and atrophy of type II muscle fibers is described in severe vitamin D 
deficient states [7]. However, not many randomized studies have assessed the impact 
of vitamin D supplementation on morphological changes in muscle fibers. In a study 
among 21 mobility-limited older women, 4 months of VD3 supplementation (100 µg/
day) tended to induce a selective type II muscle fiber hypertrophy compared to PLA, 
although, significance was only reached for total fiber size (mean type I and II fibers) 
[49]. In contrast, we did not observe any indication of increased muscle fiber size in 
response to the 6 months of supplementation with either VD3 or CAL. An increase 
in fiber size may have been more easily detected in the study by Ceglia et al. [49], 
since fiber size at baseline was substantially smaller than in our population of relatively 
healthy, predominantly pre-frail older adults; a difference that cannot only be explained 
by the inclusion of both men and women in the current study. Given the relatively low 
number of subjects included in the biopsy analyses of both studies, as well as the 
substantial intra-individual variation inherent to the muscle biopsy and histochemical 
procedures, the effects of vitamin D supplementation on myocellular characteristics in 
humans remains to be further investigated.
123CHAPTER 6
Vitamin D supplementation and muscle function
In our study, the placebo group remained on average vitamin D deficient (end of 
study serum 25(OH)D of 48 nmol/L), with only minor changes in serum 25(OH)D 
concentration related to the seasonal changes. Considering the well-established effect 
of vitamin D on bone health, this emphasizes the need for supplementation in older 
adults. Current literature points to a role of vitamin D in muscle function, especially in 
cases of extreme deficiency. However, results of randomized trials are inconclusive, 
and meta-analysis of these trials conclude either a small beneficial effect [41, 50] or no 
effect of vitamin D supplementation [51]. Therefore, it remains to be elucidated whether 
vitamin D supplementation can effectively improve or maintain muscle function in older 
adults. In conclusion, improving serum 25(OH)D concentration over 6 months did not 
significantly change muscle strength or function in a population of predominantly pre-
frail older adults.
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This thesis aimed to address three topics related to vitamin D in the older population. 
First, we examined the prevalence and the main determinants of a low vitamin D 
status. Next, we investigated strategies to improve serum 25(OH)D concentrations by 
exploring the contribution of dietary vitamin D intake and the potential of calcifediol 
as a supplementation strategy. Finally, we examined the role of vitamin D in muscle 
health, by exploring the associations of serum 25(OH)D status with measures of 
physical performance and frailty, and by performing a placebo-controlled trial to study 
the effect of vitamin D3 or calcifediol supplementation on muscle strength and physical 
performance in pre-frail and frail older adults.  
 
Findings in view of current literature
Prevalence and determinants of vitamin D deficiency
Year-round measures of serum 25(OH)D concentration in a large study sample 
of community-dwelling Dutch older adults indicated a high prevalence of vitamin D 
deficiency, with serum 25(OH)D concentrations <50 nmol/L in 45%, and <30 nmol/L 
in 14% of the population (chapter 2). These prevalence rates are in line with estimates 
across Europe, with 40% and 13% having serum 25(OH)D levels <50 nmol/L and <30 
nmol/L, respectively [1]. From a public health perspective, these numbers are alarming 
and action is needed to protect against vitamin D deficiency. However, identifying 
those at risk of a low vitamin D status requires a good understanding of its main 
determinants. Therefore, we examined to what extent vitamin D intake, frequency of 
supplement use, sun exposure and genetic factors are associated with serum 25(OH)D 
concentrations. Daily vitamin D intake from dietary sources showed a median (25-75th 
percentile) intake of 4.0 (3.0-5.4) µg/day and only 12-20% of older adults reported to 
take vitamin D supplements. This result clearly indicates that the vast majority of the 
older population does not meet the current recommendations of vitamin D intake [2]. 
Furthermore, stratification for season indicated a higher prevalence of serum 25(OH)D 
levels <50 nmol/L during winter/spring (63%). However, low vitamin D status was also 
evident during summer/autumn (37%), suggesting that many older adults are unable to 
overcome deficiencies even during the seasons when cutaneous vitamin D synthesis 
is at its highest. Previous studies indeed suggest that the cutaneous synthesis of pre-
vitamin D decreases with age [3, 4] and that older adults, especially frail older adults, 
tend to go outside less. However, we still observed positive associations between 
behavioral factors, such as, ‘being outside daily’ and serum 25(OH)D concentrations, 
suggesting that habitual summer sun exposure remains an important determinant of 
vitamin D status in the older population (chapter 2). Moreover, we learned that taking 
genetic factors into account resulted in a better understanding of the variation in serum 
25(OH)D concentrations. Single nucleotide polymorphisms (SNPs) of the genes 
encoding for the enzymes 7-dehydrocholesterol reductase (DHCR7), cytochrome P450 
2R1 (CYP2R1) and Group-specific Component (GC) were significantly associated 
with serum 25(OH)D concentrations, with differences between allele carriers ranging 
from 4-15 nmol/L. Most strongly associated with serum 25(OH)D status was the gene 
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GC, which encodes for the vitamin D binding protein (DBP). This protein plays an 
important role in vitamin D metabolism as most circulating metabolites are transported 
to target cells while bound to DBP [5]. These genetic variations can be of clinical 
relevance as risk-allele carriers have been associated with a reduced response to 
vitamin D supplementation [6, 7] and a greater risk of adverse health outcomes, such 
as fractures [8]. Taking genetic factors into account, contributed to identifying those 
at predisposed risk of a low vitamin D status. However, genetic factors never work 
individually and creating combined risk scores with environmental and behavioral 
factors might further advance our understanding of the variation in vitamin D status 
across the older population. 
 
Strategies to improve serum 25(OH)D status
When aiming to prevent vitamin D deficiency, several strategies are possible to 
achieve adequate serum 25(OH)D concentrations in the older population. In chapter 3, 
we observed that despite relatively low intakes, dietary vitamin D intake was positively 
associated with serum 25(OH)D concentration. Here, the food group ‘butter and 
margarines’ mainly contributed to total vitamin D intake, which is not surprising as 
margarines are commonly fortified with vitamin D. As a result, older adults with higher 
intakes of butter and margarines were 21% more likely to have a sufficient 25(OH)D 
status (≥50 nmol/L). We concluded that while regular intake of foods rich in vitamin D can 
support the prevention of modest 25(OH)D insufficiency, fortified foods or supplements 
are essential to meet current requirements and to substantially improve serum 25(OH)D 
concentrations across the general population. However, it is important to note that 
food fortification is not that common in the Netherlands. A previous study showed that 
only 17% of the total vitamin D intake in older adults is attributable to fortified foods 
[9]. Furthermore, a recent simulation study in the general Dutch population indicated 
that while an increased fortification of margarines and milk products can double the 
dietary vitamin D intakes in the Netherlands, additional supplementation would still 
be required to reach current recommendations [10]. Thus, the Dutch Health Council 
recommends women 50-70 years of age, and men and women ≥70 years to take a 
vitamin D supplement of 10 and 20 µg/day, respectively [2]. Supplementation with 
vitamin D3 is most common, and although alternative supplementation strategies do 
exist, these require further investigation. 
In chapter 4, we compared the dose-response effects of three different doses of 
calcifediol (5, 10 and 15 µg/day) to vitamin D3 (20 µg/day) over a 6-month period. 
Supplementation with calcifediol might result in a predictable serum response as it 
is more readily absorbed and does not require hepatic 25-hydroxylation, resulting in a 
rapid increase in serum 25(OH)D concentrations [11, 12]. In our study, a daily dose of 
10 µg calcifediol was able to correct deficiency (<50 nmol/L) within 4 weeks after start 
of supplementation, which resulted in a sustained increase towards serum 25(OH)D 
levels between 75-100 nmol/L after 8 weeks. These effects occurred along with a 
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significant suppression of parathyroid hormone (PTH). Daily supplementation with 20 µg 
vitamin D3 increased serum 25(OH)D concentrations above the >50 nmol/L threshold 
within 4 weeks as well, however, the 75 nmol/L threshold was not reached during the 
entire study period. Calcifediol supplementation was 3 times more potent compared to 
vitamin D3 (per µg supplemented) in raising serum 25(OH)D concentration. In previous 
clinical studies, calcifediol induced a 1.5-5 times higher increase in serum 25(OH)D 
concentrations when compared to vitamin D3 [13-15]. The observed variation between 
studies can be explained by the fact that the pattern of increase in serum 25(OH)D 
depends on the dosage and degree of deficiency at the start of supplementation. 
 
Vitamin D and muscle health
Vitamin D supplementation is suggested to prevent or to alleviate the age-related 
loss in muscle strength and function in older adults [16]. In chapter 5, we observed that 
community-dwelling older adults with deficient serum 25(OH)D concentrations (<50 
nmol/L) were more likely to be frail compared to their sufficient counterparts, and serum 
25(OH)D concentrations >75 nmol/L were associated with better performance on the 
gait speed and the Timed Up and Go test. These findings are largely in line with the 
current literature [17-20] and might suggest that higher thresholds than 50 nmol/L are 
required to optimize muscle function in older adults. However, while the associations 
between low vitamin D status and physical performance are well documented, the 
impact of supplementation on these outcomes is uncertain. Several studies observed 
slight positive effects of vitamin D supplementation on strength and balance [21-24], 
whereas others report no effect after supplementation [25-28]. A previous pilot trial 
(n=20) studied the effect of calcifediol supplementation in postmenopausal women 
and reported beneficial effects on lower extremity function when compared to vitamin 
D3 supplementation [13]. In chapter 6, we performed a placebo-controlled trial to 
investigate the effect of either vitamin D3 or calcifediol supplementation in vitamin D 
deficient (20-50 nmol/L), pre-frail and frail older adults, over a 6-month period. While 
both supplementation regimens resulted in significant increases in serum 25(OH)D 
status compared to placebo, no effect was observed on lower extremity strength after 
supplementation. Meta-analyses reflect the inconsistent findings from randomized 
trials, suggesting either null-effects [29], or small beneficial effects of vitamin D 
supplementation on muscle strength [30, 31]. Meanwhile, two additional randomized 
trials have been published, with daily or monthly supplementation in older adults without 
apparent deficiencies at baseline (serum 25(OH)D 47-52 nmol/L). In both studies, 
one-year supplementation did not affect lower extremity function (sit-to-stand, timed 
walk, or SPPB test) [25, 26]. Moreover, one of these studies even observed adverse 
effects on fall risk after high monthly intermitted doses (600 µg vitamin D3 + 300 µg 
calcifediol) [25]. Similar findings were observed in a previous large trial, where a high 
annual dose (12,500 µg vitamin D3) over a period of 3-5 years increased the risk of 
falls and fractures [32]. The underlying mechanism for these adverse results are not 
yet understood but may relate to induced catabolic effects of vitamin D, increasing 
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24,25(OH)2D metabolite production and decreasing 1,25(OH)2D [33, 34]. All in all, 
these studies suggest a specific therapeutic window where both the baseline serum 
25(OH)D status and the achieved target levels need to be taken into consideration 
when evaluating the effect of vitamin D supplementation. 
The contradictory findings among published studies are likely caused by the broad 
variation in dosing regimens, baseline serum 25(OH)D levels, participant characteristics, 
and the variety of tests that were used to assess muscle strength. However, part of the 
inconclusive findings might also relate to the fact that both direct and indirect effects of 
vitamin D can be expected. Vitamin D deficiency might indirectly affect muscle function 
by causing a number of metabolic changes, including secondary hyperparathyroidism, 
hypocalcemia or hypophosphatemia [16]. A recent study in mice showed that deficiency 
of both calcium and vitamin D resulted in poorer performance on tasks than vitamin 
D deficiency alone [35]. In addition, a study in rats showed that muscle force was 
affected only when vitamin D deficiency was accompanied by hypophosphatemia and 
muscle contraction could be normalized by restoring serum phosphate concentrations 
[36]. Nevertheless, this was contradicted by a recent study, showing that vitamin D 
depleted mice had weaker grip strength compared to replete controls, while maintained 
on an adequate calcium and phosphate diet [37]. Furthermore, several studies report 
independent associations between PTH and muscle function as an impaired muscle 
strength is also observed in older adults with mild secondary hyperparathyroidism [38, 
39]. In addition, plausible synergistic effects between vitamin D and other nutrients, e.g. 
protein have been suggested. Exposure of murine C2C12 muscle cells to 1,25(OH)2D 
enhanced the stimulating effect of leucine on protein synthesis rates [40]. In humans, 
a recent study indeed suggested that both sufficient serum 25(OH)D concentrations 
(>50 nmol/L) and protein intakes (>1.0 g/kg/day) were essential to increase muscle 
mass in sarcopenic older adults [41]. As such, vitamin D and its related co-factors might 
elicit distinct and complementary functions on muscle health, which require further 
investigation. 
 
Methodological considerations
Study designs
The studies described in chapter 2, 3 and 5 had a cross-sectional design and 
thus, no inferences can be made on causality of the observed associations. This may 
be especially true for our analysis on serum 25(OH)D concentrations and physical 
performance or frailty (chapter 5) as many of the factors that affect serum 25(OH)D 
concentrations (e.g. old age, BMI, physical inactivity) are also considered risk factors 
of an impaired physical functioning or frailty. Although we were able to include these 
factors into our models, along with a broad range of other lifestyle and health related 
factors, residual confounding cannot be excluded. For example, we had no or limited 
data on chronic diseases, medication use or PTH, all of which are important factors 
to consider. Also for the randomized trials, some methodological considerations are 
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noteworthy (chapters 4 and 6). To accurately estimate the dose-response relationship 
of vitamin D supplementation, one of the challenges is limiting seasonal effects (chapter 
4). Especially when investigating supplementation over a relatively long timespan (6 
months), seasonal variation is inevitable, and might reduce the external validity of the 
dose-response findings. In our study, randomization assured comparability between 
groups and participants that had planned a sunny holiday were excluded. Moreover, 
the main study period fell in winter season and as such, possible endogenous vitamin 
D synthesis was minimized. In chapter 6, we aimed to test the effect of calcifediol and 
vitamin D3 supplementation on muscle strength, compared to a placebo treatment. 
Based on our dose-response data, we chose a dosing regimen that would induce 
a significant increase of serum 25(OH)D towards the range of 75-100 nmol/L. No 
concomitant supplementation with calcium was chosen as to specifically test the 
individual effect of vitamin D and the dietary calcium intake was considered sufficient 
(1015 ± 450 mg/d). 
 
Study populations
The study populations included in the studies described in this thesis all represent 
community-dwelling older adults. Nevertheless, the fact that the participants in the 
cross-sectional studies were willing to volunteer in randomized trials might have resulted 
in the inclusion of adults who were more health conscious than the general population. 
Besides, the B-Proof study (chapter 2 and 3) only included participants with (mildly) 
elevated homocysteine levels [42]. Inverse associations have been described between 
serum 25(OH)D and homocysteine [43], which might have resulted in the inclusion of 
older adults with relatively low serum 25(OH)D concentrations. However, the observed 
prevalence of deficiency in this study sample, was comparable to previous Dutch cohorts 
of community-dwelling older adults [44, 45]. The study populations in the randomized 
trials (chapter 4 and 6), were explicitly selected to support the primary study objectives, 
taking into account factors that could affect the metabolism of the supplement, e.g. age, 
BMI, baseline 25(OH)D levels, clinical conditions and medication use. Furthermore, we 
aimed to include frail elderly with baseline 25(OH)D between 20-50 nmol/L (chapter 6), 
as the positive effects of vitamin D supplementation on muscle strength are particularly 
shown in vulnerable populations with low baseline serum 25(OH)D levels [23, 46-48]. 
However, it appeared challenging to recruit the frailest seniors, and despite being pre-
frail or frail according the Fried definition, our participants were in a relatively good 
physical state [49]. Moreover, the inclusion of participants in more severely deficient 
states i.e. <20 nmol/L, was considered unethical. These restrictions may have limited 
the inclusion of participants that might have benefited the most from supplementation.
 
Serum 25(OH)D measurements
In all chapters, vitamin D was assessed using the gold standard, liquid chromatography-
mass spectrometry (LC-MS) [50]. In chapter 5, analyses were performed in two 
different laboratories, however, measurement variation between these laboratories has 
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been reported to be acceptable [51] and will not substantially affect the ranking of the 
individuals. Moreover, laboratory site was included as a covariate in all models. Serum 
25(OH)D concentration is currently considered the best marker of vitamin D status. 
However, the accurate measurement of serum 25(OH)D status remains a challenge 
as it can interact with other vitamin D metabolites, such as 3-epi-25(OH)D (C3-
epimer) which is known to interact with LC-MS methods [52]. In addition, the impact 
of varying DBP levels on the measurement of protein-bound 25(OH)D concentrations, 
as compared to ‘free’ available 25(OH)D concentrations is debated [53, 54]. Serum 
25(OH)D binds up to 90% to DBP, around 10% to albumin, and less than 1% remains 
unbound in the circulation [55]. This ‘free’ fraction of 25(OH)D is suggested to enter 
target-cells without its protein-carrier and as such, is suggested as a potential marker 
of status and biological effect. However, the exact role of these metabolites and their 
impact on 25(OH)D assays is still under investigation.
 
Measuring determinants of intake and status
Self-reported methods were used to assess dietary intake and habitual sun exposure. 
The associations observed between these proxy measures and serum 25(OH)D 
concentrations, but also the clear seasonal trends add face validity to our findings. 
However, methods are suboptimal and could have resulted in an underestimation of 
the explained variation in 25(OH)D concentrations. Sun exposure questionnaires for 
example did not account for time of the day and UVB-intensity of exposure. The use 
of dosimeters in combination with a questionnaire can improve precision of these 
estimates, yet these might be costly in large study populations [56, 57]. Besides, vitamin 
D intake may be underestimated as certain foods also contain 25(OH)D while food 
consumption tables do not yet account for this metabolite. Food sources that contain 
25(OH)D include meat and poultry (0.2-0.4 µg/100g) and egg yolk (~1.0 µg/100g) 
[58]. Adding this metabolite to the dietary intake estimates as assessed by a food 
frequency questionnaire may result in vitamin D intake estimates that are ~1.7-2.9 µg/
day higher and may improve the association-analyses between intake and status [59].
 
Measuring muscle strength and function
In chapter 5 and 6, we measured physical performance using an extensive test battery to 
investigate various aspects of muscle strength and function. When aging, muscle strength 
decreases particularly in the lower extremities, and based on previous studies [30], 
lower limb strength was considered a relevant study endpoint. However, testing muscle 
strength in older adults is challenging as measures might be limited due to fear or pain 
complaints in the frailest elderly to perform maximum strength. Therefore, we performed 
sensitive tests according standardized procedures including a measure of isometric 
muscle strength (Biodex System), but also a measure to assess subtle changes in postural 
sway (Accusway platform). In addition, functional assessments such as the SPPB, TUG 
and gait-speed test were included to aid comparison of trial results with previous studies. 
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Translation of findings to public health
Prevention of deficiency
Considering the acknowledged role of vitamin D on bone health, the high prevalence 
of vitamin D insufficiency and the low supplement use, due attention is warranted to 
prevent vitamin D deficiencies. As most factors that contribute to a low vitamin D status 
in older adults are behavioral, small changes in sun exposure and dietary habits might 
support the prevention of deficiencies. Nevertheless, raising awareness not only about 
the behavioral factors and foods that contribute to vitamin D status, but also about the 
fortified foods and current supplementation advice is key to effectively prevent vitamin 
D deficiency in the majority of the older population [2].
 
Supplementation strategies
Both the Dutch Health Council, and international clinical guidelines endorse the use 
of vitamin D supplementation in older adults without prior screening of serum 25(OH)D 
status, although screening is supported in at-risk populations, such as patients with 
osteoporosis, or those at risk of fractures or recurrent falling [2, 60, 61]. In clinical 
practice, calcifediol could provide a valuable supplementation alternative, ensuring 
rapid correction of deficiency without the necessity to use loading-doses. Particularly in 
patients with impaired liver function, but also in cases of obesity, calcifediol might more 
effectively improve serum 25(OH)D status [62]. In previous trials among older adults, 
daily doses of calcifediol ranged between 5-20 µg/day and showed good acceptability 
in all participants, with no cases of hypercalcemia [13, 14, 63, 64]. Nevertheless, when 
supplementing with higher dosages over longer time-periods, monitoring of serum 
calcium levels might be warranted.  
 
Vitamin D and muscle health
There is considerable debate on what constitutes an optimal vitamin D status. The 
Institute of Health (IOM) and Dutch Health Council both consider serum 25(OH)D 
concentrations of 50 nmol/L sufficient [2, 65]. The International Osteoporosis 
Foundation (IOF) and Endocrine Society (ES) consider a target of 75 nmol/L sufficient 
to support musculoskeletal health and the prevention of falls and fractures [44, 45]. 
These higher thresholds are mainly supported by the observation that PTH levels start 
to increase when serum 25(OH)D concentrations fall below 75 nmol/L. However, 
the question remains whether these higher thresholds will truly benefit public health. 
Current literature indicates that older adults with severe deficiencies (serum 25(OH)D 
<25-30 nmol/L) tend to benefit most from vitamin D supplementation when aiming to 
support muscle health and reduce the risk of falls and fractures. However, the evidence 
from intervention studies in less extreme cases of deficiency appears too inconsistent to 
support the contention that an impaired muscle function can be prevented or improved 
by raising serum 25(OH)D concentrations above the threshold of >50 nmol/L. Moreover, 
caution is needed with high intermitted dosing regimens of vitamin D, given the possible 
adverse effects on fall risk [32, 46]. Thus, until more evidence becomes available, it is 
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considered best to advise a cautious approach towards vitamin D supplementation and 
place more emphasis on preventing deficiencies rather than promoting higher serum 
25(OH)D levels that go beyond current guidelines. While on-going research continues 
to provide evidence-based guidance, public health practitioners could however, pay 
specific attention to at-risk populations, such as frail, institutionalized older adults or 
persons with functional limitations by determining their vitamin D status and advising 
vitamin D supplements.
 
Future directions
Preventing vitamin D deficiency and defining the optimal serum 25(OH)D status for 
muscle health remains challenging. Future studies should therefore continue to examine 
the effectiveness of current strategies to promote adequate vitamin D intakes in older 
adults and evaluate how these strategies can be improved. The dietary reference values 
for vitamin D require regular evaluation with regard to their validity according most 
recent insights. In this context, performing individual patient data (IPD) meta-analyses 
might offer a valuable approach to better define the dose-response relationship 
between intake and status, as well as to link individual response data to health 
outcomes. A recent study indicated that the use of IPD analyses better captured the 
between-person variability compared to the use of aggregate data, resulting in intake 
estimates of 26 µg/day to maintain serum 25(OH)D status >50 nmol/L in 97.5% of the 
general population [66]. Besides that, more evidence is needed from randomized trials 
specifically designed to test the hypothesis that vitamin D supplementation benefits 
muscle health. Until now, most studies have had a small sample size, and thus, the 
chance of under-powering these studies was high. Moreover, included subjects were 
often not vitamin D deficient at the start of the study, while those might respond most to 
supplementation [30, 31]. However, performing future trials is challenged by the fact that 
studying deficient populations in placebo-controlled settings is considered unethical. 
As such, researchers might miss the ‘window of opportunity’ to perform confirmatory 
trials on vitamin D and muscle health. Currently, several mega-trials (n=2159-25,875) 
are underway to investigate the effect of vitamin D supplementation on multiple health 
outcomes, which often include physical performance measures as secondary outcomes 
[67-69]. Although these trials do not have a deficient status as inclusion criteria, 
sample sizes are expected to be large enough to stratify on baseline status and specify 
subgroups. Moreover, the observed associations between genetic factors and serum 
25(OH)D concentrations plea for new research opportunities. Several studies indicate 
that genetic variants of the VDR are linked to muscle strength and the risk of sarcopenia 
in older adults [70-73]. Mendelian randomization studies, including large population 
based datasets (e.g. biobanks), might help to identify the complex role of genes in 
the susceptibility to developing low vitamin D status and its related health outcomes. 
Lastly, there is a continuous need for mechanistic studies to better understand 
both the direct and indirect pathways between 25(OH)D, the active metabolite 
1,25(OH)2D and muscle tissue, as well as to identify the role of possible co-factors. 
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Conclusion
In an ageing society, preventing vitamin D deficiency and promoting adequate vitamin 
D intakes are important considering their beneficial effects on bone health. Besides, 
frail older adults with vitamin D deficiencies (<25-30 nmol/L) are likely to benefit from 
vitamin D supplementation with regard to muscle function. However, further trials are 
needed to ascertain these reference ranges and the magnitude of effect on functional 
outcomes before changing the recommendations on vitamin D supplementation. Until 
then, focus should be placed on the prevention and identification of deficiency.   
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Vitamin D has been identified as an important factor in healthy aging and is receiving 
growing attention in clinical research. Vitamin D is a fat-soluble molecule, which is 
synthesized by hepatic and renal or extra-renal hydroxylation into the active hormone 
1,25-dihydroxyvitamin D (1,25(OH)2D). The main function of this metabolite is to 
regulate calcium and phosphorus homeostasis and to support bone mineralization. 
In the circulation, the 25-hydroxyvitamin D metabolite (25(OH)D) is most stable and 
thus, considered the best marker of vitamin D status. A serum 25(OH)D concentration 
<30-50 nmol/L is considered deficient. Given the increased risk of deficiency and 
the potential beneficial effect of supplementation on musculoskeletal health, older 
adults present a specific target group for vitamin D interventions. However, the optimal 
serum 25(OH)D concentration is a matter of ongoing debate as randomized trials show 
conflicting results.
With the research presented in this thesis, we aimed to gain insight in the prevalence 
and main determinants of a low vitamin D status, to investigate strategies to prevent or 
reverse vitamin D deficiency, and to study the effect of vitamin D supplementation on 
muscle strength and physical performance in Dutch older adults.
In chapter 2, we examined the prevalence and the main determinants of a low vitamin 
D status in a large population of community-dwelling older adults (n=2857). Vitamin D 
deficiency was highly prevalent, with serum 25(OH)D concentrations <50 nmol/L in 
45%, and <30 nmol/L in 14% of the population. When exploring the main determinants 
of serum 25(OH)D status, significant associations were observed with age, BMI, dietary 
intake, sun exposure behavior, and genetic polymorphisms encoding for enzymes in the 
vitamin D pathway. Combined, these factors explained 35% of the variation in serum 
25(OH)D concentrations.  
To explore potential strategies that prevent vitamin D deficiency, we investigated the 
contribution of dietary vitamin D intake and specific food groups to serum 25(OH)
D concentration in chapter 3. Daily vitamin D intake from dietary sources showed 
a median (25-75th percentile) intake of 4.0 (3.0-5.4) µg/day (n=595) and only 12-
20% of older adults reported to take vitamin D supplements. These findings are in 
sharp contrast with the current nutrient guidelines and show that the vast majority of 
older adults do not meet the reference intakes for vitamin D. Nevertheless, significant 
associations were observed between the highest tertile of dietary vitamin D intake and 
serum 25(OH)D concentration, suggesting that regular intake of foods rich in vitamin D 
can support the prevention of modest insufficiency.
For the majority of older adults, supplementation is required to ensure sufficient serum 
25(OH)D concentrations throughout the year. Currently, supplementation with vitamin 
D3 is the most common strategy. However, alternative treatment regimens exist that 
require further investigation. In chapter 4, we report on a dose-response trial (n=59) 
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that investigated the efficacy of calcifediol (5, 10 or 15 µg/d) as a supplementation 
strategy. Compared to vitamin D3, calcifediol is more hydrophilic, does not require 
hepatic hydroxylation, and binds with higher affinity to its binding proteins. In our 
study, we observed that calcifediol was safe and well tolerated in the supplemented 
doses over the entire study period of 6-months. We concluded that a dose of 10 µg/
day resulted in sustained serum 25(OH)D concentrations between 75-100 nmol/L. 
Furthermore, calcifediol had a ~3 times higher potency when compared to vitamin D3, 
in increasing serum 25(OH)D concentrations. All in all, calcifediol may offer a valuable 
supplementation regimen to rapidly correct deficiency.  
Vitamin D presents an important endocrine regulator in the musculoskeletal health of 
older adults. Besides its role in bone health, low serum 25(OH)D concentrations have 
been linked to impaired physical performance and increased risk of falling. The active 
metabolite 1,25-dihydroxyvitamin D is suggested to act upon a wide variety of cells 
throughout the body, including muscle cells. Although the exact mechanisms by which 
vitamin D acts on muscle are unclear, several indirect or direct regulatory pathways have 
been described, including effects of 1,25-dihyroxyvitamin D on intracellular calcium 
and phosphate homeostasis, or via activation of transcription factors when binding to 
the vitamin D receptor in muscle cells.
In chapter 5 we observed significant associations between low serum 25(OH)D 
concentrations, physical performance and frailty in community-dwelling older adults 
(n=494-756). However, randomized trials are needed to define the causality of the 
observed associations. A previous pilot study indicated plausible beneficial effects of 
calcifediol over vitamin D3 on performance and strength. As such, we aimed to further 
explore the potential role of calcifediol or vitamin D3 on muscle function in chapter 6. 
We performed a placebo-controlled trial in pre-frail and frail, vitamin D deficient older 
adults, supplementing either 10 µg/d calcifediol or 20 µg/d vitamin D3, compared to 
placebo over a 6-month period (n=78). Again, calcifediol induced a faster and higher 
increase in serum 25(OH)D status when compared to vitamin D3. However, we observed 
no effect of either supplementation regimen on lower extremity strength or physical 
performance. Current literature suggests positive effects on strength and balance 
when supplementing with vitamin D, however, results are inconsistent. Meta-analyses of 
randomized trials indicate that the beneficial effects of vitamin D supplementation might 
be more pronounced in vulnerable populations with more severe vitamin D deficiencies. 
All in all, the high prevalence of vitamin D deficiency is alarming. Promoting adequate 
vitamin D status is important considering the beneficial effects on bone health. In the 
last decade, research has come a long way in exploring the role of vitamin D in muscle 
function. However, the evidence base remains uncertain and further research on the 
optimal vitamin D status for older adults is needed to guide clinical practice. Until then, 
focus should be placed on prevention and identification of deficiency.  
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